| Symbol | BIIB |
|---|---|
| Name | BIOGEN INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 225 BINNEY STREET, CAMBRIDGE, Massachusetts, 02142, United States |
| Telephone | +1 617 679-2000 |
| Fax | — |
| — | |
| Website | https://www.biogen.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000875045 |
| Description | Biogen and Idec merged in 2003, combining forces to market Biogens multiple sclerosis drug Avonex and Idecs cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogens MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firms first Alzheimers disease therapy in June 2021. Additional info from NASDAQ: |
2026-09-03 23:30
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Read more
2026-09-03 20:14
Parini Michael 🟢 acquired 7.4K shares (1 derivative) of BIOGEN INC. (BIIB) Transaction Date: Sep 01, 2026 | Filing ID: 000082
Read more
2026-09-03 04:00
LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China
Read more
2026-09-01 11:30
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Read more
2026-08-31 23:30
Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease
Read more
2026-08-24 12:04
LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer’s Disease
Read more
2026-08-24 12:00
LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimers Disease
Read more
2026-08-12 17:52
New Form 3 - BIOGEN INC. <b>Filed:</b> 2026-08-12 <b>AccNo:</b> 0000875045-26-000080 <b>Size:</b> 7 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT00000659 | A Phase II Trial of rsCD4 and AZT in Patients With AIDS or Advanced AIDS Relate… | Phase2 | HIV Infections | Terminated | — | — | ClinicalTrials.gov |
| NCT00000721 | An Escalating Dose Tolerance Trial of BG8962 (rCD4) in Patients Who Are HIV Ant… | Phase1 | HIV Infections | Completed | — | 1991-03-01 | ClinicalTrials.gov |
| NCT04972487 | Expanded Access Program for Tofersen in Participants With Superoxide Dismutase … | — | Superoxide Dismutase 1-Amyotropic Lateral Sclerosis | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT00535314 | Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma | Phase2 | Malignant Melanoma | Withdrawn | — | — | ClinicalTrials.gov |
| NCT03593499 | Expanded Access to Omaveloxolone for Melanoma for Patients Previously Enrolled … | — | Melanoma | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT02865109 | Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-ons… | — | Infantile-onset Spinal Muscular Atrophy | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT00451815 | BIIB014 Phase 2a Monotherapy | Phase2 | Parkinson's Disease | Withdrawn | — | — | ClinicalTrials.gov |
| NCT03460782 | An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gl… | — | Glioblastoma | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT07483632 | A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fuma… | Phase3 | Relapsing Forms of Multiple Sclerosis | Not_Yet_Recruiting | 2026-11-16 | 2035-06-19 | ClinicalTrials.gov |
| NCT06628687 | A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants… | — | Friedreich Ataxia | Recruiting | 2026-10-26 | 2035-04-30 | ClinicalTrials.gov |
| NCT07444450 | A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Give… | Phase3 | Muscular Atrophy, Spinal | Recruiting | 2026-09-04 | 2033-07-26 | ClinicalTrials.gov |
| NCT07448974 | Vitamin D and Type 2 Diabetes - Treat-To-Target | Phase3 | Prediabetes | Recruiting | 2026-08-04 | 2031-03-01 | ClinicalTrials.gov |
| NCT07722546 | A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its S… | Phase2 | Graves' Disease | Recruiting | 2026-07-30 | 2028-03-31 | ClinicalTrials.gov |
| NCT07662148 | A Study to Learn More About the Safety of a Single Dose of BIIB144 and How it i… | Phase1 | Healthy Volunteer | Recruiting | 2026-07-21 | 2028-06-19 | ClinicalTrials.gov |
| NCT07221669 | A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safet… | Phase3 | Muscular Atrophy, Spinal | Recruiting | 2026-04-28 | 2032-05-29 | ClinicalTrials.gov |
| NCT07444489 | A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Inf… | Phase3 | Antibody-mediated Rejection | Enrolling_By_Invitation | 2026-04-16 | 2031-05-28 | ClinicalTrials.gov |
| NCT07444476 | A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safet… | Phase3 | Spinal Muscular Atrophy | Recruiting | 2026-04-03 | 2032-06-22 | ClinicalTrials.gov |
| NCT07444333 | Cardiac Output and Fatigue in Friedreich's Ataxia | Na | Friedreich's Ataxia | Not_Yet_Recruiting | 2026-04-01 | 2028-04-01 | ClinicalTrials.gov |
| NCT07685015 | The Impact of Myo-Inositol on Glycemic Control and Oxidative Stress in Gestatio… | Na | Gestational Diabetes Mellitus (GDM) | Recruiting | 2026-03-23 | 2027-07-01 | ClinicalTrials.gov |
| NCT07400198 | Gait and Bone Health in SMA | — | Spinal Muscular Atrophy Type 3 | Recruiting | 2026-03-05 | 2027-06-30 | ClinicalTrials.gov |
| NCT07328087 | COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS … | Early_Phase1 | Colorectal Cancer Metastatic | Recruiting | 2026-02-02 | 2031-12-02 | ClinicalTrials.gov |
| NCT07285434 | Clinical Study of the Therapeutic Effectiveness of In-silico-Designed, Machine … | Early_Phase1 | NSCLC (Non-small Cell Lung Cancer) | Enrolling_By_Invitation | 2026-02-02 | 2030-02-02 | ClinicalTrials.gov |
| NCT07316361 | GYNORYLAQ™-VLINIVAL™: Ψ-Guided Personalized Neoantigen Peptide Vaccine for High… | Early_Phase1 | Endometrial Carcinoma | Enrolling_By_Invitation | 2026-02-02 | 2031-12-02 | ClinicalTrials.gov |
| NCT07219043 | A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidn… | Phase2 | Microvascular Inflammation | Recruiting | 2026-01-05 | 2028-02-10 | ClinicalTrials.gov |
| NCT07259980 | A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Parti… | — | Amyotrophic Lateral Sclerosis | Recruiting | 2026-01-02 | 2033-12-30 | ClinicalTrials.gov |
| NCT07294144 | Tofersen in Non-SOD1 ALS | Phase2 | ALS (Amyotrophic Lateral Sclerosis) | Recruiting | 2025-12-29 | 2028-05-01 | ClinicalTrials.gov |
| NCT07398469 | A Long-Term Study of Patient-Reported Changes in Postpartum Depression Symptoms… | — | Postpartum Depression | Recruiting | 2025-12-22 | 2027-03-29 | ClinicalTrials.gov |
| NCT07225517 | A Study to Learn More About the Safety of BIIB145 and How it is Processed in th… | Phase1 | Healthy Volunteer | Recruiting | 2025-12-18 | 2027-02-02 | ClinicalTrials.gov |
| NCT07297199 | A Study to Learn How the Body Processes BIIB141 (Omaveloxolone) When Taken as a… | Phase1 | Healthy Volunteer | Completed | 2025-12-12 | 2026-05-01 | ClinicalTrials.gov |
| NCT07223723 | A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chine… | Phase4 | Amyotrophic Lateral Sclerosis | Active_Not_Recruiting | 2025-12-11 | 2027-05-26 | ClinicalTrials.gov |
| NCT07149415 | A Study to Learn if Taking BIIB141 (Omaveloxolone) Affects How Omeprazole is Pr… | Phase1 | Healthy Volunteer | Completed | 2025-09-02 | 2025-10-16 | ClinicalTrials.gov |
| NCT07133828 | A Study to Learn About the Safety of BIIB142 and How it is Processed in the Bod… | Phase1 | Healthy Volunteer | Recruiting | 2025-08-29 | 2026-08-06 | ClinicalTrials.gov |
| NCT07027072 | Study to Evaluate the Efficacy and Safety of KDS2010 in Patients With Alzheimer… | Phase2 | Mild Cognitive Impairment (MCI) | Recruiting | 2025-08-06 | 2027-12-31 | ClinicalTrials.gov |
| NCT07009171 | Study to Evaluate the Efficacy and Safety of KDS2010 in Overweight or Obese Pat… | Phase2 | Overweight | Recruiting | 2025-07-29 | 2027-06-30 | ClinicalTrials.gov |
| NCT07077616 | Clinical Study for the Safety and Therapeutic Efficacy of the AI-QMMM Designed … | Early_Phase1 | Glioma | Recruiting | 2025-07-01 | 2029-12-01 | ClinicalTrials.gov |
| NCT07047820 | A Study to Learn More About How Zuranolone Affects Postpartum Depression Sympto… | — | Depression, Postpartum | Completed | 2025-06-30 | 2026-08-02 | ClinicalTrials.gov |
| NCT07019064 | A Study to Learn How BIIB141 (Omaveloxolone) is Processed in the Body When Take… | Phase1 | Healthy Volunteer | Completed | 2025-06-11 | 2025-08-19 | ClinicalTrials.gov |
| NCT06953583 | A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (… | Phase3 | Friedreich Ataxia | Recruiting | 2025-06-09 | 2029-11-22 | ClinicalTrials.gov |
| NCT06962800 | A Study to Learn More About the Effects and Safety of Felzartamab Infusions in … | Phase3 | Primary Membranous Nephropathy | Recruiting | 2025-05-22 | 2031-01-17 | ClinicalTrials.gov |
| NCT06935357 | A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immu… | Phase3 | Immunoglobulin A Nephropathy (IgAN) | Recruiting | 2025-05-08 | 2029-06-05 | ClinicalTrials.gov |
| NCT06955897 | Characterizing Perceived Physical Fatigability in Nusinersen-treated SMA | — | Spinal Muscular Atrophy | Recruiting | 2025-04-24 | 2027-02-26 | ClinicalTrials.gov |
| NCT06454721 | A Study to Determine the Biodistribution, Safety, and Tolerability of a Microdo… | Phase1 | Healthy Volunteer | Completed | 2025-01-30 | 2026-03-05 | ClinicalTrials.gov |
| NCT06555419 | A Study to Find Out How Nusinersen is Processed in the Body When Given Through … | Phase1 | Muscular Atrophy, Spinal | Recruiting | 2025-01-16 | 2027-09-30 | ClinicalTrials.gov |
| NCT06741657 | A Study to Find Out How Litifilimab is Processed in the Body in Healthy Partici… | Phase1 | Healthy Volunteer | Completed | 2025-01-02 | 2026-03-10 | ClinicalTrials.gov |
| NCT06623890 | A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in … | — | Friedreich Ataxia | Recruiting | 2024-12-12 | 2029-10-01 | ClinicalTrials.gov |
| NCT06685757 | A Study to Learn More About the Effects and Safety of Felzartamab Infusions in … | Phase3 | Antibody-mediated Rejection | Active_Not_Recruiting | 2024-12-03 | 2027-06-01 | ClinicalTrials.gov |
| NCT06612879 | A Study to Find Out How BIIB141 (Omaveloxolone) Moves From the Blood Into the B… | Phase1 | Healthy Volunteer | Completed | 2024-10-18 | 2025-04-08 | ClinicalTrials.gov |
| NCT06640933 | A Study to Find Out How Different Forms of BIIB091 is Processed in The Body Wit… | Phase1 | Healthy Volunteer | Completed | 2024-10-16 | 2025-02-07 | ClinicalTrials.gov |
| NCT06574828 | A Study to Find Out How Multiple Doses of BIIB091 Affect the Electrical Activit… | Phase1 | Healthy Volunteer | Completed | 2024-08-29 | 2025-03-22 | ClinicalTrials.gov |
| NCT06054893 | A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to… | Phase1 | Friedreich Ataxia | Active_Not_Recruiting | 2024-07-01 | 2030-06-04 | ClinicalTrials.gov |
| NCT05767736 | A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants … | — | Multiple Sclerosis | Active_Not_Recruiting | 2024-06-08 | 2032-12-01 | ClinicalTrials.gov |
| NCT06437938 | The Effects of Dietary Supplements on Glycemic Control, Body Composition and He… | Na | PreDiabetes | Recruiting | 2024-04-25 | 2025-08-31 | ClinicalTrials.gov |
| NCT06311786 | A Study to Look at How a Single Oral Dose of Carbon-14-Labelled [14C] BIIB091 M… | Phase1 | Healthy Volunteer | Completed | 2024-04-08 | 2024-05-11 | ClinicalTrials.gov |
| NCT05764122 | A Study to Evaluate the Efficacy and Safety of BIIB131 for Participants With Is… | Phase2 | Ischemic Stroke | Withdrawn | 2024-03-29 | 2025-07-07 | ClinicalTrials.gov |
| NCT06452082 | Risk in Devel Long-COVID in Contracting SARS-CoV-2 Infection After COVID-19 Vac… | — | Vitamin d Deficiency | Completed | 2024-03-20 | 2025-09-10 | ClinicalTrials.gov |
| NCT06264440 | A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions… | Phase1 | Healthy Volunteer | Completed | 2024-02-12 | 2024-06-18 | ClinicalTrials.gov |
| NCT06262477 | A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 … | Phase1 | Healthy Volunteer | Completed | 2024-01-02 | 2024-10-04 | ClinicalTrials.gov |
| NCT05789758 | A Study to Learn How Nusinersen (Spinraza) Affects Participants With Spinal Mus… | — | Muscular Atrophy, Spinal | Recruiting | 2023-12-15 | 2033-10-31 | ClinicalTrials.gov |
| NCT06602921 | The Effects of Nitrate, Caffeine, and Cold Exposure on Cardiovascular Function. | Na | Nitrate | Completed | 2023-12-05 | 2025-04-01 | ClinicalTrials.gov |
| NCT05866419 | Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscu… | Na | Spinal Muscular Atrophy | Recruiting | 2023-11-27 | 2030-07-01 | ClinicalTrials.gov |
| NCT06127095 | A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Mo… | — | Multiple Sclerosis, Relapsing-Remitting | Completed | 2023-11-24 | 2024-11-28 | ClinicalTrials.gov |
| NCT06064929 | A Study to Learn More About the Safety and Effects of Felzartamab in Adults Wit… | Phase1 | Lupus Nephritis | Completed | 2023-11-01 | 2026-07-08 | ClinicalTrials.gov |
| NCT05658497 | Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate) | — | Multiple Sclerosis | Recruiting | 2023-10-27 | 2032-07-06 | ClinicalTrials.gov |
| NCT06044337 | A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB… | Phase3 | Subacute Cutaneous Lupus Erythematosus | Enrolling_By_Invitation | 2023-10-03 | 2029-12-11 | ClinicalTrials.gov |
| NCT05895552 | A Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropath… | Phase2 | Diabetic Peripheral Neuropathic Pain | Terminated | 2023-07-28 | 2024-11-15 | ClinicalTrials.gov |
| NCT05798520 | A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammati… | Phase2 | Relapsing Forms of Multiple Sclerosis | Completed | 2023-07-25 | 2026-02-10 | ClinicalTrials.gov |
| NCT05927649 | A TQTc Study for Omaveloxolone | Phase1 | Health Adult Subjects | Completed | 2023-07-11 | 2023-09-01 | ClinicalTrials.gov |
| NCT05618301 | Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Ge… | Phase1 | Sickle Cell Disease | Completed | 2023-07-07 | 2025-06-24 | ClinicalTrials.gov |
| NCT05928585 | A Study of Safety and Drug Levels of HIB210 in Healthy Volunteers | Phase1 | Immune System Diseases | Completed | 2023-07-06 | 2024-06-10 | ClinicalTrials.gov |
| NCT05909644 | An Open-label DDI Study of Omaveloxolone in Healthy Subjects | Phase1 | Healthy Adult Subjects | Completed | 2023-07-05 | 2023-08-30 | ClinicalTrials.gov |
| NCT05925049 | A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS… | — | Multiple Sclerosis | Active_Not_Recruiting | 2023-06-30 | 2026-10-31 | ClinicalTrials.gov |
| NCT05658484 | A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RM… | Phase4 | Multiple Sclerosis | Completed | 2023-06-09 | 2025-04-12 | ClinicalTrials.gov |
| NCT05655507 | Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With … | Phase1 | Major Depressive Disorder | Completed | 2023-04-19 | 2024-10-18 | ClinicalTrials.gov |
| NCT03070132 | 802NP301 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal N… | Phase3 | Trigeminal Neuralgia | Withdrawn | 2023-04-19 | 2026-08-21 | ClinicalTrials.gov |
| NCT03637387 | 802NP302 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal N… | Phase3 | Trigeminal Neuralgia | Withdrawn | 2023-03-01 | 2026-09-29 | ClinicalTrials.gov |
| NCT05701423 | A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple S… | — | Multiple Sclerosis | Terminated | 2023-02-08 | 2024-07-31 | ClinicalTrials.gov |
| NCT05532163 | A Study to Investigate the Radiological Onset of Action After Treatment Initiat… | Phase4 | Multiple Sclerosis, Relapsing-Remitting | Terminated | 2023-01-23 | 2023-10-09 | ClinicalTrials.gov |
| NCT05618379 | Adult Spinal Muscular Atrophy (SMA) China Registry | — | Muscular Atrophy, Spinal | Active_Not_Recruiting | 2023-01-06 | 2028-06-01 | ClinicalTrials.gov |
| NCT05418010 | Natalizumab for the Treatment of People With Inflammatory Demyelination Suggest… | Phase2 | Multiple Sclerosis | Recruiting | 2022-12-01 | 2027-10-31 | ClinicalTrials.gov |
| NCT03426254 | Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazopa… | Phase1 | Advanced or Recurrent Solid Tumors | Withdrawn | 2022-11-10 | 2024-01-10 | ClinicalTrials.gov |
| NCT05575011 | A Study to Learn About the Safety of BIIB115 Injections and How BIIB115 is Proc… | Phase1 | Healthy Volunteer | Active_Not_Recruiting | 2022-10-10 | 2031-11-14 | ClinicalTrials.gov |
| NCT05177718 | Natalizumab and Chronic Inflammation | Phase4 | Multiple Sclerosis | Terminated | 2022-09-16 | 2023-04-05 | ClinicalTrials.gov |
| NCT05531565 | A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Sy… | Phase2 | Subacute Cutaneous Lupus Erythematosus | Active_Not_Recruiting | 2022-09-13 | 2027-12-14 | ClinicalTrials.gov |
| NCT06089018 | Observational Study of Digital Biomarkers of Myotonia and Gait in Adults and Ch… | — | Myotonic Dystrophy 1 | Unknown | 2022-09-10 | 2024-09-10 | ClinicalTrials.gov |
| NCT05418673 | A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-S… | Phase3 | Parkinson Disease | Terminated | 2022-08-26 | 2023-07-27 | ClinicalTrials.gov |
| NCT05399888 | A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whethe… | Phase2 | Mild Cognitive Impairment Due to Alzheimer's Disease | Active_Not_Recruiting | 2022-08-24 | 2028-06-06 | ClinicalTrials.gov |
| NCT05475691 | Longitudinal Data Collection in Pediatric and Adult Patients With Spinal Muscul… | — | Spinal Muscular Atrophy | Unknown | 2022-08-17 | 2025-01-30 | ClinicalTrials.gov |
| NCT06978985 | Adult SMA Research and Clinical Hub | — | Spinal Muscular Atrophy (SMA) | Recruiting | 2022-07-29 | 2027-04-30 | ClinicalTrials.gov |
| NCT05561621 | Prediction of Non-motor Symptoms in Fully Ambulatory MS Patients Using Vocal Bi… | — | Multiple Sclerosis | Completed | 2022-07-15 | 2022-12-20 | ClinicalTrials.gov |
| NCT05209815 | Safety of Exposure to Natalizumab During Pregnancy | — | Multiple Sclerosis | Completed | 2022-06-20 | 2023-12-22 | ClinicalTrials.gov |
| NCT05352919 | An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BII… | Phase3 | Systemic Lupus Erythematosus (SLE) | Enrolling_By_Invitation | 2022-06-10 | 2030-03-29 | ClinicalTrials.gov |
| NCT05310071 | A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early… | Phase3 | Alzheimer's Disease | Terminated | 2022-06-02 | 2024-08-12 | ClinicalTrials.gov |
| NCT07433010 | German Dementia Registry | — | Dementia Disorder | Recruiting | 2022-05-16 | 2099-12-01 | ClinicalTrials.gov |
| NCT05354414 | Virtual Reality for the Mitigation of Anxiety During Intrathecal Administration… | Na | Spinal Muscular Atrophy (SMA) | Completed | 2022-05-11 | 2024-07-12 | ClinicalTrials.gov |
| NCT05265728 | A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of… | Phase3 | Multiple Sclerosis, Relapsing-Remitting | Terminated | 2022-04-26 | 2024-05-27 | ClinicalTrials.gov |
| NCT05348785 | A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow … | Phase2 | Parkinson Disease | Completed | 2022-04-19 | 2026-03-09 | ClinicalTrials.gov |
| NCT05229562 | A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety… | Phase1 | Healthy Volunteer | Completed | 2022-02-17 | 2022-09-07 | ClinicalTrials.gov |
| NCT05109637 | A Study to Assess the Clinical Validity of Konectom™ in Adults Living With Neur… | Na | Spinal Muscular Atrophy | Completed | 2022-02-10 | 2023-07-25 | ClinicalTrials.gov |
| NCT05446285 | Multiple Sclerosis Outcome Determination Evaluating Real Differences After TimE | — | Relapsing Remitting Multiple Sclerosis | Unknown | 2022-02-07 | 2023-08-01 | ClinicalTrials.gov |
| NCT05160558 | A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar A… | Phase1 | Spinocerebellar Ataxia Type 3 | Terminated | 2022-02-02 | 2023-07-25 | ClinicalTrials.gov |
| NCT05216887 | A Study to Assess the Pharmacokinetic (PK) Comparability of 2 Fixed Subcutaneou… | Phase1 | Healthy Volunteer | Completed | 2022-02-01 | 2022-07-27 | ClinicalTrials.gov |
| NCT05195008 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics, With Target… | Phase1 | Healthy Volunteer | Completed | 2022-01-24 | 2023-07-10 | ClinicalTrials.gov |
| NCT05067790 | A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given… | Phase3 | Spinal Muscular Atrophy | Active_Not_Recruiting | 2022-01-21 | 2027-09-24 | ClinicalTrials.gov |
| NCT05173012 | Study to Evaluate SAGE-324 in Participants With Essential Tremor | Phase2 | Essential Tremor | Completed | 2022-01-05 | 2024-05-16 | ClinicalTrials.gov |
| NCT05106465 | A Study to Explore Association Patterns Between Digital Outcome Assessments Fro… | — | Multiple Sclerosis (MS) | Completed | 2021-12-15 | 2024-04-03 | ClinicalTrials.gov |
| NCT05152485 | A Study to Evaluate the Relative Bioavailability of Two Formulations of BIIB104… | Phase1 | Healthy Volunteers | Completed | 2021-12-15 | 2022-01-31 | ClinicalTrials.gov |
| NCT04948606 | Exploring Diroximel Fumarate Real-world Experience in Canada and Israel | — | Relapsing Forms of MS | Terminated | 2021-12-09 | 2023-04-14 | ClinicalTrials.gov |
| NCT05127564 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Diroximel… | Phase1 | Healthy Volunteers | Completed | 2021-12-03 | 2022-06-29 | ClinicalTrials.gov |
| NCT05148481 | A Study to Evaluate Safety and Pharmacokinetics of BIIB104 in Healthy Japanese … | Phase1 | Healthy Volunteer | Completed | 2021-11-23 | 2022-02-12 | ClinicalTrials.gov |
| NCT05042921 | Pediatric Spinal Muscular Atrophy (SMA) China Registry | — | Muscular Atrophy, Spinal | Active_Not_Recruiting | 2021-11-18 | 2027-09-02 | ClinicalTrials.gov |
| NCT05097131 | An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Dise… | — | Alzheimers Disease | Terminated | 2021-11-18 | 2022-05-20 | ClinicalTrials.gov |
| NCT05083923 | A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific… | Phase3 | Relapsing Forms of Multiple Sclerosis | Completed | 2021-11-18 | 2024-09-11 | ClinicalTrials.gov |
| NCT05304520 | A Study for Tysabri Participant Preference | — | Relapsing-Remitting Multiple Sclerosis (RRMS) | Completed | 2021-10-12 | 2024-04-30 | ClinicalTrials.gov |
| NCT03481842 | Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the… | Phase1 | Endometriosis | Withdrawn | 2021-10-10 | 2021-10-10 | ClinicalTrials.gov |
| NCT05021484 | Felzartamab in Late Antibody-Mediated Rejection | Phase2 | Antibody-mediated Rejection | Completed | 2021-10-06 | 2024-03-07 | ClinicalTrials.gov |
| NCT05688436 | A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Par… | — | Multiple Sclerosis | Active_Not_Recruiting | 2021-09-24 | 2031-01-17 | ClinicalTrials.gov |
| NCT05058950 | An Observational Study Using Multimodal Sensors to Measure Cognitive Health in … | — | Mild Cognitive Impairment | Terminated | 2021-09-20 | 2023-09-19 | ClinicalTrials.gov |
| NCT05065970 | Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Fe… | Phase2 | Immunoglobulin A (IgA) Nephropathy | Completed | 2021-08-31 | 2024-05-06 | ClinicalTrials.gov |
| NCT05119790 | A Study of Mass Balance, Pharmacokinetics, Metabolite Profile, and Metabolite I… | Phase1 | Healthy Volunteers | Completed | 2021-08-27 | 2021-11-05 | ClinicalTrials.gov |
| NCT04924153 | A Natural History Study of Participants With Potassium Sodium-Activated Channel… | — | KCNT1-Related Epilepsy | Completed | 2021-08-17 | 2023-08-29 | ClinicalTrials.gov |
| NCT05005338 | A Study to Determine the Absolute Bioavailability of BIIB122/DNL151 in Healthy … | Phase1 | Healthy Volunteers | Completed | 2021-07-28 | 2021-09-23 | ClinicalTrials.gov |
| NCT04961567 | A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Wheth… | Phase3 | Lupus Erythematosus, Systemic | Active_Not_Recruiting | 2021-07-16 | 2027-03-16 | ClinicalTrials.gov |
| NCT04870203 | Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis | Phase3 | Rheumatoid Arthritis | Active_Not_Recruiting | 2021-07-15 | 2027-03-01 | ClinicalTrials.gov |
| NCT05197699 | Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2)-Related Multi… | — | Multiple Sclerosis (MS) | Terminated | 2021-07-01 | 2023-09-30 | ClinicalTrials.gov |
| NCT04079088 | Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer… | Phase2 | Relapsing Multiple Sclerosis | Withdrawn | 2021-06-30 | 2024-09-18 | ClinicalTrials.gov |
| NCT04924140 | A Study to Assess Absolute Bioavailability of Aducanumab in Healthy Volunteers | Phase1 | Healthy Volunteers | Completed | 2021-06-30 | 2021-10-01 | ClinicalTrials.gov |
| NCT04895241 | A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Wheth… | Phase3 | Lupus Erythematosus, Systemic | Active_Not_Recruiting | 2021-05-25 | 2027-03-16 | ClinicalTrials.gov |
| NCT04856982 | A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults Wit… | Phase3 | Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation | Active_Not_Recruiting | 2021-05-17 | 2028-04-30 | ClinicalTrials.gov |
| NCT04655222 | Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcu… | — | Multiple Sclerosis | Completed | 2021-04-30 | 2021-10-15 | ClinicalTrials.gov |
| NCT04819555 | Frequency of SOD1 and C9orf72 Gene Mutations in French ALS | — | Amyotrophic Lateral Sclerosis | Completed | 2021-04-30 | 2023-05-15 | ClinicalTrials.gov |
| NCT04729907 | A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB… | Phase3 | Muscular Atrophy, Spinal | Completed | 2021-04-19 | 2026-07-30 | ClinicalTrials.gov |
| NCT04756687 | Real World Analysis on Lymphocyte Reconstitution After Lymphopenia in Participa… | — | Multiple Sclerosis | Completed | 2021-03-10 | 2021-06-15 | ClinicalTrials.gov |
| NCT04746976 | Study of Diroximel Fumarate in the Real-World Setting | — | Relapsing Forms of MS | Terminated | 2021-03-01 | 2023-04-14 | ClinicalTrials.gov |
| NCT04490096 | Multimodal Imaging Outcome Measures for ALS (Image ALS) | Phase1 | ALS | Terminated | 2021-02-25 | 2022-03-17 | ClinicalTrials.gov |
| NCT04702997 | A Trial of Bardoxolone Methyl in Patients With CKD at Risk of Rapid Progression… | Phase2 | Chronic Kidney Diseases | Completed | 2021-02-09 | 2021-11-23 | ClinicalTrials.gov |
| NCT04702087 | Omega 3, Leucine, Probiotic Lactobacillus Paracasei PS23 on Muscle Mass in Sarc… | Na | Sarcopenia | Unknown | 2021-01-22 | 2022-12-01 | ClinicalTrials.gov |
| NCT04733040 | Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R+ Membranous Nephropathy (aMN… | Phase2 | Glomerulonephritis | Completed | 2021-01-20 | 2023-12-14 | ClinicalTrials.gov |
| NCT04488133 | A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections t… | Phase4 | Muscular Atrophy, Spinal | Completed | 2021-01-04 | 2025-10-09 | ClinicalTrials.gov |
| NCT04750785 | A Study to Assess Choroideremia (CHM) Health Outcomes | — | Choroideremia | Completed | 2020-12-15 | 2021-09-27 | ClinicalTrials.gov |
| NCT05058729 | MS PATHS COVID-19 Questionnaire Data Linkage Sub-Study | — | Multiple Sclerosis (MS) | Completed | 2020-12-07 | 2021-10-08 | ClinicalTrials.gov |
| NCT04289909 | Identification of Retinal Perivascular Inflammation in Patients With Multiple S… | Na | Relapsing Remitting Multiple Sclerosis | Completed | 2020-12-01 | 2024-07-17 | ClinicalTrials.gov |
| NCT05260151 | Tau Protein and SV2a Imaging in Patients With Tau Protein-related Diseases | — | Alzheimer Disease | Unknown | 2020-11-18 | 2022-12-31 | ClinicalTrials.gov |
| NCT04419233 | Non-Interventional, Postmarketing Surveillance Study of Nusinersen Sodium Injec… | — | Muscular Atrophy, Spinal | Completed | 2020-11-18 | 2023-11-21 | ClinicalTrials.gov |
| NCT04476030 | A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plu… | Phase3 | Depressive Disorder, Major | Completed | 2020-11-09 | 2021-12-22 | ClinicalTrials.gov |
| NCT04593121 | Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics o… | Phase1 | Healthy Volunteers | Completed | 2020-10-30 | 2024-03-05 | ClinicalTrials.gov |
| NCT04599023 | Assessing the Feasibility of the MSPT Device in Routine Clinical Practice in th… | — | Multiple Sclerosis | Terminated | 2020-10-16 | 2022-08-31 | ClinicalTrials.gov |
| NCT04571424 | A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic… | Phase1 | Healthy Volunteers | Completed | 2020-10-14 | 2021-04-08 | ClinicalTrials.gov |
| NCT04756700 | Validation of DigiCog and Konectom Tools to Support Digitalized Clinical Assess… | Na | Multiple Sclerosis | Completed | 2020-10-12 | 2022-07-26 | ClinicalTrials.gov |
| NCT04106050 | Pharmacodynamic Study of BIIB095 and BIIB074 in Healthy Participants and Partic… | Phase1 | Healthy Volunteers | Withdrawn | 2020-09-30 | 2022-01-21 | ClinicalTrials.gov |
| NCT04494256 | A Study to Assess the Safety, Tolerability, and Effect on Disease Progression o… | Phase1 | Amyotrophic Lateral Sclerosis | Terminated | 2020-09-28 | 2024-08-13 | ClinicalTrials.gov |
| NCT04564612 | Study of BIIB091 Formulations in Healthy Participants | Phase1 | Healthy Volunteers | Completed | 2020-09-28 | 2022-09-07 | ClinicalTrials.gov |
| NCT04580381 | Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Co… | — | Multiple Sclerosis, Relapsing-Remitting | Completed | 2020-09-01 | 2021-10-30 | ClinicalTrials.gov |
| NCT04795206 | Natural Disease Progression in Participants With Choroideremia | — | Choroideremia | Completed | 2020-08-26 | 2021-08-10 | ClinicalTrials.gov |
| NCT04442503 | A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Se… | Phase3 | Depression, Postpartum | Completed | 2020-06-08 | 2022-04-12 | ClinicalTrials.gov |
| NCT04288128 | Integrated Functional Evaluation of the Cerebellum | — | Spinocerebellar Ataxia Type 2 | Completed | 2020-05-28 | 2022-06-01 | ClinicalTrials.gov |
| NCT04442490 | A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Particip… | Phase3 | Depressive Disorder, Major | Completed | 2020-05-12 | 2021-04-21 | ClinicalTrials.gov |
| NCT04288856 | Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disea… | Phase1 | Amyotrophic Lateral Sclerosis | Terminated | 2020-04-28 | 2022-05-03 | ClinicalTrials.gov |
| NCT05017142 | Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD) | — | Optic Neuritis | Recruiting | 2020-04-14 | 2071-01-01 | ClinicalTrials.gov |
| NCT04089566 | Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy | Phase3 | Muscular Atrophy, Spinal | Completed | 2020-03-26 | 2024-05-30 | ClinicalTrials.gov |
| NCT04241068 | A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With … | Phase3 | Alzheimer's Disease | Terminated | 2020-03-02 | 2024-07-22 | ClinicalTrials.gov |
| NCT04103333 | Angelman Syndrome (AS) Biomarker Study | Early_Phase1 | Angelman Syndrome | Completed | 2019-12-18 | 2022-01-02 | ClinicalTrials.gov |
| NCT04068532 | A Study to Explore Pharmacodynamic Effects of BIIB104 on Brain Circuitry in Hea… | Phase1 | Healthy Volunteers | Completed | 2019-11-15 | 2020-11-11 | ClinicalTrials.gov |
| NCT03958877 | A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginter… | Phase3 | Multiple Sclerosis, Relapsing-Remitting | Active_Not_Recruiting | 2019-10-18 | 2027-05-20 | ClinicalTrials.gov |
| NCT04145440 | Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephro… | Phase1 | Glomerulonephritis, Membranous | Completed | 2019-10-15 | 2022-08-02 | ClinicalTrials.gov |
| NCT04079101 | Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB104 in He… | Phase1 | Healthy Volunteers | Completed | 2019-10-02 | 2019-12-27 | ClinicalTrials.gov |
| NCT04221191 | Dimethyl Fumarate (DMF, Tecfidera®) Persistence in RR-MS Patients Included in t… | — | Multiple Sclerosis, Relapsing-Remitting | Completed | 2019-08-19 | 2022-09-14 | ClinicalTrials.gov |
| NCT04007367 | A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants Wi… | Phase3 | Major Depressive Disorder | Terminated | 2019-08-06 | 2020-01-06 | ClinicalTrials.gov |
| NCT04056689 | Study to Evaluate DNL151 in Subjects With Parkinson's Disease | Phase1 | Parkinson's Disease | Completed | 2019-07-23 | 2020-12-02 | ClinicalTrials.gov |
| NCT03902002 | A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment an… | Phase1 | Hepatic Impairment | Completed | 2019-07-19 | 2020-01-27 | ClinicalTrials.gov |
| NCT04048577 | A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Do… | Phase4 | Multiple Sclerosis | Unknown | 2019-07-03 | 2021-12-01 | ClinicalTrials.gov |
| NCT04317794 | Observational, Postmarketing Surveillance Study of Spinraza Injection (Nusiners… | — | Muscular Atrophy, Spinal | Active_Not_Recruiting | 2019-07-02 | 2027-02-05 | ClinicalTrials.gov |
| NCT04002492 | Effects of a Weight Based Training Program on MS Patients | Na | Multiple Sclerosis | Unknown | 2019-07-01 | 2019-12-01 | ClinicalTrials.gov |
| NCT04089514 | A Real-world Study of Imraldi® Use | — | Arthritis, Rheumatoid (RA) | Completed | 2019-06-30 | 2021-11-30 | ClinicalTrials.gov |
| NCT03926637 | Feasibility of the Multiple Sclerosis Performance Test in Participants With Mul… | — | Multiple Sclerosis | Terminated | 2019-06-17 | 2022-12-05 | ClinicalTrials.gov |
| NCT04008186 | A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone | Phase1 | Healthy Adult Subjects | Completed | 2019-06-14 | 2019-08-28 | ClinicalTrials.gov |
| NCT04268147 | Instrumented Data Exchange for Ataxia Study | — | Spinocerebellar Ataxia Type 1 | Completed | 2019-06-01 | 2024-06-30 | ClinicalTrials.gov |
| NCT03945279 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodyn… | Phase1 | Amyotrophic Lateral Sclerosis | Completed | 2019-05-30 | 2021-06-21 | ClinicalTrials.gov |
| NCT03918447 | A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON | Phase3 | Autosomal Dominant Polycystic Kidney | Terminated | 2019-05-29 | 2023-08-08 | ClinicalTrials.gov |
| NCT03943056 | A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of BIIB091, … | Phase1 | Healthy Volunteer | Completed | 2019-05-13 | 2020-01-10 | ClinicalTrials.gov |
| NCT04145284 | Quantitative Magnetic Resonance Imaging (MRI) Sub-Study of MS PATHS | — | Multiple Sclerosis | Completed | 2019-04-30 | 2020-04-30 | ClinicalTrials.gov |
| NCT03681015 | Wearable Assessments in the Clinic and Home in PD | — | Parkinson Disease | Completed | 2019-04-24 | 2022-03-30 | ClinicalTrials.gov |
| NCT03931590 | A Human AME Study for Omaveloxolone | Phase1 | Healthy Male Subjects | Completed | 2019-04-11 | 2019-05-31 | ClinicalTrials.gov |
| NCT03887455 | A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early … | Phase3 | Early Alzheimer's Disease | Active_Not_Recruiting | 2019-03-27 | 2029-06-30 | ClinicalTrials.gov |
| NCT03870763 | Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and … | Phase3 | Multiple Sclerosis, Relapsing-Remitting | Terminated | 2019-03-19 | 2022-07-21 | ClinicalTrials.gov |
| NCT03716570 | A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic… | Phase1 | Parkinson's Disease | Terminated | 2019-03-12 | 2021-04-23 | ClinicalTrials.gov |
| NCT03749447 | An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE) | Phase3 | Chronic Kidney Diseases | Terminated | 2019-03-08 | 2023-08-23 | ClinicalTrials.gov |
| NCT03864614 | A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disord… | Phase3 | Major Depressive Disorder | Completed | 2019-02-27 | 2023-06-22 | ClinicalTrials.gov |
| NCT03771664 | A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared… | Phase3 | Major Depressive Disorder | Terminated | 2019-02-04 | 2020-01-17 | ClinicalTrials.gov |
| NCT05236777 | TOPIK Study: A Study to Report Progressive Multifocal Leukoencephalopathy and O… | — | Multiple Sclerosis | Completed | 2019-01-01 | 2025-04-30 | ClinicalTrials.gov |
| NCT03639987 | A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alz… | Phase2 | Cognitive Dysfunction | Terminated | 2018-12-20 | 2019-07-30 | ClinicalTrials.gov |
| NCT03764488 | A Study to Evaluate Safety, Tolerability, and Distribution of a Microdose of Ra… | Phase1 | Healthy Volunteers | Completed | 2018-12-20 | 2021-07-10 | ClinicalTrials.gov |
| NCT03689972 | A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (B… | Phase3 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2018-11-27 | 2023-07-24 | ClinicalTrials.gov |
| NCT03672175 | A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Particip… | Phase3 | Major Depressive Disorder | Completed | 2018-11-19 | 2020-03-17 | ClinicalTrials.gov |
| NCT03745820 | A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cog… | Phase2 | Cognitive Impairment Associated With Schizophrenia | Completed | 2018-11-15 | 2022-04-07 | ClinicalTrials.gov |
| NCT03664453 | A Pharmacokinetic Study of Omaveloxolone in Healthy Volunteers | Phase1 | Healthy | Completed | 2018-10-29 | 2018-11-20 | ClinicalTrials.gov |
| NCT04591678 | Adults With SMA Treated With Nusinersen | — | Spinal Muscular Atrophy | Completed | 2018-10-01 | 2021-06-25 | ClinicalTrials.gov |
| NCT03573505 | An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmona… | Phase2 | Idiopathic Pulmonary Fibrosis | Terminated | 2018-09-24 | 2019-11-14 | ClinicalTrials.gov |
| NCT03626012 | A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in … | Phase1 | Amyotrophic Lateral Sclerosis | Completed | 2018-09-10 | 2021-11-17 | ClinicalTrials.gov |
| NCT03692910 | A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a … | Phase2 | Bipolar Disorder I | Completed | 2018-08-23 | 2019-05-21 | ClinicalTrials.gov |
| NCT02454907 | The Use of Technology to Improve MS Clinical Trials and Patient Care | Na | Multiple Sclerosis | Completed | 2018-07-31 | 2026-05-25 | ClinicalTrials.gov |
| NCT03662919 | One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi:… | — | Arthritis, Rheumatoid | Completed | 2018-07-02 | 2022-06-30 | ClinicalTrials.gov |
| NCT03579030 | Safety and PK/PD of RTA 1701 in Healthy Adults | Phase1 | Healthy | Completed | 2018-06-20 | 2019-06-28 | ClinicalTrials.gov |
| NCT03584165 | Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroid… | Phase3 | Choroideremia | Completed | 2018-06-04 | 2026-06-22 | ClinicalTrials.gov |
| NCT03339336 | Efficacy and Safety Study of BIIB074 in Participants With Small Fiber Neuropathy | Phase2 | Small Fiber Neuropathy | Terminated | 2018-05-31 | 2021-04-12 | ClinicalTrials.gov |
| NCT03352557 | Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease | Phase2 | Alzheimer's Disease | Terminated | 2018-05-03 | 2021-08-30 | ClinicalTrials.gov |
| NCT03454126 | Evaluating the Safety, Tolerability, and Pharmacokinetics of BIIB095 in Healthy… | Phase1 | Healthy Volunteer | Completed | 2018-03-29 | 2019-04-30 | ClinicalTrials.gov |
| NCT03283371 | Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilep… | Phase2 | Epilepsy, Focal Seizures, Partial Seizures | Completed | 2018-03-20 | 2020-11-18 | ClinicalTrials.gov |
| NCT03498625 | Crohn's Disease Endoscopic REmission Definition in an Objective Way | Na | CD | Completed | 2018-03-13 | 2021-12-31 | ClinicalTrials.gov |
| NCT03487900 | Is the Endoscopic Remission Evaluation, Using the CREDO 1 Index / Score in CD P… | Na | CD | Unknown | 2018-03-13 | 2023-12-31 | ClinicalTrials.gov |
| NCT03554343 | Sun May Arise on SMA : Newborn Screening of Spinal Muscular Atrophy in Belgium | — | Spinal Muscular Atrophy | Completed | 2018-03-05 | 2021-02-28 | ClinicalTrials.gov |
| NCT03088956 | Cognitive, Behavioral, and Functional Change in Behavioral Variant Frontotempor… | — | Frontotemporal Dementia | Completed | 2018-01-19 | 2019-09-23 | ClinicalTrials.gov |
| NCT03318523 | Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB… | Phase2 | Parkinson's Disease | Terminated | 2018-01-10 | 2021-04-29 | ClinicalTrials.gov |
| NCT03366337 | A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients Wi… | Phase2 | IgA Nephropathy | Completed | 2017-12-26 | 2019-01-29 | ClinicalTrials.gov |
| NCT02996084 | MS PATHS Normative Sub-Study | — | Healthy Volunteer | Completed | 2017-12-12 | 2022-12-31 | ClinicalTrials.gov |
| NCT03496012 | Efficacy and Safety of BIIB111 for the Treatment of Choroideremia | Phase3 | Choroideremia | Completed | 2017-12-11 | 2020-12-01 | ClinicalTrials.gov |
| NCT03507686 | A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of… | Phase2 | Choroideremia | Completed | 2017-11-29 | 2022-06-29 | ClinicalTrials.gov |
| NCT03347370 | A Post-Authorization Safety Study of Interferon Beta Therapy in Participants Wi… | — | Multiple Sclerosis, Relapsing-Remitting | Completed | 2017-11-27 | 2019-07-31 | ClinicalTrials.gov |
| NCT03222973 | Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Mod… | Phase2 | Multiple Sclerosis | Terminated | 2017-11-15 | 2021-02-12 | ClinicalTrials.gov |
| NCT03324685 | A Drug Interaction Study of BIIB074 and an Oral Contraceptive Regimen | Phase1 | Drug Interactions | Completed | 2017-11-11 | 2018-03-15 | ClinicalTrials.gov |
| NCT03264079 | Effect of Itraconazole on the Pharmacokinetics of Bardoxolone Methyl in Healthy… | Phase1 | Healthy Volunteers | Completed | 2017-10-16 | 2017-11-13 | ClinicalTrials.gov |
| NCT03224793 | Safety, Tolerability, and Pharmacokinetics of Single Doses of BIIB059 in Health… | Phase1 | Healthy Subjects | Completed | 2017-10-04 | 2018-06-12 | ClinicalTrials.gov |
| NCT03424733 | Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side … | Phase4 | Multiple Sclerosis | Unknown | 2017-09-25 | 2020-05-31 | ClinicalTrials.gov |
| NCT03284931 | A Study to Assess the Pharmacodynamic Effects of SAGE-217 in Healthy Adults Usi… | Phase1 | Healthy | Completed | 2017-09-14 | 2017-12-18 | ClinicalTrials.gov |
| NCT04926129 | Natural History of the Progression of X-Linked Retinitis Pigmentosa | — | X-Linked Retinitis Pigmentosa | Completed | 2017-09-13 | 2022-12-16 | ClinicalTrials.gov |
| NCT03385525 | Study to Evaluate the Effect of UGT Inhibition by Valproic Acid on the Pharmaco… | Phase1 | Drug Interaction | Completed | 2017-09-12 | 2017-10-13 | ClinicalTrials.gov |
| NCT03300869 | Natural History of Types 2 and 3 SMA in Taiwan | — | Spinal Muscular Atrophy | Unknown | 2017-09-01 | 2019-12-01 | ClinicalTrials.gov |
| NCT03662750 | TSPO PET as a Measure of Post-stroke Brain Inflammation: a Natural History Coho… | Na | Stroke, Ischemic | Completed | 2017-08-31 | 2019-12-31 | ClinicalTrials.gov |
| NCT03327454 | Benepali® PEN Patient Satisfaction Survey | — | Rheumatoid Arthritis | Completed | 2017-08-10 | 2018-06-21 | ClinicalTrials.gov |
| NCT03100734 | Observational Study to Evaluate the Real-Life Effectiveness of Benepali Followi… | — | Rheumatoid Arthritis | Completed | 2017-06-01 | 2018-11-30 | ClinicalTrials.gov |
| NCT03068468 | Study of BIIB092 in Participants With Progressive Supranuclear Palsy | Phase2 | Supranuclear Palsy, Progressive | Terminated | 2017-06-01 | 2020-02-07 | ClinicalTrials.gov |
| NCT03399981 | Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries | — | Progressive Multifocal Leukoencephalopathy | Completed | 2017-06-01 | 2023-12-31 | ClinicalTrials.gov |
| NCT02881567 | Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Nata… | Phase3 | Relapsing-Remitting Multiple Sclerosis (RRMS) | Terminated | 2017-04-18 | 2018-09-12 | ClinicalTrials.gov |
| NCT03068130 | Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Pat… | Phase3 | Pulmonary Hypertension | Terminated | 2017-04-18 | 2020-09-30 | ClinicalTrials.gov |
| NCT02978781 | A Study to Evaluate SAGE-217 in Participants With Essential Tremor | Phase2 | Essential Tremor | Completed | 2017-03-24 | 2017-12-05 | ClinicalTrials.gov |
| NCT03093324 | A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple… | Phase3 | Relapsing Remitting Multiple Sclerosis | Completed | 2017-03-15 | 2019-06-27 | ClinicalTrials.gov |
| NCT03091569 | Effects of Vitamin K on Redness Associated With Injection Site Reactions in Par… | Phase4 | Relapsing-Remitting Multiple Sclerosis | Completed | 2017-03-10 | 2018-01-27 | ClinicalTrials.gov |
| NCT03070119 | Long-Term Evaluation of BIIB067 (Tofersen) | Phase3 | ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation | Completed | 2017-03-08 | 2024-08-12 | ClinicalTrials.gov |
| NCT03116113 | A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Usin… | Phase1 | X-Linked Retinitis Pigmentosa | Completed | 2017-03-08 | 2020-11-18 | ClinicalTrials.gov |
| NCT03019185 | A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients … | Phase2 | Alport Syndrome | Completed | 2017-03-02 | 2020-10-30 | ClinicalTrials.gov |
| NCT03056729 | Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants W… | Phase1 | Alzheimer's Disease | Completed | 2017-02-17 | 2020-03-03 | ClinicalTrials.gov |
| NCT04123353 | Scan-Rescan Sub-Study of MS PATHS | — | Multiple Sclerosis | Completed | 2017-02-11 | 2017-05-09 | ClinicalTrials.gov |
| NCT02957617 | Extension Study to Evaluate the Long-Term Safety, Tolerability, and Maintenance… | Phase2 | Neuropathic Pain From Lumbosacral Radiculopathy | Terminated | 2017-02-10 | 2019-02-07 | ClinicalTrials.gov |
| NCT03218111 | Glymphatic Kinetics In Healthy Adult Volunteers | Na | Healthy | Completed | 2017-02-06 | 2018-02-08 | ClinicalTrials.gov |
| NCT03177083 | Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning… | Phase4 | Relapsing Remitting Multiple Sclerosis | Completed | 2017-01-30 | 2020-10-26 | ClinicalTrials.gov |
| NCT02978326 | A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression | Phase3 | Postpartum Depression | Completed | 2017-01-04 | 2018-12-11 | ClinicalTrials.gov |
| NCT02666963 | A Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multipl… | Phase1 | Healthy | Completed | 2017-01-01 | 2017-07-23 | ClinicalTrials.gov |
| NCT02969304 | Study of Utilization Patterns of Dimethyl Fumarate in Germany | — | Multiple Sclerosis | Completed | 2016-12-30 | 2017-03-02 | ClinicalTrials.gov |
| NCT03047369 | The Myelin Disorders Biorepository Project | — | Leukodystrophy | Recruiting | 2016-12-08 | 2030-12-08 | ClinicalTrials.gov |
| NCT03000530 | A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depr… | Phase2 | Major Depression | Completed | 2016-12-07 | 2017-11-08 | ClinicalTrials.gov |
| NCT02959658 | Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis | Phase2 | Primary Progressive Multiple Sclerosis | Completed | 2016-12-01 | 2020-12-09 | ClinicalTrials.gov |
| NCT02951221 | New Formulation and Food Effect Study of BIIB074 | Phase1 | Trigeminal Neuralgia (TN) | Completed | 2016-12-01 | 2017-02-01 | ClinicalTrials.gov |
| NCT02981082 | Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hyp… | Phase1 | Systemic Sclerosis | Terminated | 2016-12-01 | 2020-02-10 | ClinicalTrials.gov |
| NCT03000569 | A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease | Phase2 | Parkinson Disease | Completed | 2016-11-30 | 2017-09-11 | ClinicalTrials.gov |
| NCT02839460 | A Prospective Study Of Biomarkers Of Skeletal Muscle Atrophy | — | Sarcopenia | Completed | 2016-11-01 | 2019-03-01 | ClinicalTrials.gov |
| NCT02935608 | Study to Evaluate the Efficacy and Safety of BIIB074 in Neuropathic Pain From L… | Phase2 | Lumbosacral Radiculopathy | Completed | 2016-10-31 | 2018-08-06 | ClinicalTrials.gov |
| NCT02956486 | A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in… | Phase3 | Alzheimer's Disease | Terminated | 2016-10-20 | 2020-01-15 | ClinicalTrials.gov |
| NCT02847598 | Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) … | Phase2 | Systemic Lupus Erythematosus | Completed | 2016-10-20 | 2019-11-18 | ClinicalTrials.gov |
| NCT02657356 | Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmon… | Phase3 | Connective Tissue Disease-Associated Pulmonary Arterial Hypertension | Terminated | 2016-10-04 | 2020-05-07 | ClinicalTrials.gov |
| NCT02917187 | A Phase 2a Study of BIIB074 in the Treatment of Erythromelalgia | Phase2 | Primary Inherited Erythromelalgia | Completed | 2016-09-09 | 2017-01-05 | ClinicalTrials.gov |
| NCT02855411 | A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cog… | Phase2 | Cognitive Impairment Associated With Schizophrenia (CIAS) | Terminated | 2016-08-29 | 2016-09-26 | ClinicalTrials.gov |
| NCT02133924 | Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk … | Phase2 | Acute Graft Versus Host Disease | Completed | 2016-08-01 | 2021-11-21 | ClinicalTrials.gov |
| NCT02831517 | PK and Safety Study of BIIB074 in Healthy Japanese and Caucasian Participants | Phase1 | Healthy | Completed | 2016-08-01 | 2017-02-01 | ClinicalTrials.gov |
| NCT02829541 | A Phase 1, Single-Ascending-Dose, Safety, Tolerability, Pharmacokinetic(PK), an… | Phase1 | Systemic Lupos Erythematosus, SLE | Completed | 2016-08-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02730455 | Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke | Phase2 | Acute Ischemic Stroke | Completed | 2016-07-18 | 2017-11-20 | ClinicalTrials.gov |
| NCT02833142 | Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinuma… | Phase1 | Multiple Sclerosis | Completed | 2016-07-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT02795897 | Genomic Translation for Amyotrophic Lateral Sclerosis Care | — | ALS | Completed | 2016-06-08 | 2022-06-29 | ClinicalTrials.gov |
| NCT02749396 | EPID Multiple Sclerosis Pregnancy Study | — | Multiple Sclerosis | Completed | 2016-05-02 | 2018-08-14 | ClinicalTrials.gov |
| NCT02776072 | Observational Study to Characterize Real-world Clinical Outcomes With Relapsing… | — | Multiple Sclerosis | Completed | 2016-05-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02428218 | Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Sub… | Phase3 | Relapsing-Remitting Multiple Sclerosis | Withdrawn | 2016-05-01 | 2027-01-01 | ClinicalTrials.gov |
| NCT02782975 | Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in … | Phase1 | Alzheimer's Disease | Completed | 2016-05-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT02675413 | Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS | Phase4 | Multiple Sclerosis | Withdrawn | 2016-04-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02796222 | Factor Product Utilization and Health Outcomes in Patients With Hemophilia | — | Hemophilia A, Congenital | Completed | 2016-04-01 | 2021-04-26 | ClinicalTrials.gov |
| NCT02751905 | Absorption, Metabolism, and Excretion Study of BIIB074 | Phase1 | Neuropathic Pain | Completed | 2016-04-01 | 2016-05-01 | ClinicalTrials.gov |
| NCT02691702 | Multiple Dose Study Of BIIB118 (PF-05251749) In Healthy Volunteers | Phase1 | Healthy Adult Subjects | Completed | 2016-03-28 | 2017-01-12 | ClinicalTrials.gov |
| NCT02739542 | Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS) | Phase4 | Multiple Sclerosis (MS) | Completed | 2016-03-19 | 2021-03-31 | ClinicalTrials.gov |
| NCT02657915 | Long-Term Assessment of Remyelinating Therapy | Phase2 | Acute Optic Neuritis | Completed | 2016-03-10 | 2017-01-23 | ClinicalTrials.gov |
| NCT02664324 | MSPT Device Usability Study | — | Multiple Sclerosis | Completed | 2016-03-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02555215 | Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multi… | Phase3 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2016-02-22 | 2018-09-24 | ClinicalTrials.gov |
| NCT02658916 | Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy … | Phase1 | Supranuclear Palsy, Progressive | Terminated | 2016-02-22 | 2020-03-31 | ClinicalTrials.gov |
| NCT02587065 | Plegridy Satisfaction Study in Participants | Phase4 | Relapsing-Remitting Multiple Sclerosis (RRMS) | Completed | 2016-02-03 | 2017-12-21 | ClinicalTrials.gov |
| NCT02698267 | Effect of Itraconazole on the Pharmacokinetics of BIIB074 | Phase1 | Neuropathic Pain | Completed | 2016-02-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02778438 | A Validation Study of the Novel Application of Telehealth in Clinical Drug Deve… | — | Mild Cognitive Impairment | Completed | 2016-02-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02641041 | Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB… | Phase1 | Central Nervous System (CNS) Demyelinating Disease | Completed | 2016-02-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT02568111 | Brimonidine Tartrate for the Treatment of Injection Related Erythema | Phase4 | Relapsing-Remitting Multiple Sclerosis (RRMS) | Withdrawn | 2016-02-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02644083 | Tecfidera and MRI for Brain Energy in MS | — | Multiple Sclerosis | Terminated | 2016-02-01 | 2018-07-01 | ClinicalTrials.gov |
| NCT02623699 | An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study … | Phase3 | Amyotrophic Lateral Sclerosis | Completed | 2016-01-20 | 2021-07-16 | ClinicalTrials.gov |
| NCT02611674 | Methodology Study of Novel Outcome Measures to Assess Progression of ALS | — | Amyotrophic Lateral Sclerosis | Completed | 2016-01-06 | 2019-08-01 | ClinicalTrials.gov |
| NCT02677077 | Clinical Disease Activity With Long Term Natalizumab Treatment | — | Relapsing-Remitting Multiple Sclerosis | Completed | 2015-12-31 | 2016-08-18 | ClinicalTrials.gov |
| NCT02634307 | A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS)… | Phase3 | Multiple Sclerosis | Completed | 2015-12-10 | 2021-11-11 | ClinicalTrials.gov |
| NCT02531009 | Systemic Sclerosis Clinical and Biomarker Study | — | Healthy | Withdrawn | 2015-12-01 | 2017-03-01 | ClinicalTrials.gov |
| NCT02471560 | Tecfidera and the Gut Microbiota | Phase4 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2015-11-06 | 2017-06-12 | ClinicalTrials.gov |
| NCT02594124 | A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Part… | Phase3 | Spinal Muscular Atrophy | Completed | 2015-11-04 | 2023-08-21 | ClinicalTrials.gov |
| NCT02460094 | Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092… | Phase1 | Progressive Supranuclear Palsy | Completed | 2015-10-02 | 2016-10-19 | ClinicalTrials.gov |
| NCT02543346 | Comparability and Standardization of Controlled Allergen Challenge Facilities | Phase4 | Allergic Rhinitis | Completed | 2015-10-01 | 2016-05-01 | ClinicalTrials.gov |
| NCT02410200 | Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric… | Phase2 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2015-09-30 | 2016-09-23 | ClinicalTrials.gov |
| NCT02555085 | Single Ascending Doses of BIIB063 in Healthy Volunteers | Phase1 | Healthy | Terminated | 2015-09-30 | 2016-06-01 | ClinicalTrials.gov |
| NCT02484547 | 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease | Phase3 | Alzheimer's Disease | Terminated | 2015-09-15 | 2019-08-05 | ClinicalTrials.gov |
| NCT02462759 | A Study to Assess the Safety and Tolerability of Nusinersen (ISIS 396443) in Pa… | Phase2 | Spinal Muscular Atrophy | Terminated | 2015-08-19 | 2018-09-24 | ClinicalTrials.gov |
| NCT02477800 | 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease | Phase3 | Alzheimer's Disease | Terminated | 2015-08-13 | 2019-08-08 | ClinicalTrials.gov |
| NCT02525874 | Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Re… | Phase3 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2015-08-11 | 2018-04-23 | ClinicalTrials.gov |
| NCT02683863 | Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers | Phase4 | Multiple Sclerosis | Completed | 2015-08-01 | 2017-01-31 | ClinicalTrials.gov |
| NCT01532154 | Fampridine Pregnancy Exposure Registry | — | Multiple Sclerosis | Terminated | 2015-08-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT02521545 | Single-Dose Study of a New Formulation of BIIB061 | Phase1 | Multiple Sclerosis | Completed | 2015-07-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT02472938 | Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity o… | Phase4 | Relapsing Remitting Multiple Sclerosis | Withdrawn | 2015-07-01 | 2020-07-01 | ClinicalTrials.gov |
| NCT02459886 | Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkin… | Phase1 | Parkinson's Disease | Completed | 2015-07-01 | 2017-11-20 | ClinicalTrials.gov |
| NCT02519413 | Tecfidera Lymphocyte Chart Review | — | Multiple Sclerosis | Completed | 2015-07-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT03359551 | Natural History of the Progression of Choroideremia Study | — | Choroideremia | Completed | 2015-06-30 | 2020-10-01 | ClinicalTrials.gov |
| NCT02434718 | Single and Multiple Ascending Dose Study of Aducanumab (BIIB037) in Japanese Pa… | Phase1 | Alzheimer's Disease | Completed | 2015-06-24 | 2016-12-09 | ClinicalTrials.gov |
| NCT02090348 | Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Scl… | Phase4 | Relapsing-Remitting Multiple Sclerosis | Withdrawn | 2015-06-01 | 2017-10-01 | ClinicalTrials.gov |
| NCT02466529 | Natural History of Spinal Muscular Atrophy Type 1 in Taiwan | — | Natural History of Type 1 Spinal Muscular Atrophy (SMA) | Completed | 2015-06-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02443740 | Safety, Tolerability and Pharmacokinetics of BIIB118 (PF-05251749) | Phase1 | Healthy | Completed | 2015-05-31 | 2015-10-31 | ClinicalTrials.gov |
| NCT02386553 | A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With… | Phase2 | Spinal Muscular Atrophy | Completed | 2015-05-18 | 2024-12-17 | ClinicalTrials.gov |
| NCT02461069 | Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Re… | Phase4 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2015-05-06 | 2018-05-07 | ClinicalTrials.gov |
| NCT02255422 | RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTOR | Phase2 | MItochondrial Myopathies | Completed | 2015-05-05 | 2017-11-30 | ClinicalTrials.gov |
| NCT02430532 | BG00012 and Delay of Disability Progression in Secondary Progressive Multiple S… | Phase3 | Multiple Sclerosis, Secondary Progressive | Terminated | 2015-05-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT02323269 | Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Report… | — | Multiple Sclerosis, Relapsing-Remitting | Terminated | 2015-05-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT02736279 | Impact of Tecfidera on Gut Microbiota | — | Multiple Sclerosis | Unknown | 2015-05-01 | 2020-12-01 | ClinicalTrials.gov |
| NCT02551497 | Study to Evaluate the Interaction Between a Drug and CNV1014802 in Healthy Subj… | Phase1 | Healthy | Completed | 2015-04-30 | 2016-08-26 | ClinicalTrials.gov |
| NCT02428231 | Tecfidera Slow-Titration Study | Phase3 | Multiple Sclerosis | Terminated | 2015-04-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT02422407 | A Longitudinal, Observational Biomarker Study in Participants With Primary Sjog… | — | Healthy | Completed | 2015-03-26 | 2017-08-22 | ClinicalTrials.gov |
| NCT02386566 | Observational Study to Assess the Correlation of EDSS With Quality of Life in M… | — | Multiple Sclerosis | Completed | 2015-03-20 | 2018-01-28 | ClinicalTrials.gov |
| NCT02410278 | Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsin… | Phase4 | Multiple Sclerosis | Completed | 2015-03-12 | 2017-04-27 | ClinicalTrials.gov |
| NCT03093545 | Effect of Rabies Immunoglobulin on Immunogenicity of Post-exposure Rabies Vacci… | Na | Rabies | Completed | 2015-03-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT02343159 | Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Impro… | Phase4 | Multiple Sclerosis | Terminated | 2015-02-28 | 2016-04-15 | ClinicalTrials.gov |
| NCT02097849 | Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participant… | Phase2 | Relapsing Forms of Multiple Sclerosis | Completed | 2015-02-28 | 2016-05-02 | ClinicalTrials.gov |
| NCT02341482 | A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of PF-04… | Phase1 | Healthy | Completed | 2015-02-05 | 2015-03-31 | ClinicalTrials.gov |
| NCT02359344 | PK & Tolerability of CNV1014802 in Young and Elderly Healthy Volunteers | Phase1 | Trigeminal Neuralgia | Completed | 2015-02-03 | 2015-04-20 | ClinicalTrials.gov |
| NCT03092544 | Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fum… | Phase4 | Multiple Sclerosis | Unknown | 2015-02-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT02686268 | Understanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS | — | C9ORF72 Amyotrophic Lateral Sclerosis (ALS) | Completed | 2015-02-01 | 2018-10-02 | ClinicalTrials.gov |
| NCT02255435 | A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in Peo… | Phase2 | Friedreich Ataxia | Completed | 2015-01-31 | 2025-12-19 | ClinicalTrials.gov |
| NCT02332798 | Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia | Phase1 | Schizophrenia | Completed | 2015-01-06 | 2015-04-15 | ClinicalTrials.gov |
| NCT02176031 | Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD | Phase2 | Graft Versus Host Disease | Completed | 2015-01-01 | 2019-02-01 | ClinicalTrials.gov |
| NCT02369224 | Multicenter Validation of The Evergreen Myometric Strength Test for Lower Extre… | — | Multiple Sclerosis | Completed | 2015-01-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT02294851 | A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of … | Phase1 | Tauopathies | Completed | 2014-12-31 | 2016-04-30 | ClinicalTrials.gov |
| NCT02142192 | Natalizumab Subcutaneous Immunogenicity and Safety Study | Phase2 | Relapsing Multiple Sclerosis | Terminated | 2014-12-01 | 2015-06-04 | ClinicalTrials.gov |
| NCT02342704 | Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Scleros… | Phase4 | Relapsing-Remitting Multiple Sclerosis | Terminated | 2014-11-30 | 2016-05-18 | ClinicalTrials.gov |
| NCT02322021 | Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in P… | Phase2 | Alzheimer Disease | Terminated | 2014-11-26 | 2019-12-20 | ClinicalTrials.gov |
| NCT02292537 | A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Partic… | Phase3 | Spinal Muscular Atrophy | Completed | 2014-11-24 | 2017-02-20 | ClinicalTrials.gov |
| NCT02230969 | Plegridy Observational Program | — | Relapsing Forms of Multiple Sclerosis | Completed | 2014-11-12 | 2022-01-20 | ClinicalTrials.gov |
| NCT02283918 | Observational Study to Establish Patient-Matched Population Norms for the Multi… | — | Healthy | Completed | 2014-11-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT02259231 | RTA 408 Capsules in Patients With Melanoma - REVEAL | Phase1 | Melanoma | Completed | 2014-10-31 | 2018-07-23 | ClinicalTrials.gov |
| NCT02269930 | Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1… | Phase1 | Multiple Sclerosis | Completed | 2014-10-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT02440126 | Longitudinal Analysis And Sample Collection To Evaluate PML Risk Host Markers f… | — | Multiple Sclerosis | Completed | 2014-10-01 | 2020-07-01 | ClinicalTrials.gov |
| NCT02234869 | Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Ther… | Phase4 | Relapsing Multiple Sclerosis | Withdrawn | 2014-10-01 | 2018-03-01 | ClinicalTrials.gov |
| NCT02241785 | Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Scler… | Phase4 | Relapsing Multiple Sclerosis | Terminated | 2014-09-30 | 2016-05-02 | ClinicalTrials.gov |
| NCT02228395 | Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses… | Phase1 | Healthy | Completed | 2014-09-22 | 2014-11-13 | ClinicalTrials.gov |
| NCT02219932 | Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With … | Phase3 | Multiple Sclerosis | Completed | 2014-09-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT02283853 | Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Rel… | Phase3 | Relapsing-Remitting Multiple Sclerosis | Completed | 2014-08-28 | 2025-07-08 | ClinicalTrials.gov |
| NCT02193074 | A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infant… | Phase3 | Spinal Muscular Atrophy | Terminated | 2014-08-19 | 2016-11-21 | ClinicalTrials.gov |
| NCT02228707 | Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB061 in He… | Phase1 | Healthy | Completed | 2014-08-01 | 2016-05-01 | ClinicalTrials.gov |
| NCT02217982 | Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation | Phase4 | Relapsing Remitting Multiple Sclerosis | Terminated | 2014-07-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT02159573 | Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG0… | — | Relapsing-Remitting Multiple Sclerosis | Completed | 2014-07-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT02201849 | A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults | Phase1 | Multiple Sclerosis | Completed | 2014-07-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT02142959 | RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE | Phase2 | Breast Cancer | Completed | 2014-06-30 | 2015-04-30 | ClinicalTrials.gov |
| NCT02125604 | Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With R… | Phase4 | Relapsing-Remitting Multiple Sclerosis | Completed | 2014-06-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT02171208 | A Healthy Volunteer Study to Establish the Bioequivalence of BG00012 Supplied b… | Phase1 | Healthy | Completed | 2014-06-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT02036970 | Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LA… | Phase2 | Pulmonary Arterial Hypertension | Completed | 2014-05-31 | 2018-05-16 | ClinicalTrials.gov |
| NCT02128113 | RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Lo… | Phase2 | Corneal Endothelial Cell Loss | Completed | 2014-05-31 | 2015-04-30 | ClinicalTrials.gov |
| NCT02090413 | Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Par… | Phase4 | Relapsing-Remitting Multiple Sclerosis | Completed | 2014-05-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02143167 | Resistance Training and Amino Pyridine in Multiple Sclerosis | Phase4 | Multiple Sclerosis | Completed | 2014-05-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT02125695 | Pilot Tape Harvesting Study | — | Atopic Dermatitis | Completed | 2014-05-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02106897 | Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses… | Phase1 | Systemic Lupus Erythematosus | Completed | 2014-04-30 | 2016-05-24 | ClinicalTrials.gov |
| NCT02579681 | Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Pati… | Phase3 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2014-04-30 | 2016-12-21 | ClinicalTrials.gov |
| NCT02137109 | Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri | — | Multiple Sclerosis | Completed | 2014-03-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02099370 | Adherence to Treatment With Tecfidera™ in Multiple Sclerosis Patients | — | Multiple Sclerosis | Completed | 2014-03-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT02236624 | Aerobic Exercise and Flu-like Symptoms Following Interferon Beta 1a Injections … | Na | Multiple Sclerosis | Completed | 2014-03-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02065375 | RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain… | Phase2 | Inflammation and Pain Following Ocular Surgery | Completed | 2014-02-28 | 2014-09-30 | ClinicalTrials.gov |
| NCT02052791 | An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Part… | Phase1 | Spinal Muscular Atrophy | Completed | 2014-01-31 | 2017-01-31 | ClinicalTrials.gov |
| NCT01955707 | Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke | Phase2 | Acute Ischemic Stroke | Completed | 2014-01-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT02029729 | RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER | Phase1 | Metastatic or Incurable Non-small Cell Lung Cancer | Completed | 2013-12-31 | 2015-10-01 | ClinicalTrials.gov |
| NCT02029716 | RTA 408 Lotion in Healthy Volunteers | Phase1 | Healthy | Completed | 2013-12-31 | 2014-04-01 | ClinicalTrials.gov |
| NCT02071121 | Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics o… | Phase1 | Healthy | Completed | 2013-12-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT01978652 | Pharmacokinetic Study of Peginterferon Beta-1a in Japanese and Caucasian Adult … | Phase1 | Healthy | Completed | 2013-12-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT02047097 | Dimethyl Fumarate (DMF) Observational Study | — | Multiple Sclerosis | Completed | 2013-11-19 | 2022-10-31 | ClinicalTrials.gov |
| NCT04832399 | Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants | — | Relapsing Remitting Multiple Sclerosis | Completed | 2013-11-12 | 2023-10-02 | ClinicalTrials.gov |
| NCT01930890 | BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis | Phase2 | Lupus Nephritis | Terminated | 2013-11-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT01939002 | Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transit… | Phase3 | Relapsing Multiple Sclerosis | Completed | 2013-11-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02308657 | Multicenter Observational Study of Myotonic Dystrophy Type 1 | — | Myotonic Dystrophy Type 1 | Completed | 2013-11-01 | 2017-10-01 | ClinicalTrials.gov |
| NCT01930708 | A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multip… | Phase4 | Relapsing-Remitting Multiple Sclerosis | Completed | 2013-10-31 | 2020-01-09 | ClinicalTrials.gov |
| NCT01911767 | Biogen Multiple Sclerosis Pregnancy Exposure Registry | — | Multiple Sclerosis | Completed | 2013-10-30 | 2022-02-10 | ClinicalTrials.gov |
| NCT01943513 | A Study of the Effect of BIIB023 on Muscle Atrophy in Healthy Male Volunteers | Phase1 | Healthy | Completed | 2013-10-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01929746 | Daclizumab Japanese PK Study | Phase1 | Healthy | Completed | 2013-10-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01816100 | The Effect of Exercise on Strength and Mobility and Corresponding CNS Plasticit… | Na | Multiple Sclerosis | Completed | 2013-09-16 | 2015-09-01 | ClinicalTrials.gov |
| NCT01945359 | Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate C… | — | Relapsing Remitting Multiple Sclerosis | Completed | 2013-09-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT01915901 | PeptoBismol® Use to Reduce Gastrointestinal Events in Healthy Volunteers Receiv… | Phase1 | Healthy | Completed | 2013-08-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01924832 | BG00012 Regional Absorption Study | Phase1 | Healthy | Completed | 2013-08-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01917019 | A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in J… | Phase3 | Multiple Sclerosis, Remittent Progressive | Completed | 2013-08-01 | 2017-03-01 | ClinicalTrials.gov |
| NCT01903291 | Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS | — | Relapsing Forms of Multiple Sclerosis | Completed | 2013-08-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT01864148 | Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BII… | Phase2 | Multiple Sclerosis | Completed | 2013-08-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT02076841 | Tolerability and Quality of Life Study in Participants Who Switched to Avonex P… | — | Relapsing-Remitting Multiple Sclerosis | Completed | 2013-07-01 | 2016-10-01 | ClinicalTrials.gov |
| NCT01884935 | PK and PD Study of Natalizumab in Pediatric Subjects With RRMS | Phase1 | Relapsing-Remitting Multiple Sclerosis | Completed | 2013-07-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT01873404 | BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With… | Phase2 | Painful Lumbar Radiculopathy | Completed | 2013-06-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01731054 | Functional MRI in Lupus Nephritis | — | Healthy | Completed | 2013-06-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01839656 | A Study to Assess the Efficacy, Safety and Pharmacokinetics of Nusinersen (ISIS… | Phase2 | Spinal Muscular Atrophy | Completed | 2013-05-08 | 2017-08-21 | ClinicalTrials.gov |
| NCT01873417 | Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients Wi… | Phase4 | Relapsing Forms of Multiple Sclerosis | Completed | 2013-05-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01842126 | Phase 1 Subcutaneous Single and Multiple Ascending Dose Study of BG00010 (Neubl… | Phase1 | Painful Lumbar Radiculopathy | Completed | 2013-04-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01838668 | An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects W… | Phase3 | Relapsing-Remitting Multiple Sclerosis | Completed | 2013-03-28 | 2018-09-04 | ClinicalTrials.gov |
| NCT01797965 | Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Comp… | Phase3 | Relapsing-Remitting Multiple Sclerosis | Terminated | 2013-02-15 | 2018-09-24 | ClinicalTrials.gov |
| NCT01780246 | An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Part… | Phase1 | Spinal Muscular Atrophy | Completed | 2013-01-31 | 2014-02-28 | ClinicalTrials.gov |
| NCT01764594 | Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus | Phase1 | Immune System Diseases | Completed | 2013-01-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01767311 | A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects… | Phase2 | Alzheimer's Disease | Completed | 2012-12-20 | 2024-12-10 | ClinicalTrials.gov |
| NCT01749098 | A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Imp… | Phase1 | Schizophrenia | Completed | 2012-12-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01721161 | BIIB033 In Acute Optic Neuritis (AON) | Phase2 | Acute Optic Neuritis | Completed | 2012-12-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01272128 | Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - … | — | Multiple Sclerosis | Completed | 2012-12-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT01706107 | Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remittin… | — | Relapsing-Remitting Multiple Sclerosis | Terminated | 2012-11-07 | 2015-10-02 | ClinicalTrials.gov |
| NCT01767493 | Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS … | Phase4 | Multiple Sclerosis | Completed | 2012-11-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01703988 | An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Dos… | Phase1 | Spinal Muscular Atrophy | Completed | 2012-10-31 | 2015-01-31 | ClinicalTrials.gov |
| NCT01677572 | Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ I… | Phase1 | Alzheimer's Disease | Terminated | 2012-10-05 | 2019-07-31 | ClinicalTrials.gov |
| NCT01655186 | A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Effects of … | Phase2 | Renal Insufficiency, Chronic | Withdrawn | 2012-09-30 | 2012-10-31 | ClinicalTrials.gov |
| NCT01689428 | Ism1 Versus EmbryoGen Media for Embryo Culture in Previous Pregnancy Loss Cases | — | Infertility | Unknown | 2012-09-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01689454 | ISM1 Versus EmbrioGen Media for Embryo Culture With Previous Failure Implantati… | — | Infertility | Unknown | 2012-09-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01689116 | Multiple-Dose Study of Effect of Bardoxolone Methyl on QT/QTC Interval Voluntee… | Phase1 | Healthy Volunteers | Completed | 2012-08-31 | 2012-11-30 | ClinicalTrials.gov |
| NCT01652937 | BIIB057 in Subjects With Rheumatoid Arthritis and Inadequate Response to Diseas… | Phase2 | Rheumatoid Arthritis | Withdrawn | 2012-08-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01597297 | Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Abili… | Phase2 | Multiple Sclerosis | Completed | 2012-08-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01576887 | A Double-Blind, Randomized, Placebo-Controlled Safety Study Evaluating the Effe… | Phase2 | End-Stage Renal Disease | Withdrawn | 2012-07-31 | 2012-10-31 | ClinicalTrials.gov |
| NCT01371305 | STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) | Phase2 | Idiopathic Pulmonary Fibrosis (IPF) | Completed | 2012-07-16 | 2017-03-31 | ClinicalTrials.gov |
| NCT01749943 | Validation of Hand Held Dynamometer for Assessment of Lower Limb Muscle Strengt… | — | Multiple Sclerosis | Completed | 2012-07-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01646840 | Study Of The PF-04958242 Blood Concentrations Of A Capsule Formulation Of PF-04… | Phase1 | Healthy | Completed | 2012-07-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01632449 | Study in Healthy Volunteers to Establish the Bioequivalence of Two Different Ma… | Phase1 | Healthy Volunteers | Completed | 2012-07-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01626248 | Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab P… | — | Multiple Sclerosis | Completed | 2012-07-01 | 2013-04-01 | ClinicalTrials.gov |
| NCT01552681 | Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögr… | Phase2 | Primary Sjögren's Syndrome | Terminated | 2012-07-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT01499355 | BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis | Phase2 | Lupus Nephritis | Terminated | 2012-07-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT01598363 | An Open-Label Study of the Effect of Bardoxolone Methyl on the Single Dose Phar… | Phase1 | Healthy Volunteers | Completed | 2012-06-30 | 2012-07-31 | ClinicalTrials.gov |
| NCT01622088 | Phase 3 Extension Study of Dexpramipexole in ALS | Phase3 | Amyotrophic Lateral Sclerosis | Terminated | 2012-06-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01610310 | Peginterferon Beta-1a (BIIB017) Autoinjector Pharmacokinetic Study in Healthy V… | Phase1 | Healthy | Completed | 2012-06-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01656148 | FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on… | Phase4 | Multiple Sclerosis | Completed | 2012-06-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT02142205 | Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants … | Phase4 | Relapsing-Remitting Multiple Sclerosis | Completed | 2012-05-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01641120 | Assessing Tolerability of Avonex Intramuscular Injections | Na | Multiple Sclerosis | Completed | 2012-05-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01551446 | Pilot Assessment of the Effects of Bardoxolone Methyl on Renal Perfusion, Syste… | Phase1 | Renal Insufficiency, Chronic | Withdrawn | 2012-04-30 | 2012-11-30 | ClinicalTrials.gov |
| NCT01563562 | Single-Dose, Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects… | Phase1 | Hepatic Impairment | Completed | 2012-04-30 | 2012-11-30 | ClinicalTrials.gov |
| NCT01549769 | Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients Wit… | Phase1 | Renal Insufficiency, Chronic | Terminated | 2012-04-30 | 2013-10-31 | ClinicalTrials.gov |
| NCT01480063 | An Observational Study to Collect Information on Safety and to Document the Dru… | — | Multiple Sclerosis | Completed | 2012-04-16 | 2019-02-08 | ClinicalTrials.gov |
| NCT01568112 | Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastroint… | Phase3 | Healthy | Completed | 2012-04-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01540630 | A Phase IIa Withdrawal Study of CNV1014802 in Patients With Trigeminal Neuralgia | Phase2 | Trigeminal Neuralgia | Completed | 2012-03-31 | 2014-06-30 | ClinicalTrials.gov |
| NCT01489748 | Canadian Avonex PEN Productivity Study | — | Multiple Sclerosis | Completed | 2012-03-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01591551 | NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple S… | Phase4 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2012-03-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01485003 | Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis … | — | Relapsing-Remitting Multiple Sclerosis | Completed | 2012-02-07 | 2018-11-26 | ClinicalTrials.gov |
| NCT01518660 | Multiple Sclerosis and Progressive Resistance Training | Na | Multiple Sclerosis (Relapsing Remitting) | Completed | 2012-02-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01480076 | Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine… | Phase4 | Multiple Sclerosis | Completed | 2012-02-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01500798 | A Pharmacodynamic Study of Measured Glomerular Filtration Rate in Patients With… | Phase1 | Chronic Kidney Disease | Terminated | 2012-01-31 | 2013-10-01 | ClinicalTrials.gov |
| NCT01453426 | Phase 1 Study to Evaluate the PK, Safety, and Tolerability of BG00012 in Chines… | Phase1 | Healthy | Completed | 2012-01-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01500408 | Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two… | Phase1 | Multiple Sclerosis | Completed | 2012-01-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01518920 | A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss | Phase1 | Hearing Loss, Sensorineural | Completed | 2011-12-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01503866 | A Phase I Study to Investigate the Absorption, Metabolism and Excretion in Heal… | Phase1 | Healthy | Completed | 2011-12-01 | 2011-12-31 | ClinicalTrials.gov |
| NCT01943526 | Ireland Natalizumab (TYSABRI) Observational Program | — | Relapsing-Remitting Multiple Sclerosis | Completed | 2011-11-30 | 2017-12-31 | ClinicalTrials.gov |
| NCT01494701 | An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen … | Phase1 | Spinal Muscular Atrophy | Completed | 2011-11-30 | 2013-01-31 | ClinicalTrials.gov |
| NCT01477801 | Effects of Cholecalciferol Supplementation in Patients With Chronic Heart Failu… | Phase2 | Heart Failure | Unknown | 2011-11-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01518894 | A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242… | Phase1 | Schizophrenia | Completed | 2011-11-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT01462318 | An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yiel… | Phase3 | Relapsing-Remitting Multiple Sclerosis | Completed | 2011-11-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT01461161 | A Single-Dose, Open-Label, Randomized, Food Effect and Blinded, Randomized, Dos… | Phase1 | Healthy Volunteers | Completed | 2011-10-31 | 2011-12-31 | ClinicalTrials.gov |
| NCT01450046 | Vitamin E δ-Tocotrienol Multiple Dose in Healthy Subjects | Phase1 | Pancreatic Cancer | Completed | 2011-10-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT01416181 | A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progress… | Phase3 | Secondary Progressive Multiple Sclerosis | Terminated | 2011-09-13 | 2016-04-13 | ClinicalTrials.gov |
| NCT01446952 | Vitamin E δ-Tocotrienol (VEDT) Single Dose in Healthy Subjects | Phase1 | Pancreatic Cancer | Completed | 2011-09-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT01405872 | Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex… | — | Multiple Sclerosis | Completed | 2011-09-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01407406 | Phase 1 Study to Evaluate the PK, Safety, Tolerability of BIIB023 in Chinese, J… | Phase1 | Healthy Volunteers | Completed | 2011-09-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01416207 | A Multiple-Dose, Open-Label, Phase 1, Pharmacokinetic, Pharmacodynamic, and Saf… | Phase1 | Healthy | Completed | 2011-08-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01424163 | Dexpramipexole Japanese PK Study | Phase1 | Amyotrophic Lateral Sclerosis | Completed | 2011-08-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01420458 | Study in Healthy Volunteers to Establish the BioEquivalence of Two Formulations… | Phase1 | Healthy Volunteers | Completed | 2011-08-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT01405820 | Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens… | Phase2 | Relapsing-Remitting Multiple Sclerosis | Completed | 2011-08-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01405833 | Study of the Safety, Tolerability, Pharmacokinetics and Safety of BG00010 (Neub… | Phase1 | Sciatica | Completed | 2011-07-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01351675 | Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type … | Phase3 | Renal Insufficiency, Chronic | Terminated | 2011-06-30 | 2012-12-31 | ClinicalTrials.gov |
| NCT01365338 | A Study To Assess Effects Of PF-04958242 On Bold Functional Magnetic Resonance … | Phase1 | Healthy Volunteer | Completed | 2011-06-24 | 2012-12-14 | ClinicalTrials.gov |
| NCT01366040 | Avonex PEN Satisfaction and Patients Experience Clinical Trial | — | Multiple Sclerosis | Completed | 2011-06-01 | 2012-05-01 | ClinicalTrials.gov |
| NCT01397539 | Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's Disease | Phase1 | Alzheimer's Disease | Completed | 2011-06-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01511510 | Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeated Dos… | Phase1 | Schizophrenia | Completed | 2011-06-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT01561027 | Crossover Study of CNV1014802 in Subjects With Neuropathic Pain From Lumbosacra… | Phase2 | Lumbosacral Radiculopathy | Completed | 2011-04-30 | 2012-08-31 | ClinicalTrials.gov |
| NCT01332019 | Long-Term Safety and Efficacy Study of Peginterferon Beta-1a | Phase3 | Relapsing Multiple Sclerosis | Completed | 2011-04-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT01330498 | Longitudinal Pharmacokinetic, Pharmacodynamic, Immunological, and Biochemical | — | Multiple Sclerosis | Completed | 2011-04-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01313364 | A Safety Study in Healthy Volunteers of the Single-Use Autoinjector Containing … | Phase1 | Healthy | Terminated | 2011-03-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT01556685 | MATRIX: Measuring Neutralizing Antibodies in the Patients Treated With Interfer… | Phase4 | Multiple Sclerosis | Completed | 2011-03-01 | — | ClinicalTrials.gov |
| NCT01335633 | Psychometric Validation of Cognitive Endpoints | — | Multiple Sclerosis | Completed | 2011-03-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01281111 | Alternate Dosing Regimens of BG00012 in Healthy Volunteers | Phase1 | Healthy | Completed | 2011-02-01 | 2011-03-18 | ClinicalTrials.gov |
| NCT01250678 | Neurocognitive Changes in Patients With Remitting Relapsing Multiple Sclerosis … | — | Multiple Sclerosis | Unknown | 2011-01-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT01235221 | Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Famp… | Phase3 | Multiple Sclerosis | Completed | 2010-12-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01238679 | Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PF-04958242 … | Phase1 | Healthy Volunteers | Terminated | 2010-11-24 | 2011-05-03 | ClinicalTrials.gov |
| NCT01440101 | Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Re… | Phase2 | Multiple Sclerosis | Completed | 2010-11-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01327729 | Y- Shaped Pegylated Interferon (YPEG-IFNα-2a) Plus Ribavirin in Egyptian Patien… | Phase2 | Self Efficacy | Unknown | 2010-11-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT01244139 | Safety Study of BIIB033 in Subjects With Multiple Sclerosis | Phase1 | Relapsing-Remitting Multiple Sclerosis | Completed | 2010-10-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01416155 | Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Part… | Phase2 | Relapsing-Remitting Multiple Sclerosis | Completed | 2010-10-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01215084 | A Pharmacokinetics (PK) and Safety Study of Oral Fampridine-PR 10 mg in Chinese… | Phase1 | Healthy | Completed | 2010-10-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT01211639 | Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal … | — | Progressive Multifocal Leukoencephalopathy | Terminated | 2010-10-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT02004444 | JC Virus Reactivation in Multiple Sclerosis | — | Progressive Multifocal Leukoencephalopathy | Completed | 2010-10-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT01211665 | Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS) | Phase4 | Immune Reconstitution Inflammatory Syndrome | Terminated | 2010-09-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT01185717 | JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS) | — | Multiple Sclerosis | Completed | 2010-09-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01181089 | Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects o… | Phase1 | Secondary Progressive Multiple Sclerosis | Withdrawn | 2010-09-01 | — | ClinicalTrials.gov |
| NCT01337427 | Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of… | Phase3 | Relapsing Remitting Multiple Sclerosis | Withdrawn | 2010-08-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01159483 | First-in-Human Study of PF-04958242 in Healthy Volunteers | Phase1 | Healthy Volunteer | Completed | 2010-07-15 | 2010-10-16 | ClinicalTrials.gov |
| NCT01156298 | Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neu… | — | Multiple Sclerosis | Terminated | 2010-06-01 | 2017-03-01 | ClinicalTrials.gov |
| NCT01065090 | A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Part… | — | Exercise | Completed | 2010-06-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01156311 | BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis | Phase2 | Relapsing-Remitting Multiple Sclerosis | Completed | 2010-06-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT01211678 | Biomarkers of Anti-TNF-α Therapy Efficacy in Rheumatoid Arthritis to Define Unr… | — | Arthritis, Rheumatoid | Completed | 2010-06-01 | 2013-07-01 | ClinicalTrials.gov |
| NCT01119677 | A Study of Avonex to Determine the Effects of Dose Titration on the Incidence o… | Phase1 | Healthy Volunteers | Completed | 2010-05-05 | 2010-10-23 | ClinicalTrials.gov |
| NCT01119781 | A Single-Dose, Pharmacokinetic/Pharmacodynamic (PK/PD), & Safety Study of BIIB0… | Phase1 | Healthy | Completed | 2010-05-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01064401 | Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interfero… | Phase3 | Relapsing-Remitting Multiple Sclerosis | Completed | 2010-05-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01181115 | Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Scle… | Phase3 | Multiple Sclerosis | Completed | 2010-04-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01071512 | Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis | Na | Multiple Sclerosis | Completed | 2010-04-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT01051349 | Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) … | Phase2 | Relapsing-Remitting Multiple Sclerosis | Completed | 2010-03-31 | 2016-08-25 | ClinicalTrials.gov |
| NCT01070823 | JC-Virus (JCV) Antibody Program | — | Multiple Sclerosis | Completed | 2010-03-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01077466 | Natalizumab Treatment of Progressive Multiple Sclerosis | Phase2 | Primary Progressive Multiple Sclerosis | Completed | 2010-03-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT01071083 | Treatment Interruption of Natalizumab | Phase2 | Relapsing Remitting Multiple Sclerosis | Completed | 2010-03-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT01070836 | JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Tr… | — | Relapsing Multiple Sclerosis | Completed | 2010-03-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT01058005 | Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis | Phase3 | Relapsing Remitting Multiple Sclerosis | Terminated | 2010-03-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01070719 | Pharmacokinetic, Immunological and Biochemical Sample Collection and Analysis o… | — | Multiple Sclerosis | Completed | 2010-02-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT01053936 | Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl o… | Phase2 | Renal Insufficiency, Chronic | Completed | 2010-01-31 | 2011-02-28 | ClinicalTrials.gov |
| NCT01132703 | Safety Study of RP-1127 (Glyburide for Injection) in Healthy Volunteers | Phase1 | Traumatic Brain Injury | Completed | 2010-01-07 | 2010-05-07 | ClinicalTrials.gov |
| NCT01056848 | International, Multicenter Study of a Twenty-eight Week, Open-label, Titrated O… | — | Hyponatremia With Normal Extracellular Fluid Volume | Completed | 2010-01-01 | — | ClinicalTrials.gov |
| NCT01052506 | BIIB033 Single Ascending Dose Study in Healthy Volunteer Subjects | Phase1 | Healthy | Completed | 2010-01-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT01035515 | BIIB014 Cardiovascular Monitoring Study | Phase1 | Healthy | Completed | 2009-12-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT01017666 | BIIB014 Effects on the Pharmacokinetics (PK) of Rosiglitazone, Warfarin, and Mi… | Phase1 | Healthy | Completed | 2009-11-01 | 2010-06-02 | ClinicalTrials.gov |
| NCT01017198 | Effect of Food and Antacid on BIIB021 With Advanced Solid Tumors | Phase1 | Advanced Solid Tumors | Completed | 2009-11-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT01004081 | Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aroma… | Phase2 | Breast Cancer | Completed | 2009-11-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT00970580 | A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects W… | Phase1 | Non-Small Cell Lung Cancer | Completed | 2009-10-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT01069913 | Pharmacokinetics Profile Study of BG00012 Standard Formulation and BG00012 Acti… | Phase1 | Healthy | Completed | 2009-10-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00961766 | Evaluate the Safety, Tolerability and Pharmacokinetics of BG00010 (Neublastin) … | Phase1 | Sciatica | Completed | 2009-08-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT00956436 | Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC) | Phase1 | Hepatocellular Carcinoma | Completed | 2009-08-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT00871780 | A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natal… | Phase4 | Relapsing Remitting Multiple Sclerosis (RRMS) | Completed | 2009-08-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT00964288 | Effect of GSK1014802 on Electrical Hyperalgesia and Threshold Tracking in Healt… | Phase1 | Pain, Neuropathic | Terminated | 2009-07-31 | 2009-11-30 | ClinicalTrials.gov |
| NCT00955396 | Study to Investigate the Effect of GSK1014802 on Ambulatory Blood Pressure | Phase1 | Healthy Volunteer | Completed | 2009-07-31 | 2009-12-31 | ClinicalTrials.gov |
| NCT00876876 | International, Multicenter, Open-Label and Randomized Withdrawal Study of Oral … | Phase3 | Hypervolemic Hyponatremia | Withdrawn | 2009-07-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00876798 | A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate t… | Phase3 | Euvolemic Hyponatremia | Completed | 2009-06-01 | — | ClinicalTrials.gov |
| NCT00906399 | Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsi… | Phase3 | Relapsing Multiple Sclerosis | Completed | 2009-06-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT00811889 | Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With T… | Phase2 | Chronic Kidney Disease | Completed | 2009-04-30 | 2010-12-31 | ClinicalTrials.gov |
| NCT00858156 | BG9928 in Subjects With Hepatic Impairment | Phase1 | Hepatic Impairment | Completed | 2009-04-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00884481 | Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participan… | — | Relapsing-Remitting Multiple Sclerosis | Completed | 2009-03-23 | 2011-06-30 | ClinicalTrials.gov |
| NCT00818038 | A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing … | — | Relapsing-Remitting Multiple Sclerosis | Completed | 2009-03-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT00837785 | A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Admini… | Phase1 | Relapsing Remitting Multiple Sclerosis | Completed | 2009-02-28 | 2009-10-31 | ClinicalTrials.gov |
| NCT00835770 | BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (… | Phase3 | Relapsing-Remitting Multiple Sclerosis | Completed | 2009-02-03 | 2019-11-08 | ClinicalTrials.gov |
| NCT00870740 | Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) … | Phase2 | Relapsing-Remitting Multiple Sclerosis | Completed | 2009-02-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT00745316 | Oral Tonapofylline (BG9928) in Patients With Heart Failure and Renal Insufficie… | Phase2 | Renal Insufficiency | Terminated | 2009-02-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00498368 | Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy | Phase4 | IgA Nephropathy | Completed | 2009-02-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT00746941 | Study to Explore the Effect of Mefloquine in Participants With Progressive Mult… | Phase1 | Progressive Multifocal Leukoencephalopathy | Terminated | 2009-01-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00828204 | Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in M… | Phase3 | Multiple Sclerosis | Completed | 2009-01-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00810836 | Efficacy and Safety Study of BG00012 With Methotrexate in Patients With Active … | Phase2 | Rheumatoid Arthritis | Completed | 2008-12-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00752778 | Magnetic Resonance Imaging (MRI) Follow-up of Macrophagic Infiltration in MS Pa… | Phase4 | Multiple Sclerosis | Terminated | 2008-12-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT00801125 | Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy | Phase4 | Crohn's Disease | Withdrawn | 2008-12-01 | — | ClinicalTrials.gov |
| NCT00771043 | A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Pati… | Phase4 | Relapsing-remitting Multiple Sclerosis | Withdrawn | 2008-11-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT00744679 | A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State | Phase4 | Multiple Sclerosis | Completed | 2008-11-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00784836 | Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Bet… | Phase3 | Multiple Sclerosis | Terminated | 2008-10-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00771329 | BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis | Phase1 | Rheumatoid Arthritis | Completed | 2008-10-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT00675428 | Study of Natalizumab in Relapsed/Refractory Multiple Myeloma | Phase1 | Multiple Myeloma | Terminated | 2008-09-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00651443 | Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicul… | Phase1 | Lymphoma, Non-Hodgkin's | Terminated | 2008-08-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00709865 | Study to Assess the Safety and Tolerability of IV Tonapofylline in Subjects Wit… | Phase3 | Renal Insufficiency | Completed | 2008-07-31 | 2009-12-31 | ClinicalTrials.gov |
| NCT04292574 | UK SMA Patient Registry | — | Spinal Muscular Atrophy | Recruiting | 2008-07-13 | 2040-01-01 | ClinicalTrials.gov |
| NCT00726648 | CDP323 Biomarker Study | Phase1 | Relapsing Multiple Sclerosis | Completed | 2008-07-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00707512 | CD INFORM: Investigating Natalizumab Through Further Observational Research and… | — | Crohn's Disease | Terminated | 2008-06-30 | 2015-05-28 | ClinicalTrials.gov |
| NCT00674947 | A Phase I Study of BIIB015 in Relapsed/Refractory Solid Tumors | Phase1 | Solid Tumors | Completed | 2008-06-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT00725933 | Administration of BIIB028 to Subjects With Solid Tumors | Phase1 | Advanced Solid Tumors | Completed | 2008-06-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT00908154 | Safety, Tolerability and Pharmacokinetics of Repeat Doses of GSK1014802. | Phase1 | Bipolar Depression | Completed | 2008-05-31 | 2008-12-31 | ClinicalTrials.gov |
| NCT00675701 | A Study to Define the ECG Effects of Lixivaptan Compared to Placebo and Moxiflo… | Phase1 | Healthy | Completed | 2008-05-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00675883 | COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS | — | Multiple Sclerosis, Relapsing-Remitting | Completed | 2008-05-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT00616434 | A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis | Phase2 | Active Ulcerative Colitis | Completed | 2008-05-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00664027 | Phase IIa Trial to Determine the Effects of Bardoxolone Methyl on Renal Functio… | Phase2 | Diabetic Nephropathy | Completed | 2008-04-30 | 2009-05-31 | ClinicalTrials.gov |
| NCT00660959 | Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the… | Phase3 | Hyponatremia With Normal Extracellular Fluid Volume | Completed | 2008-04-01 | — | ClinicalTrials.gov |
| NCT02125578 | A Multiple Dose Safety Study of PEG-IFN in Healthy Volunteers | Phase1 | Healthy | Completed | 2008-03-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00618267 | ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay. | — | Multiple Sclerosis | Completed | 2008-03-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00618735 | Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid T… | Phase1 | Advanced Solid Tumors | Completed | 2008-02-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00390221 | Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat R… | Phase2 | Relapsing-Remitting Multiple Sclerosis | Completed | 2008-02-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT00801060 | Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituxim… | Phase2 | Chronic Lymphocytic Leukemia | Terminated | 2008-02-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT00618319 | An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in… | Phase2 | GIST | Completed | 2008-02-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT01848028 | PsoBest - The German Psoriasis Registry | — | Psoriasis | Recruiting | 2008-01-01 | 2032-12-01 | ClinicalTrials.gov |
| NCT00536120 | The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets… | Phase4 | Multiple Sclerosis | Completed | 2008-01-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00555724 | Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refracto… | Phase1 | Solid Tumors | Completed | 2008-01-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00412412 | CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study | Phase1 | Breast Cancer | Completed | 2007-12-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT00937677 | Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Fo… | — | Multiple Sclerosis | Completed | 2007-11-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00664573 | 104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthriti… | Phase2 | Rheumatoid Arthritis | Terminated | 2007-11-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00384150 | Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma… | Phase3 | Lymphoma, Non-Hodgkin's | Terminated | 2007-11-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00538343 | RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Bra… | Phase2 | Brain Metastases | Terminated | 2007-10-31 | 2009-01-01 | ClinicalTrials.gov |
| NCT00559702 | Safety Study of Natalizumab to Treat Multiple Sclerosis (MS) | Phase1 | Relapsing-Remitting Multiple Sclerosis | Completed | 2007-10-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT00529113 | Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Ca… | Phase1 | Pancreatic Neoplasms | Terminated | 2007-09-30 | 2009-11-01 | ClinicalTrials.gov |
| NCT00531193 | Using PET Scans to Study Brain Receptor Occupancy of BIIB014 in Healthy Male Vo… | Phase1 | Healthy | Completed | 2007-09-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00516841 | A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinu… | Phase2 | Ovarian Cancer | Terminated | 2007-08-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00464074 | Evaluation of Natalizumab for thE Relief of MS Associated FatiGue | — | Multiple Sclerosis | Completed | 2007-08-01 | 2010-07-31 | ClinicalTrials.gov |
| NCT00442780 | Dose-Finding Safety Study of BIIB014 in Early-Stage Parkinson's Disease | Phase2 | Parkinson's Disease | Completed | 2007-08-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00523328 | BG9924 in Combination With Methotrexate Extension of Study 104RA203 (NCT 004588… | Phase2 | Rheumatoid Arthritis | Terminated | 2007-08-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00664716 | Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Pa… | Phase2 | Rheumatoid Arthritis | Completed | 2007-07-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00635193 | Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Dox… | Phase1 | Ovarian Cancer, Primary Peritoneal Cancer | Completed | 2007-07-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00493298 | Tysabri Observational Program | — | Relapsing-Remitting Multiple Sclerosis | Completed | 2007-06-29 | 2023-11-01 | ClinicalTrials.gov |
| NCT00451451 | Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Re… | Phase3 | Relapsing-Remitting Multiple Sclerosis | Completed | 2007-06-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT00574041 | How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs… | Phase4 | Relapsing Remitting Multiple Sclerosis | Terminated | 2007-06-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00424749 | Rituxan in Churg Strauss Syndrome With Renal Involvement | Phase2 | Churg-Strauss Syndrome | Terminated | 2007-06-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00488566 | GSK Drug Single Dose Escalation And Their Effect On Resting Motor Threshold In … | Phase1 | Bipolar Disorder | Completed | 2007-05-31 | 2008-05-31 | ClinicalTrials.gov |
| NCT00484536 | Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the… | Phase2 | Multiple Sclerosis | Terminated | 2007-05-01 | 2010-07-01 | ClinicalTrials.gov |
| NCT00550849 | Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 in Pa… | Phase1 | Liver Disease | Terminated | 2007-04-30 | 2007-11-30 | ClinicalTrials.gov |
| NCT00438607 | Dose-Finding Safety Study of BIIB014 in Combination With Levodopa in Moderate t… | Phase2 | Parkinson's Disease | Completed | 2007-04-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00458861 | BG9924 in Combination With Methotrexate for Participants With Active Rheumatoid… | Phase2 | Rheumatoid Arthritis | Terminated | 2007-03-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00525343 | Avonex 15 Year Long Term Follow-up Study | — | Multiple Sclerosis | Completed | 2007-03-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00476515 | Rituximab Therapy for Patients on Kidney Transplant Waiting List With Positive … | Phase1 | Kidney Insufficiency | Withdrawn | 2007-03-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00420212 | Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis | Phase3 | Relapsing-Remitting Multiple Sclerosis | Completed | 2007-01-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT00424788 | A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the… | Early_Phase1 | Relapsing Forms of Multiple Sclerosis | Completed | 2007-01-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00578695 | THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class … | Phase3 | Hyponatremia | Completed | 2007-01-01 | — | ClinicalTrials.gov |
| NCT00443651 | A Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Dru… | Phase3 | Rheumatoid Arthritis | Completed | 2007-01-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT00472992 | Pregnancy Exposure Registry for Tysabri® | — | Crohn's Disease | Completed | 2007-01-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT00443443 | A Study of the Safety of Rituxan in Patients With Rheumatoid Arthritis After an… | — | Rheumatoid Arthritis | Completed | 2007-01-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT00477113 | TYSABRI Global Observational Program in Safety | — | Multiple Sclerosis | Completed | 2007-01-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT00369395 | A Study of Volociximab in Metastatic Melanoma | Phase2 | Stage IV Melanoma | Terminated | 2006-12-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00415909 | TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients | Phase2 | Chronic Myelogenous Leukemia | Terminated | 2006-12-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT00391066 | Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR … | Phase2 | Chronic Lymphocytic Leukemia | Terminated | 2006-11-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00527410 | A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Me… | Phase1 | Leptomeningeal Carcinomatosis | Terminated | 2006-10-31 | — | ClinicalTrials.gov |
| NCT00516893 | Natalizumab High Titer Immunogenicity and Safety | Phase2 | Multiple Sclerosis | Completed | 2006-10-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00483847 | TYGRIS - ROW: TYSABRI Global Observational Program in Safety - Rest of World | — | Multiple Sclerosis | Completed | 2006-09-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT00363636 | A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-H… | Phase3 | Lymphoma, Non-Hodgkin's | Terminated | 2006-09-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00379587 | Rituximab for Prevention of Chronic GVHD | Phase1 | Hematological Malignancies | Completed | 2006-09-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT00493467 | Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas | Phase2 | Lymphoma | Completed | 2006-06-01 | 2022-08-11 | ClinicalTrials.gov |
| NCT00298272 | Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotre… | Phase2 | Rheumatoid Arthritis | Terminated | 2006-05-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00529438 | RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies | Phase1 | Advanced Solid Tumors | Completed | 2006-04-30 | 2008-12-01 | ClinicalTrials.gov |
| NCT00493454 | Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas | Phase2 | Lymphoma | Terminated | 2006-04-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT00492570 | GER-009-06-AVX Early Therapy in Multiple Sclerosis | — | Relapsing-Remitting Multiple Sclerosis | Completed | 2006-04-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00299962 | Gene Therapy for Pleural Malignancies | Phase1 | Pleural Mesothelioma | Completed | 2006-03-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00106184 | Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (D… | Phase2 | Myositis | Completed | 2006-03-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00297232 | Natalizumab (Tysabri) Re-Initiation of Dosing | Phase3 | Relapsing-Remitting Multiple Sclerosis | Terminated | 2006-03-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT00306592 | Natalizumab Re-Initiation of Dosing | Phase3 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2006-03-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00344786 | Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL | Phase1 | B-Cell Chronic Lymphocytic Leukemia | Terminated | 2006-02-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00345189 | Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors | Phase1 | Tumors | Completed | 2006-02-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00492765 | Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of R… | Phase4 | Multiple Sclerosis | Completed | 2006-02-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00288990 | A Serologic Study to Correlate Beta-IFN NAb Titers to Beta-IFN Induced Biomarke… | — | Multiple Sclerosis | Completed | 2006-01-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00376129 | Open-Label,Singel Center Study of Alefacept in Patients With Atopic Dermatitis | Phase2 | Atopic Dermatitis | Completed | 2006-01-01 | 2007-01-01 | ClinicalTrials.gov |
| NCT00584935 | Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid | Phase1 | Ocular Cicatricial Pemphigoid | Completed | 2006-01-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00526812 | A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas | Phase1 | Glioma | Completed | 2005-11-30 | — | ClinicalTrials.gov |
| NCT00292422 | Dose-Escalating Study of BG9924 in Combination With Methotrexate in Active Rheu… | Phase2 | Rheumatoid Arthritis | Completed | 2005-11-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00242268 | A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remi… | Phase3 | Relapsing Remitting Multiple Sclerosis | Unknown | 2005-10-01 | — | ClinicalTrials.gov |
| NCT01592474 | Evaluation of Brain Atrophy in CIS Patients on Avonex | — | Multiple Sclerosis | Completed | 2005-10-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT00642655 | Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal Tr… | Phase1 | Kidney Transplant | Completed | 2005-09-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00915577 | Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-F… | Phase3 | Multiple Sclerosis | Completed | 2005-08-01 | 2006-04-01 | ClinicalTrials.gov |
| NCT00301002 | Study to Evaluate the Efficacy of Alefacept to Treat Palmar Plantar Pustulosis | Phase2 | Psoriasis | Completed | 2005-06-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00697996 | Rituximab for Pediatric Renal Transplant Rejection | Phase2 | Kidney Transplantation | Completed | 2005-06-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00463710 | Effect of Interferon Beta-1a (Avonex®) on Changes of Non-conventional MRI Measu… | — | Multiple Sclerosis | Completed | 2005-06-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00107861 | Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorecta… | Phase1 | Colorectal Carcinoma | Completed | 2005-05-01 | 2006-09-01 | ClinicalTrials.gov |
| NCT00319930 | Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positiv… | Phase1 | Chronic Lymphocytic Leukemia | Terminated | 2005-05-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00119730 | Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma | Phase2 | Mantle Cell Lymphoma | Completed | 2005-02-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT00422617 | Evaluate the Efficacy and Safety of One Course of Amevive in Taiwan Patients | Na | Chronic Plaque Psoriasis | Completed | 2005-01-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00102024 | Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorec… | Phase1 | Colorectal Cancer | Terminated | 2005-01-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT00588822 | Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal … | Phase2 | Precancerous Condition | Terminated | 2005-01-01 | 2011-02-01 | ClinicalTrials.gov |
| NCT00105170 | Safety and Tolerability of hCBE-11 in Subjects With Advanced Solid Tumors | Phase1 | Tumors | Terminated | 2005-01-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00168701 | Efficacy and Safety of BG00012 in MS | Phase2 | Multiple Sclerosis | Completed | 2004-10-01 | 2006-03-31 | ClinicalTrials.gov |
| NCT00831649 | A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerabilit… | Phase2 | Rheumatoid Arthritis | Terminated | 2004-09-01 | — | ClinicalTrials.gov |
| NCT00223301 | Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept… | Phase2 | Multiple Sclerosis | Completed | 2004-07-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT00168753 | Community Based Trial for AMEVIVE® | Phase4 | Moderate to Severe Chronic Plaque Psoriasis | Completed | 2004-07-01 | 2005-03-01 | ClinicalTrials.gov |
| NCT00290511 | Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for Hi… | Phase2 | Lymphoma | Completed | 2004-06-29 | 2021-02-12 | ClinicalTrials.gov |
| NCT00280241 | Protocol for the Treatment of Patients With Previously Untreated Chronic Lympho… | Phase2 | Chronic Lymphocytic Leukemia | Completed | 2004-06-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT02097745 | A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients … | Phase3 | Rheumatoid Arthritis | Completed | 2004-06-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT00186589 | 90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplan… | Phase1 | Lymphoma, Non-Hodgkin | Completed | 2004-05-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00493077 | Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Ant… | Phase4 | Multiple Sclerosis | Completed | 2004-05-01 | 2006-05-01 | ClinicalTrials.gov |
| NCT00083759 | Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Meth… | Phase2 | Rheumatoid Arthritis | Terminated | 2004-05-01 | — | ClinicalTrials.gov |
| NCT00135733 | A Safety and Efficacy Study of Alefacept in the Treatment of Moderate to Severe… | Phase2 | Lichen Planus | Terminated | 2004-04-01 | 2004-12-01 | ClinicalTrials.gov |
| NCT00223457 | Factors That Influence Compliance With Disease-Modifying Therapy in Multiple Sc… | — | Multiple Sclerosis | Completed | 2004-04-01 | 2005-09-01 | ClinicalTrials.gov |
| NCT00103558 | Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocyt… | Phase1 | Chronic Lymphocytic Leukemia | Completed | 2004-03-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00078611 | A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Acti… | Phase3 | Crohn's Disease | Completed | 2004-03-01 | 2005-03-01 | ClinicalTrials.gov |
| NCT00794807 | Safety and Tolerability of Repeat Courses of IM Alefacept | Phase4 | Chronic Plaque Psoriasis | Completed | 2004-02-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00099489 | Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinati… | Phase2 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Completed | 2004-02-01 | 2006-02-01 | ClinicalTrials.gov |
| NCT00168714 | Pregnancy Exposure Registry for Avonex (Interferon Beta-1a) | — | Prenatal Exposure Delayed Effects | Completed | 2004-02-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT00387023 | Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma | Na | Non-Hodgkin's Lymphoma | Completed | 2004-02-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT00246324 | Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to… | Phase4 | Multiple Sclerosis | Completed | 2003-12-01 | 2009-10-01 | ClinicalTrials.gov |
| NCT00117156 | Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymp… | Phase2 | Lymphoma, Non-Hodgkin | Completed | 2003-12-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT00276172 | Open-Label Natalizumab Safety Extension Study | Phase3 | Multiple Sclerosis | Completed | 2003-12-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT00232193 | Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MS | — | Relapsing-remitting Multiple Sclerosis | Completed | 2003-12-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00774202 | Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, … | Phase2 | Immune Thrombocytopenic Purpura | Completed | 2003-11-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00177554 | Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma | Phase2 | Non-Hodgkin Lymphoma | Completed | 2003-11-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00193505 | Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refrac… | Phase2 | Non-Hodgkins Lymphoma | Completed | 2003-10-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00673556 | A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients fo… | Phase3 | Chronic Plaque Psoriasis | Completed | 2003-10-01 | 2005-05-01 | ClinicalTrials.gov |
| NCT00493116 | Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neut… | Phase4 | Relapsing-Remitting Multiple Sclerosis | Completed | 2003-10-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00090038 | Effect of Rituximab on Immunological Recall Response to Specific Antigens in th… | Phase4 | Non-Hodgkin's Lymphoma | Completed | 2003-10-01 | 2007-11-01 | ClinicalTrials.gov |
| NCT00143806 | Transitioning From Cyclosporine to Alefacept in Psoriasis | Phase2 | Psoriasis | Completed | 2003-10-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00150982 | Alefacept Mechanism of Action in Psoriasis | Phase2 | Psoriasis | Completed | 2003-09-01 | 2005-02-01 | ClinicalTrials.gov |
| NCT01538472 | Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma | Phase1 | Lymphoma | Completed | 2003-09-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT00659412 | A Placebo-controlled Study With an Extension Examining the Safety and Efficacy … | Phase2 | Psoriatic Arthritis | Completed | 2003-09-01 | 2005-03-01 | ClinicalTrials.gov |
| NCT00913250 | A Bioequivalence Study of Serum Free Avonex and Serum Containing Avonex in Heal… | Phase1 | Multiple Sclerosis | Completed | 2003-08-01 | 2003-10-01 | ClinicalTrials.gov |
| NCT00090051 | FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in R… | Phase3 | Chronic Lymphocytic Leukemia | Completed | 2003-07-31 | 2012-05-31 | ClinicalTrials.gov |
| NCT00674063 | A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept i… | Phase3 | Chronic Plaque Psoriasis | Completed | 2003-07-01 | 2004-04-01 | ClinicalTrials.gov |
| NCT00112034 | AVONEX® Combination Trial - "ACT" | Phase4 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2003-06-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00097760 | Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relaps… | Phase2 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2003-06-01 | 2004-03-01 | ClinicalTrials.gov |
| NCT00168727 | Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-H… | Phase4 | Lymphoma, Non-Hodgkin | Completed | 2003-06-01 | 2005-10-31 | ClinicalTrials.gov |
| NCT01713738 | Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic… | Phase1 | Idiopathic Thrombocytopenic Purpura (ITP) | Completed | 2003-05-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00468546 | A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combinat… | Phase3 | Rheumatoid Arthritis | Completed | 2003-05-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT00492466 | Investigating if Interferon-Beta Can be Used in Patients With MS After They Hav… | Phase4 | Relapsing-Remitting Multiple Sclerosis | Completed | 2003-03-01 | 2006-08-01 | ClinicalTrials.gov |
| NCT00057343 | Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma | Phase3 | Non-Hodgkin's Lymphoma | Terminated | 2003-03-01 | — | ClinicalTrials.gov |
| NCT00912860 | Immunogenicity and Safety Study of Serum-Free Avonex | Phase2 | Multiple Sclerosis | Completed | 2003-01-01 | 2005-01-01 | ClinicalTrials.gov |
| NCT00168766 | Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatmen… | Phase4 | Relapsing-remitting Multiple Sclerosis | Completed | 2003-01-01 | 2008-11-01 | ClinicalTrials.gov |
| NCT00233662 | Safety and Tolerability of Repeat Courses of IM Alefacept | Phase3 | Chronic Plaque Psoriasis | Completed | 2002-12-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00048555 | Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of… | Phase1 | Non-Hodgkin's Lymphoma | Completed | 2002-11-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00913666 | Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunom… | Phase4 | Multiple Sclerosis | Completed | 2002-11-01 | 2004-11-01 | ClinicalTrials.gov |
| NCT00048737 | Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymp… | Phase1 | Lymphoma | Completed | 2002-10-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT00046488 | Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemi… | Phase1 | Chronic Lymphocytic Leukemia | Completed | 2002-09-01 | 2010-03-01 | ClinicalTrials.gov |
| NCT00599274 | Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Re… | — | Multiple Sclerosis | Completed | 2002-08-01 | 2003-05-01 | ClinicalTrials.gov |
| NCT00280956 | Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease | Phase4 | Crohn's Disease | Completed | 2002-07-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT00031083 | Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the … | Phase1 | Glioblastoma Multiforme | Completed | 2002-04-02 | 2003-10-10 | ClinicalTrials.gov |
| NCT00055536 | Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatmen… | Phase2 | Crohn's Disease | Completed | 2002-04-01 | 2003-07-01 | ClinicalTrials.gov |
| NCT00193440 | Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Lo… | Phase2 | Non-Hodgkins Lymphoma | Completed | 2002-04-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00055367 | Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Activ… | Phase2 | Crohn's Disease | Completed | 2002-04-01 | 2004-05-01 | ClinicalTrials.gov |
| NCT00038623 | Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relap… | Phase2 | Lymphoma, Mantle-Cell | Completed | 2002-04-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT00032786 | Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease | Phase3 | Crohn's Disease | Completed | 2002-03-01 | 2004-03-01 | ClinicalTrials.gov |
| NCT00030966 | Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment … | Phase3 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2002-01-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00575068 | Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma | Phase1 | Non-Hodgkin's Lymphoma | Completed | 2002-01-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00031642 | Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Au… | Phase1 | Lymphoma | Completed | 2002-01-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00692172 | Open-label Study to Evaluate Safety of Multiple Courses of IM Alefacept During … | Phase3 | Psoriasis | Completed | 2001-12-01 | 2004-11-01 | ClinicalTrials.gov |
| NCT00032799 | Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease | Phase3 | Crohn's Disease | Completed | 2001-12-01 | 2003-09-01 | ClinicalTrials.gov |
| NCT00027300 | Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis | Phase3 | Multiple Sclerosis, Relapsing-Remitting | Completed | 2001-11-01 | 2005-01-01 | ClinicalTrials.gov |
| NCT00037102 | Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexat… | Phase4 | Multiple Sclerosis | Completed | 2001-07-01 | 2003-12-01 | ClinicalTrials.gov |
| NCT00179478 | Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis | Phase4 | Multiple Sclerosis | Completed | 2001-02-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT01863069 | Avonex®: Safety, Blood Levels and Effects | Phase1 | Multiple Sclerosis (MS) | Completed | 2001-01-01 | 2001-10-01 | ClinicalTrials.gov |
| NCT00005592 | Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lympho… | Phase2 | Lymphoma | Completed | 1999-11-01 | 2005-11-01 | ClinicalTrials.gov |
| NCT00534261 | Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interf… | Phase4 | Relapsing Remitting Multiple Sclerosis | Completed | 1999-11-01 | 2004-02-01 | ClinicalTrials.gov |
| NCT00915460 | Open-Label Safety Extension Study of Avonex | Phase4 | Multiple Sclerosis | Completed | 1999-09-01 | 2003-07-01 | ClinicalTrials.gov |
| NCT00168740 | Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Kno… | Phase3 | Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma | Completed | 1995-04-01 | — | ClinicalTrials.gov |
Total clinical trials: 703
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT05531565 |
| Litifilimab | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT05531565 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Felzartamab | Other | Phase PHASE3 | Antibody-mediated Rejection | ENROLLING_BY_INVITATION | NCT07444489 |
| Zuranolone | Other | Preclinical | Depression, Postpartum | COMPLETED | NCT07047820 |
| Zuranolone | Other | Preclinical | Postpartum Depression | RECRUITING | NCT07398469 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Placebo | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT05531565 |
| Litifilimab | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT05531565 |
| Placebo | Other | Phase PHASE2 | Graves' Disease | RECRUITING | NCT07722546 |
| Felzartamab | Other | Phase PHASE2 | Graves' Disease | RECRUITING | NCT07722546 |
| Omaveloxolone | Other | Phase PHASE1 | Friedreich Ataxia | ACTIVE_NOT_RECRUITING | NCT06054893 |
| Omaveloxolone Capsules, 150 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 300 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 160 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 80 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 40 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 20 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Placebo | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 10 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 5 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 2.5 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| ThecaFlex DRx System | Other | Phase PHASE1 | Muscular Atrophy, Spinal | RECRUITING | NCT06555419 |
| Nusinersen | Other | Phase PHASE1 | Muscular Atrophy, Spinal | RECRUITING | NCT06555419 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Placebo | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT05531565 |
| Litifilimab | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT05531565 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Antibody-mediated Rejection | ENROLLING_BY_INVITATION | NCT07444489 |
| ThecaFlex DRx System | Other | Phase PHASE1 | Muscular Atrophy, Spinal | RECRUITING | NCT06555419 |
| Nusinersen | Other | Phase PHASE1 | Muscular Atrophy, Spinal | RECRUITING | NCT06555419 |
| Placebo | Other | Phase PHASE2 | Graves' Disease | RECRUITING | NCT07722546 |
| Felzartamab | Other | Phase PHASE2 | Graves' Disease | RECRUITING | NCT07722546 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Placebo | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT05531565 |
| Litifilimab | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT05531565 |
| Patient Registry | Other | Preclinical | Spinal Muscular Atrophy | RECRUITING | NCT04292574 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| ThecaFlex DRx System | Other | Approved | Spinal Muscular Atrophy | RECRUITING | NCT05866419 |
| Placebo | Other | Phase PHASE3 | Prediabetes | RECRUITING | NCT07448974 |
| Vitamin D (Cholecalciferol ) | Other | Phase PHASE3 | Prediabetes | RECRUITING | NCT07448974 |
| Salanersen | Other | Phase PHASE3 | Muscular Atrophy, Spinal | RECRUITING | NCT07221669 |
| Placebo | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT05531565 |
| Litifilimab | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT05531565 |
| Tofersen | Other | Phase PHASE4 | Amyotrophic Lateral Sclerosis | ACTIVE_NOT_RECRUITING | NCT07223723 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Dimethyl Fumarate | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05658497 |
| Tysabri | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05658497 |
| Avonex | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05658497 |
| Diroximel Fumarate | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05658497 |
| Placebo | Other | Phase PHASE2 | Graves' Disease | RECRUITING | NCT07722546 |
| Felzartamab | Other | Phase PHASE2 | Graves' Disease | RECRUITING | NCT07722546 |
| Nusinersen | Other | Phase PHASE3 | Muscular Atrophy, Spinal | COMPLETED | NCT04729907 |
| Salanersen | Other | Phase PHASE3 | Muscular Atrophy, Spinal | RECRUITING | NCT07221669 |
| Sham Procedure | Procedure | Phase PHASE3 | Muscular Atrophy, Spinal | RECRUITING | NCT07444450 |
| Salanersen | Other | Phase PHASE3 | Muscular Atrophy, Spinal | RECRUITING | NCT07444450 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Antibody-mediated Rejection | ENROLLING_BY_INVITATION | NCT07444489 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| BIIB059 (litifilimab) | Other | Phase PHASE3 | Subacute Cutaneous Lupus Erythematosus | ENROLLING_BY_INVITATION | NCT06044337 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Salanersen | Other | Phase PHASE3 | Muscular Atrophy, Spinal | RECRUITING | NCT07221669 |
| Placebo | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT05531565 |
| Litifilimab | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT05531565 |
| Nusinersen Sodium Injection | Other | Preclinical | Muscular Atrophy, Spinal | ACTIVE_NOT_RECRUITING | NCT04317794 |
| Placebo | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT05531565 |
| Litifilimab | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT05531565 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | RECRUITING | NCT07662148 |
| BIIB144 | Other | Phase PHASE1 | Healthy Volunteer | RECRUITING | NCT07662148 |
| Placebo | Other | Phase PHASE2 | Graves' Disease | NOT_YET_RECRUITING | NCT07722546 |
| Felzartamab | Other | Phase PHASE2 | Graves' Disease | NOT_YET_RECRUITING | NCT07722546 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE1 | Lupus Nephritis | COMPLETED | NCT06064929 |
| Placebo | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT05531565 |
| Litifilimab | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT05531565 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Diranersen | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06454721 |
| [89Zr]Zr-DFO-Diranersen | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06454721 |
| Omaveloxolone | Other | Preclinical | Friedreich Ataxia | RECRUITING | NCT06628687 |
| BIIB115-Matching Placebo | Other | Phase PHASE1 | Healthy Volunteer | ACTIVE_NOT_RECRUITING | NCT05575011 |
| BIIB115 | Other | Phase PHASE1 | Healthy Volunteer | ACTIVE_NOT_RECRUITING | NCT05575011 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Placebo | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT05531565 |
| Litifilimab | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT05531565 |
| Salanersen | Other | Phase PHASE3 | Muscular Atrophy, Spinal | RECRUITING | NCT07221669 |
| Nutrition therapy | Drug | Approved | Gestational Diabetes Mellitus (GDM) | RECRUITING | NCT07685015 |
| Insulin therapy | Drug | Approved | Gestational Diabetes Mellitus (GDM) | RECRUITING | NCT07685015 |
| Folic acid 200 µg | Other | Approved | Gestational Diabetes Mellitus (GDM) | RECRUITING | NCT07685015 |
| Myo-inositol 2 g + Folic acid 200 µg | Other | Approved | Gestational Diabetes Mellitus (GDM) | RECRUITING | NCT07685015 |
| BIIB112 | Other | Phase PHASE3 | Choroideremia | COMPLETED | NCT03584165 |
| BIIB111 | Other | Phase PHASE3 | Choroideremia | COMPLETED | NCT03584165 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Diranersen-matching placebo | Other | Phase PHASE2 | Mild Cognitive Impairment Due to Alzheimer's Disease | ACTIVE_NOT_RECRUITING | NCT05399888 |
| Diranersen | Other | Phase PHASE2 | Mild Cognitive Impairment Due to Alzheimer's Disease | ACTIVE_NOT_RECRUITING | NCT05399888 |
| Felzartamab | Other | Phase PHASE3 | Antibody-mediated Rejection | ENROLLING_BY_INVITATION | NCT07444489 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Placebo | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT05531565 |
| Litifilimab | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT05531565 |
| Tofersen | Other | Phase PHASE2 | ALS (Amyotrophic Lateral Sclerosis) | RECRUITING | NCT07294144 |
| Placebo | Other | Phase PHASE2 | Overweight | RECRUITING | NCT07009171 |
| KDS2010 | Other | Phase PHASE2 | Overweight | RECRUITING | NCT07009171 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | NOT_YET_RECRUITING | NCT07662148 |
| BIIB144 | Other | Phase PHASE1 | Healthy Volunteer | NOT_YET_RECRUITING | NCT07662148 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Placebo | Other | Phase PHASE2 | Mild Cognitive Impairment (MCI) | RECRUITING | NCT07027072 |
| KDS2010 | Other | Phase PHASE2 | Mild Cognitive Impairment (MCI) | RECRUITING | NCT07027072 |
| Placebo | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT05531565 |
| Litifilimab | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT05531565 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Placebo | Other | Phase PHASE2 | Overweight | RECRUITING | NCT07009171 |
| KDS2010 | Other | Phase PHASE2 | Overweight | RECRUITING | NCT07009171 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Placebo | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT05531565 |
| Litifilimab | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING | NCT05531565 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Placebo | Other | Phase PHASE3 | Friedreich Ataxia | RECRUITING | NCT06953583 |
| Omaveloxolone | Other | Phase PHASE3 | Friedreich Ataxia | RECRUITING | NCT06953583 |
| Sham Procedure | Procedure | Phase PHASE3 | Muscular Atrophy, Spinal | NOT_YET_RECRUITING | NCT07444450 |
| Salanersen | Other | Phase PHASE3 | Muscular Atrophy, Spinal | NOT_YET_RECRUITING | NCT07444450 |
| Salanersen | Other | Phase PHASE3 | Muscular Atrophy, Spinal | RECRUITING | NCT07221669 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Tofersen | Other | Phase PHASE2 | ALS (Amyotrophic Lateral Sclerosis) | RECRUITING | NCT07294144 |
| Salanersen | Other | Phase PHASE3 | Muscular Atrophy, Spinal | RECRUITING | NCT07221669 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Sham Procedure | Procedure | Phase PHASE3 | Muscular Atrophy, Spinal | NOT_YET_RECRUITING | NCT07444450 |
| Salanersen | Other | Phase PHASE3 | Muscular Atrophy, Spinal | NOT_YET_RECRUITING | NCT07444450 |
| Placebo | Other | Phase PHASE3 | Antibody-mediated Rejection | ACTIVE_NOT_RECRUITING | NCT06685757 |
| Felzartamab | Other | Phase PHASE3 | Antibody-mediated Rejection | ACTIVE_NOT_RECRUITING | NCT06685757 |
| BIIB080-matching placebo | Other | Phase PHASE2 | Mild Cognitive Impairment Due to Alzheimer's Disease | ACTIVE_NOT_RECRUITING | NCT05399888 |
| BIIB080 | Other | Phase PHASE2 | Mild Cognitive Impairment Due to Alzheimer's Disease | ACTIVE_NOT_RECRUITING | NCT05399888 |
| BIIB122-Matching Placebo | Other | Phase PHASE2 | Parkinson Disease | COMPLETED | NCT05348785 |
| BIIB122 | Other | Phase PHASE2 | Parkinson Disease | COMPLETED | NCT05348785 |
| Siponimod | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Ponesimod | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Peginterferon beta-1a | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Ozanimod | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Ofatumumab | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Ocrelizumab | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Natalizumab | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Interferon beta | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Glatiramer acetate | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Fingolimod | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Alemtuzumab | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Diroximel Fumarate | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Placebo | Other | Phase PHASE3 | Friedreich Ataxia | RECRUITING | NCT06953583 |
| Omaveloxolone | Other | Phase PHASE3 | Friedreich Ataxia | RECRUITING | NCT06953583 |
| Communication with the clinic | Other | Approved | Multiple Sclerosis | COMPLETED | NCT02454907 |
| Siponimod | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Ponesimod | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Peginterferon beta-1a | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Ozanimod | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Ofatumumab | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Ocrelizumab | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Natalizumab | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Interferon beta | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Glatiramer acetate | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Fingolimod | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Alemtuzumab | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Diroximel Fumarate | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05688436 |
| Placebo | Other | Phase PHASE3 | Friedreich Ataxia | RECRUITING | NCT06953583 |
| Omaveloxolone | Other | Phase PHASE3 | Friedreich Ataxia | RECRUITING | NCT06953583 |
| BIIB122-Matching Placebo | Other | Phase PHASE2 | Parkinson Disease | COMPLETED | NCT05348785 |
| BIIB122 | Other | Phase PHASE2 | Parkinson Disease | COMPLETED | NCT05348785 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| AI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| PFS | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| OBI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| Litifilimab | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| AI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| PFS | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| OBI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| Litifilimab | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| AI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| PFS | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| OBI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| Litifilimab | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| AI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| PFS | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| OBI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| Litifilimab | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| AI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| PFS | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| OBI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| Litifilimab | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| AI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| PFS | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| OBI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| Litifilimab | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| AI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| PFS | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| OBI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| Litifilimab | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| AI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| PFS | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| OBI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| Litifilimab | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| AI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| PFS | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| OBI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| Litifilimab | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| AI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| PFS | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| OBI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| Litifilimab | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| AI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| PFS | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| OBI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| Litifilimab | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Nusinersen | Other | Phase PHASE3 | Spinal Muscular Atrophy | ACTIVE_NOT_RECRUITING | NCT05067790 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Nusinersen | Other | Phase PHASE3 | Spinal Muscular Atrophy | ACTIVE_NOT_RECRUITING | NCT05067790 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Nusinersen | Other | Phase PHASE3 | Spinal Muscular Atrophy | ACTIVE_NOT_RECRUITING | NCT05067790 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Nusinersen | Other | Phase PHASE3 | Spinal Muscular Atrophy | ACTIVE_NOT_RECRUITING | NCT05067790 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Nusinersen | Other | Phase PHASE3 | Spinal Muscular Atrophy | ACTIVE_NOT_RECRUITING | NCT05067790 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Interferon β-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Interferon β-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Interferon β-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Interferon β-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Interferon β-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Interferon β-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Interferon β-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Interferon β-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Interferon β-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Interferon β-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Interferon β-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Interferon β-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Interferon β-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Interferon β-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Interferon β-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Interferon β-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Interferon beta-1a | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT00534261 |
| Interferon beta-1a | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT00534261 |
| rituximab | Other | Phase PHASE3 | Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma | COMPLETED | NCT00168740 |
| Simvastatin | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | UNKNOWN | NCT00242268 |
| Simvastatin | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | UNKNOWN | NCT00242268 |
| Rituxan (rituximab) | Other | Phase PHASE3 | Non-Hodgkin's Lymphoma | TERMINATED | NCT00057343 |
| Zevalin (ibritumomab tiuxetan) | Other | Phase PHASE3 | Non-Hodgkin's Lymphoma | TERMINATED | NCT00057343 |
| Rituxan (rituximab) | Other | Phase PHASE3 | Non-Hodgkin's Lymphoma | TERMINATED | NCT00057343 |
| Zevalin (ibritumomab tiuxetan) | Other | Phase PHASE3 | Non-Hodgkin's Lymphoma | TERMINATED | NCT00057343 |
| Rituxan (rituximab) | Other | Phase PHASE3 | Non-Hodgkin's Lymphoma | TERMINATED | NCT00057343 |
| Zevalin (ibritumomab tiuxetan) | Other | Phase PHASE3 | Non-Hodgkin's Lymphoma | TERMINATED | NCT00057343 |
| Alefacept | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT00301002 |
| Alefacept | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT00301002 |
| Alefacept | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT00301002 |
| Alefacept (Amevive) | Other | Approved | Chronic Plaque Psoriasis | COMPLETED | NCT00422617 |
| Factors that influence compliance | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT00223457 |
| Factors that influence compliance | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT00223457 |
| Factors that influence compliance | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT00223457 |
| Alefacept | Other | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT00376129 |
| Alefacept | Other | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT00376129 |
| low immunogenic interferon-beta-1a | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00493077 |
| low immunogenic interferon-beta-1a | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00493077 |
| methylprednisolone | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00492466 |
| Interferon-beta-1a | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00492466 |
| methylprednisolone | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00492466 |
| Interferon-beta-1a | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00492466 |
| BG9924 | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00292422 |
| BG9924 | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00292422 |
| BG9924 | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00292422 |
| Transitioning patients from cyclosporine to alefacept | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT00143806 |
| Transitioning patients from cyclosporine to alefacept | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT00143806 |
| Placebo | Other | Phase PHASE2 | Parkinson's Disease | COMPLETED | NCT00442780 |
| BIIB014 | Other | Phase PHASE2 | Parkinson's Disease | COMPLETED | NCT00442780 |
| Placebo | Other | Phase PHASE2 | Parkinson's Disease | COMPLETED | NCT00442780 |
| BIIB014 | Other | Phase PHASE2 | Parkinson's Disease | COMPLETED | NCT00442780 |
| Placebo | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00030966 |
| Natalizumab | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00030966 |
| Placebo | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00030966 |
| Natalizumab | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00030966 |
| Interferon Beta-1a | Other | Phase PHASE2 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | COMPLETED | NCT00099489 |
| Interferon Beta-1a | Other | Phase PHASE2 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | COMPLETED | NCT00099489 |
| 90Y-IDEC-159 | Other | Phase PHASE1 | Colorectal Cancer | TERMINATED | NCT00102024 |
| 111In-IDEC-159 | Other | Phase PHASE1 | Colorectal Cancer | TERMINATED | NCT00102024 |
| Unconjugated IDEC-159 | Other | Phase PHASE1 | Colorectal Cancer | TERMINATED | NCT00102024 |
| 90Y-IDEC-159 | Other | Phase PHASE1 | Colorectal Cancer | TERMINATED | NCT00102024 |
| 111In-IDEC-159 | Other | Phase PHASE1 | Colorectal Cancer | TERMINATED | NCT00102024 |
| Unconjugated IDEC-159 | Other | Phase PHASE1 | Colorectal Cancer | TERMINATED | NCT00102024 |
| Omaveloxolone | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT07297199 |
| Observational | Other | Preclinical | Spinal Muscular Atrophy | RECRUITING | NCT06955897 |
| Omaveloxolone | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT07297199 |
| Observational | Other | Preclinical | Spinal Muscular Atrophy | RECRUITING | NCT06955897 |
| Omaveloxolone | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT07297199 |
| Observational | Other | Preclinical | Spinal Muscular Atrophy | RECRUITING | NCT06955897 |
| Omaveloxolone | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT07297199 |
| Observational | Other | Preclinical | Spinal Muscular Atrophy | RECRUITING | NCT06955897 |
| Omaveloxolone | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT07297199 |
| Observational | Other | Preclinical | Spinal Muscular Atrophy | RECRUITING | NCT06955897 |
| Omaveloxolone | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT07297199 |
| Observational | Other | Preclinical | Spinal Muscular Atrophy | RECRUITING | NCT06955897 |
| IV methylprednisolone | Other | Phase PHASE4 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00112034 |
| Methotrexate | Other | Phase PHASE4 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00112034 |
| Chemotherapy and Radioimmunotherapy | Drug | Phase PHASE2 | Non-Hodgkin Lymphoma | COMPLETED | NCT00177554 |
| Chemotherapy and Radioimmunotherapy | Drug | Phase PHASE2 | Non-Hodgkin Lymphoma | COMPLETED | NCT00177554 |
| [11C]SCH442416 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00531193 |
| BIIB014 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00531193 |
| [11C]SCH442416 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00531193 |
| BIIB014 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00531193 |
| Mechanism of action of alefacept | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT00150982 |
| Mechanism of action of alefacept | Other | Phase PHASE2 | Psoriasis | COMPLETED | NCT00150982 |
| Interferon beta-1a | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT00574041 |
| Interferon beta-1a | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT00574041 |
| Alefacept | Other | Phase PHASE4 | Chronic Plaque Psoriasis | COMPLETED | NCT00794807 |
| Alefacept | Other | Phase PHASE4 | Chronic Plaque Psoriasis | COMPLETED | NCT00794807 |
| Alefacept | Other | Phase PHASE4 | Chronic Plaque Psoriasis | COMPLETED | NCT00794807 |
| Rituximab for transplant rejection | Other | Phase PHASE2 | Kidney Transplantation | COMPLETED | NCT00697996 |
| Rituximab for transplant rejection | Other | Phase PHASE2 | Kidney Transplantation | COMPLETED | NCT00697996 |
| Placebo | Other | Phase PHASE2 | Lichen Planus | TERMINATED | NCT00135733 |
| Amevive (Alefacept) | Other | Phase PHASE2 | Lichen Planus | TERMINATED | NCT00135733 |
| Placebo | Other | Phase PHASE2 | Lichen Planus | TERMINATED | NCT00135733 |
| Amevive (Alefacept) | Other | Phase PHASE2 | Lichen Planus | TERMINATED | NCT00135733 |
| Placebo | Other | Phase PHASE2 | Lichen Planus | TERMINATED | NCT00135733 |
| Amevive (Alefacept) | Other | Phase PHASE2 | Lichen Planus | TERMINATED | NCT00135733 |
| Interferon beta-1a (Avonex) | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00913666 |
| Interferon beta-1a (Avonex) | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00913666 |
| Interferon beta-1a (Avonex) | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00913666 |
| Interferon beta-1a (Avonex) | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00913666 |
| Serum Free Avonex | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT00913250 |
| Serum containing Avonex | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT00913250 |
| Serum Free Avonex | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT00913250 |
| Serum containing Avonex | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT00913250 |
| CNF2024 (BIIB021) | Other | Phase PHASE1 | B-Cell Chronic Lymphocytic Leukemia | TERMINATED | NCT00344786 |
| Single-use autoinjector | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT00915577 |
| Interferon beta-1a | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT00915577 |
| Single-use autoinjector | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT00915577 |
| Interferon beta-1a | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT00915577 |
| Interferon beta-1a (Avonex) | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00915460 |
| Interferon beta-1a (Avonex) | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00915460 |
| Interferon beta-1a | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT00912860 |
| Interferon beta-1a | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT00912860 |
| Placebo | Other | Phase PHASE2 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00097760 |
| Natalizumab | Other | Phase PHASE2 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00097760 |
| Placebo | Other | Phase PHASE2 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00097760 |
| Natalizumab | Other | Phase PHASE2 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00097760 |
| Placebo | Other | Phase PHASE2 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00097760 |
| Natalizumab | Other | Phase PHASE2 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00097760 |
| Natalizumab | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT00276172 |
| Placebo | Other | Phase PHASE2 | Parkinson's Disease | COMPLETED | NCT00438607 |
| BIIB014 | Other | Phase PHASE2 | Parkinson's Disease | COMPLETED | NCT00438607 |
| CNF2024 | Other | Phase PHASE1 | Tumors | COMPLETED | NCT00345189 |
| CNF2024 | Other | Phase PHASE1 | Tumors | COMPLETED | NCT00345189 |
| Ad.hIFN-β (BG00001, IDEC-201) | Other | Phase PHASE1 | Colorectal Carcinoma | COMPLETED | NCT00107861 |
| Ad.hIFN-β (BG00001, IDEC-201) | Other | Phase PHASE1 | Colorectal Carcinoma | COMPLETED | NCT00107861 |
| natalizumab treatment | Drug | Phase EARLY_PHASE1 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT00424788 |
| Plasma exchange | Other | Phase EARLY_PHASE1 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT00424788 |
| natalizumab treatment | Drug | Phase EARLY_PHASE1 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT00424788 |
| Plasma exchange | Other | Phase EARLY_PHASE1 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT00424788 |
| natalizumab treatment | Drug | Phase EARLY_PHASE1 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT00424788 |
| Plasma exchange | Other | Phase EARLY_PHASE1 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT00424788 |
| rituximab | Other | Phase PHASE4 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00090038 |
| rituximab | Other | Phase PHASE4 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00090038 |
| BG9928 | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT00858156 |
| Interferon beta-1a | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT00599274 |
| Interferon beta-1a | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT00599274 |
| Interferon beta-1a | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT00599274 |
| BG00012 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01069913 |
| BG00012 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01069913 |
| BG00012 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01069913 |
| CNF1010 (17-AAG) | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | TERMINATED | NCT00319930 |
| CNF1010 (17-AAG) | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | TERMINATED | NCT00319930 |
| BIIB014 100mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01035515 |
| BIIB014 50mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01035515 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01035515 |
| BIIB014 100mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01035515 |
| BIIB014 50mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01035515 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01035515 |
| Placebo | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00492765 |
| Simvastatin | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00492765 |
| Interferon-beta-1a | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00492765 |
| Placebo | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00492765 |
| Simvastatin | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00492765 |
| Interferon-beta-1a | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00492765 |
| Lixivaptan | Other | Phase PHASE3 | Hypervolemic Hyponatremia | WITHDRAWN | NCT00876876 |
| Lixivaptan | Other | Phase PHASE3 | Hypervolemic Hyponatremia | WITHDRAWN | NCT00876876 |
| Galiximab | Other | Phase PHASE1 | Lymphoma, Non-Hodgkin's | TERMINATED | NCT00651443 |
| Zidovudine | Other | Phase PHASE2 | HIV Infections | TERMINATED | NCT00000659 |
| CD4 Antigens | Other | Phase PHASE2 | HIV Infections | TERMINATED | NCT00000659 |
| Zidovudine | Other | Phase PHASE2 | HIV Infections | TERMINATED | NCT00000659 |
| CD4 Antigens | Other | Phase PHASE2 | HIV Infections | TERMINATED | NCT00000659 |
| Zidovudine | Other | Phase PHASE2 | HIV Infections | TERMINATED | NCT00000659 |
| CD4 Antigens | Other | Phase PHASE2 | HIV Infections | TERMINATED | NCT00000659 |
| pegylated interferon alpha 2a YPEG-IFN α-2a 180mcg | Other | Phase PHASE2 | Self Efficacy | UNKNOWN | NCT01327729 |
| pegylated interferon alpha 2a YPEG-IFN α-2a 180mcg | Other | Phase PHASE2 | Self Efficacy | UNKNOWN | NCT01327729 |
| Avonex | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01416207 |
| Avonex | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01416207 |
| Natalizumab | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05925049 |
| Omaveloxolone | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT07297199 |
| Observational | Other | Preclinical | Spinal Muscular Atrophy | RECRUITING | NCT06955897 |
| moxifloxacin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00675701 |
| lixivaptan | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00675701 |
| placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00675701 |
| moxifloxacin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00675701 |
| lixivaptan | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00675701 |
| placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00675701 |
| moxifloxacin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00675701 |
| lixivaptan | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00675701 |
| placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00675701 |
| Placebo | Other | Phase PHASE3 | Euvolemic Hyponatremia | COMPLETED | NCT00876798 |
| Lixivaptan | Other | Phase PHASE3 | Euvolemic Hyponatremia | COMPLETED | NCT00876798 |
| Placebo | Other | Phase PHASE3 | Euvolemic Hyponatremia | COMPLETED | NCT00876798 |
| Lixivaptan | Other | Phase PHASE3 | Euvolemic Hyponatremia | COMPLETED | NCT00876798 |
| placebo | Other | Phase PHASE3 | Hyponatremia With Normal Extracellular Fluid Volume | COMPLETED | NCT00660959 |
| lixivaptan | Other | Phase PHASE3 | Hyponatremia With Normal Extracellular Fluid Volume | COMPLETED | NCT00660959 |
| placebo | Other | Phase PHASE3 | Hyponatremia With Normal Extracellular Fluid Volume | COMPLETED | NCT00660959 |
| lixivaptan | Other | Phase PHASE3 | Hyponatremia With Normal Extracellular Fluid Volume | COMPLETED | NCT00660959 |
| Placebo | Other | Phase PHASE3 | Hyponatremia | COMPLETED | NCT00578695 |
| lixivaptan | Other | Phase PHASE3 | Hyponatremia | COMPLETED | NCT00578695 |
| 25G x 1" Needle Autoinjector | Other | Phase PHASE1 | Healthy | TERMINATED | NCT01313364 |
| 25G x 1" Needle Autoinjector | Other | Phase PHASE1 | Healthy | TERMINATED | NCT01313364 |
| Tysabri | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT00937677 |
| Tysabri | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT00937677 |
| Rituximab | Other | Phase PHASE2 | Lymphoma, Mantle-Cell | COMPLETED | NCT00038623 |
| Yttrium-ibritumomab (Zevalin) | Other | Phase PHASE2 | Lymphoma, Mantle-Cell | COMPLETED | NCT00038623 |
| Rituximab | Other | Phase PHASE2 | Lymphoma, Mantle-Cell | COMPLETED | NCT00038623 |
| Yttrium-ibritumomab (Zevalin) | Other | Phase PHASE2 | Lymphoma, Mantle-Cell | COMPLETED | NCT00038623 |
| Experimental | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01420458 |
| Experimental | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01420458 |
| Experimental | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01420458 |
| PLACEBO | Other | Phase PHASE2 | Heart Failure | UNKNOWN | NCT01477801 |
| CHOLECALCIFEROL | Other | Phase PHASE2 | Heart Failure | UNKNOWN | NCT01477801 |
| PLACEBO | Other | Phase PHASE2 | Heart Failure | UNKNOWN | NCT01477801 |
| CHOLECALCIFEROL | Other | Phase PHASE2 | Heart Failure | UNKNOWN | NCT01477801 |
| Volociximab | Other | Phase PHASE2 | Ovarian Cancer | TERMINATED | NCT00516841 |
| Volociximab | Other | Phase PHASE2 | Ovarian Cancer | TERMINATED | NCT00516841 |
| Natalizumab | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05925049 |
| Omaveloxolone | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT07297199 |
| Observational | Other | Preclinical | Spinal Muscular Atrophy | RECRUITING | NCT06955897 |
| Natalizumab | Other | Phase PHASE2 | Primary Progressive Multiple Sclerosis | COMPLETED | NCT01077466 |
| Natalizumab | Other | Phase PHASE2 | Primary Progressive Multiple Sclerosis | COMPLETED | NCT01077466 |
| 90Y Ibritumomab tiuxetan | Other | Phase PHASE1 | Lymphoma, Non-Hodgkin | COMPLETED | NCT00186589 |
| 90Y Ibritumomab tiuxetan | Other | Phase PHASE1 | Lymphoma, Non-Hodgkin | COMPLETED | NCT00186589 |
| IDEC-114 | Other | Phase PHASE1 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00575068 |
| IDEC-114 | Other | Phase PHASE1 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00575068 |
| CNF2024 + trastuzumab | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00412412 |
| CNF2024 | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00412412 |
| methylprednisolone | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00493116 |
| Interferon-beta-1a | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00493116 |
| methylprednisolone | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00493116 |
| Interferon-beta-1a | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00493116 |
| Interferon-beta-1a (Avonex) plus methylprednisolone | Other | Phase PHASE4 | Relapsing-remitting Multiple Sclerosis | COMPLETED | NCT00168766 |
| Interferon-beta-1a (Avonex) plus methylprednisolone | Other | Phase PHASE4 | Relapsing-remitting Multiple Sclerosis | COMPLETED | NCT00168766 |
| IDEC-114 | Other | Phase PHASE1 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00048555 |
| IDEC-114 | Other | Phase PHASE1 | Non-Hodgkin's Lymphoma | COMPLETED | NCT00048555 |
| Natalizumab (Tysabri) | Other | Phase PHASE4 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT01591551 |
| Natalizumab (Tysabri) | Other | Phase PHASE4 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT01591551 |
| BIIB019 subcutaneous injection | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01929746 |
| BIIB019 subcutaneous injection | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01929746 |
| BG9418 (interferon beta-1a) | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT00828204 |
| Avonex prefilled syringe via manual IM injection | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT00828204 |
| single-use autoinjector with a prefilled liquid Avonex syringe | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT00828204 |
| BG9418 (interferon beta-1a) | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT00828204 |
| Avonex prefilled syringe via manual IM injection | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT00828204 |
| single-use autoinjector with a prefilled liquid Avonex syringe | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT00828204 |
| BIIB017 (peginterferon beta-1a) Autoinjector | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01610310 |
| BIIB017 (peginterferon beta-1a) Pre-filled syringe (PFS) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01610310 |
| Placebo | Other | Phase PHASE2 | Active Ulcerative Colitis | COMPLETED | NCT00616434 |
| BG9418 (Interferon beta-1a) | Other | Phase PHASE2 | Active Ulcerative Colitis | COMPLETED | NCT00616434 |
| standard of care | Other | Phase PHASE1 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00559702 |
| natalizumab | Other | Phase PHASE1 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00559702 |
| Placebo | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | COMPLETED | NCT00906399 |
| BIIB017 (peginterferon beta-1a) | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | COMPLETED | NCT00906399 |
| BG00002 (natalizumab) | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT00675428 |
| BG00002 (natalizumab) | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT00675428 |
| PF-04958242 oral solution | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01646840 |
| PF-04958242 capsule | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01646840 |
| Natalizumab | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05925049 |
| Natalizumab | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05925049 |
| pet-scan FDG-F18 | Other | Phase PHASE4 | Multiple Sclerosis | TERMINATED | NCT00752778 |
| pet-scan FDG-F18 | Other | Phase PHASE4 | Multiple Sclerosis | TERMINATED | NCT00752778 |
| pet-scan FDG-F18 | Other | Phase PHASE4 | Multiple Sclerosis | TERMINATED | NCT00752778 |
| Interferon beta-1a (new process, manufactured without FBS) | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT01500408 |
| Interferon beta-1a (current approved manufacturing process invloving FBS) | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT01500408 |
| hCBE-11 | Other | Phase PHASE1 | Tumors | TERMINATED | NCT00105170 |
| hCBE-11 | Other | Phase PHASE1 | Tumors | TERMINATED | NCT00105170 |
| hCBE-11 | Other | Phase PHASE1 | Tumors | TERMINATED | NCT00105170 |
| (IM) AVONEX® | Other | Phase PHASE1 | Multiple Sclerosis (MS) | COMPLETED | NCT01863069 |
| Interferon beta 1a | Other | Phase PHASE1 | Multiple Sclerosis (MS) | COMPLETED | NCT01863069 |
| (IM) AVONEX® | Other | Phase PHASE1 | Multiple Sclerosis (MS) | COMPLETED | NCT01863069 |
| Interferon beta 1a | Other | Phase PHASE1 | Multiple Sclerosis (MS) | COMPLETED | NCT01863069 |
| Reference product | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01632449 |
| Test product | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01632449 |
| Reference product | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01632449 |
| Test product | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01632449 |
| ^111 In Ibritumomab Tiuxetan | Other | Phase PHASE2 | Lymphoma | TERMINATED | NCT00493454 |
| Rituximab | Other | Phase PHASE2 | Lymphoma | TERMINATED | NCT00493454 |
| Zevalin | Other | Phase PHASE2 | Lymphoma | TERMINATED | NCT00493454 |
| ^111 In Ibritumomab Tiuxetan | Other | Phase PHASE2 | Lymphoma | TERMINATED | NCT00493454 |
| Rituximab | Other | Phase PHASE2 | Lymphoma | TERMINATED | NCT00493454 |
| Zevalin | Other | Phase PHASE2 | Lymphoma | TERMINATED | NCT00493454 |
| Allogeneic Stem Cell Transplantation | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00048737 |
| Cyclophosphamide | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00048737 |
| Fludarabine | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00048737 |
| Rituximab | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00048737 |
| Zevalin Radioimmunotherapy | Drug | Phase PHASE1 | Lymphoma | COMPLETED | NCT00048737 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | WITHDRAWN | NCT01652937 |
| BIIB057 | Other | Phase PHASE2 | Rheumatoid Arthritis | WITHDRAWN | NCT01652937 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | WITHDRAWN | NCT01652937 |
| BIIB057 | Other | Phase PHASE2 | Rheumatoid Arthritis | WITHDRAWN | NCT01652937 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | WITHDRAWN | NCT01652937 |
| BIIB057 | Other | Phase PHASE2 | Rheumatoid Arthritis | WITHDRAWN | NCT01652937 |
| Blood Sample | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT01556685 |
| clinical and neurological evaluation | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT01556685 |
| Blood Sample | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT01556685 |
| clinical and neurological evaluation | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT01556685 |
| BG00012 Dose 2 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01453426 |
| BG00012 Dose 1 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01453426 |
| BG00012 Dose 2 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01453426 |
| BG00012 Dose 1 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01453426 |
| BIIB023 - high dose IV Dose | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01407406 |
| BIIB023 - low dose IV Dose | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01407406 |
| BIIB023 - high dose IV Dose | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01407406 |
| BIIB023 - low dose IV Dose | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01407406 |
| Avonex | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT01181115 |
| Avonex | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT01181115 |
| Baminercept | Other | Phase PHASE1 | Secondary Progressive Multiple Sclerosis | WITHDRAWN | NCT01181089 |
| Placebo | Other | Phase PHASE1 | Secondary Progressive Multiple Sclerosis | WITHDRAWN | NCT01181089 |
| Baminercept | Other | Phase PHASE1 | Secondary Progressive Multiple Sclerosis | WITHDRAWN | NCT01181089 |
| Placebo | Other | Phase PHASE1 | Secondary Progressive Multiple Sclerosis | WITHDRAWN | NCT01181089 |
| BIIB0121 and Antacid | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT01017198 |
| BIIB021 and Food | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT01017198 |
| BIIB0121 and Antacid | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT01017198 |
| BIIB021 and Food | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT01017198 |
| BIIB022 With Paclitaxel and Carboplatin | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | COMPLETED | NCT00970580 |
| BIIB022 With Paclitaxel and Carboplatin | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | COMPLETED | NCT00970580 |
| Sorafenib | Other | Phase PHASE1 | Hepatocellular Carcinoma | COMPLETED | NCT00956436 |
| BIIB022 | Other | Phase PHASE1 | Hepatocellular Carcinoma | COMPLETED | NCT00956436 |
| placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00810836 |
| BG00012 | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00810836 |
| placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00810836 |
| BG00012 | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00810836 |
| Placebo (sterile normal saline) | Other | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT00771329 |
| BIIB023 | Other | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT00771329 |
| Placebo (sterile normal saline) | Other | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT00771329 |
| BIIB023 | Other | Phase PHASE1 | Rheumatoid Arthritis | COMPLETED | NCT00771329 |
| BIIB015 | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT00674947 |
| IDEC-152 | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT00046488 |
| glatiramer acetate | Other | Phase PHASE2 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT01071083 |
| IV placebo | Other | Phase PHASE2 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT01071083 |
| methylprednisolone | Other | Phase PHASE2 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT01071083 |
| interferon beta 1-a | Other | Phase PHASE2 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT01071083 |
| natalizumab | Other | Phase PHASE2 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT01071083 |
| glatiramer acetate | Other | Phase PHASE2 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT01071083 |
| IV placebo | Other | Phase PHASE2 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT01071083 |
| methylprednisolone | Other | Phase PHASE2 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT01071083 |
| interferon beta 1-a | Other | Phase PHASE2 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT01071083 |
| natalizumab | Other | Phase PHASE2 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT01071083 |
| Zevalin | Other | Approved | Non-Hodgkin's Lymphoma | COMPLETED | NCT00387023 |
| Rituximab | Other | Approved | Non-Hodgkin's Lymphoma | COMPLETED | NCT00387023 |
| Zevalin | Other | Approved | Non-Hodgkin's Lymphoma | COMPLETED | NCT00387023 |
| Rituximab | Other | Approved | Non-Hodgkin's Lymphoma | COMPLETED | NCT00387023 |
| dimethyl fumarate (DMF) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01915901 |
| matching placebo (bismuth subsalicylate) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01915901 |
| bismuth subsalicylate (Pepto-Bismol®) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01915901 |
| Zevalin | Other | Phase PHASE2 | Mantle Cell Lymphoma | COMPLETED | NCT00119730 |
| Rituximab | Other | Phase PHASE2 | Mantle Cell Lymphoma | COMPLETED | NCT00119730 |
| Mitoxantrone | Other | Phase PHASE2 | Mantle Cell Lymphoma | COMPLETED | NCT00119730 |
| Fludarabine | Other | Phase PHASE2 | Mantle Cell Lymphoma | COMPLETED | NCT00119730 |
| Zevalin | Other | Phase PHASE2 | Mantle Cell Lymphoma | COMPLETED | NCT00119730 |
| Rituximab | Other | Phase PHASE2 | Mantle Cell Lymphoma | COMPLETED | NCT00119730 |
| Mitoxantrone | Other | Phase PHASE2 | Mantle Cell Lymphoma | COMPLETED | NCT00119730 |
| Fludarabine | Other | Phase PHASE2 | Mantle Cell Lymphoma | COMPLETED | NCT00119730 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02125578 |
| BIIB017 (PEGylated Interferon Beta-1a) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02125578 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02125578 |
| BIIB017 (PEGylated Interferon Beta-1a) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02125578 |
| BG9418 (interferon beta 1-a) | Other | Phase PHASE3 | Multiple Sclerosis | TERMINATED | NCT00784836 |
| BG00002-E (natalizumab high titer) | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT00516893 |
| BG00002-E (natalizumab high titer) | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT00516893 |
| BG00002 | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02142205 |
| BIIB017(peginterferon beta-1a) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01119781 |
| BIIB017(peginterferon beta-1a) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01119781 |
| BG9418 (interferon beta-1a) | Other | Preclinical | Prenatal Exposure Delayed Effects | COMPLETED | NCT00168714 |
| BG9418 (interferon beta-1a) | Other | Preclinical | Prenatal Exposure Delayed Effects | COMPLETED | NCT00168714 |
| BG9418 (interferon beta-1a) | Other | Preclinical | Prenatal Exposure Delayed Effects | COMPLETED | NCT00168714 |
| BIIB017 (peginterferon beta-1a) Autoinjector | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01610310 |
| BIIB017 (peginterferon beta-1a) Pre-filled syringe (PFS) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01610310 |
| BG0002 (natalizumab) | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00818038 |
| TALL-104 cells | Other | Phase PHASE2 | Chronic Myelogenous Leukemia | TERMINATED | NCT00415909 |
| Imatinib Mesylate (IM) | Other | Phase PHASE2 | Chronic Myelogenous Leukemia | TERMINATED | NCT00415909 |
| TALL-104 cells | Other | Phase PHASE2 | Chronic Myelogenous Leukemia | TERMINATED | NCT00415909 |
| Imatinib Mesylate (IM) | Other | Phase PHASE2 | Chronic Myelogenous Leukemia | TERMINATED | NCT00415909 |
| mefloquine | Other | Phase PHASE1 | Progressive Multifocal Leukoencephalopathy | TERMINATED | NCT00746941 |
| mefloquine | Other | Phase PHASE1 | Progressive Multifocal Leukoencephalopathy | TERMINATED | NCT00746941 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01943513 |
| BIIB023 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01943513 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01943513 |
| BIIB023 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01943513 |
| glatiramer acetate | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT01058005 |
| interferon beta-1a | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT01058005 |
| BG00002 (natalizumab) | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT01058005 |
| glatiramer acetate | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT01058005 |
| interferon beta-1a | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT01058005 |
| BG00002 (natalizumab) | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT01058005 |
| glatiramer acetate | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT01058005 |
| interferon beta-1a | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT01058005 |
| BG00002 (natalizumab) | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT01058005 |
| Prednisolone | Other | Phase PHASE4 | Immune Reconstitution Inflammatory Syndrome | TERMINATED | NCT01211665 |
| Methylprednisolone | Other | Phase PHASE4 | Immune Reconstitution Inflammatory Syndrome | TERMINATED | NCT01211665 |
| Prednisolone | Other | Phase PHASE4 | Immune Reconstitution Inflammatory Syndrome | TERMINATED | NCT01211665 |
| Methylprednisolone | Other | Phase PHASE4 | Immune Reconstitution Inflammatory Syndrome | TERMINATED | NCT01211665 |
| Prednisolone | Other | Phase PHASE4 | Immune Reconstitution Inflammatory Syndrome | TERMINATED | NCT01211665 |
| Methylprednisolone | Other | Phase PHASE4 | Immune Reconstitution Inflammatory Syndrome | TERMINATED | NCT01211665 |
| AVONEX PEN | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT01405872 |
| Placebo | Other | Phase PHASE1 | Sciatica | COMPLETED | NCT01405833 |
| BG00010 (Neublastin) | Other | Phase PHASE1 | Sciatica | COMPLETED | NCT01405833 |
| Placebo | Other | Phase PHASE1 | Sciatica | COMPLETED | NCT01405833 |
| BG00010 (Neublastin) | Other | Phase PHASE1 | Sciatica | COMPLETED | NCT01405833 |
| Placebo | Other | Phase PHASE1 | Sciatica | COMPLETED | NCT01405833 |
| BG00010 (Neublastin) | Other | Phase PHASE1 | Sciatica | COMPLETED | NCT01405833 |
| standard of care | Other | Phase PHASE1 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00559702 |
| natalizumab | Other | Phase PHASE1 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00559702 |
| standard of care | Other | Phase PHASE1 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00559702 |
| natalizumab | Other | Phase PHASE1 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00559702 |
| G-CSF | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01538472 |
| Stem Cell Infusion | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01538472 |
| Melphalan | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01538472 |
| Ara-C | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01538472 |
| VP -16 | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01538472 |
| BCNU | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01538472 |
| Rituxan | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01538472 |
| In Zevalin | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01538472 |
| Y Zevalin | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01538472 |
| G-CSF | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01538472 |
| Stem Cell Infusion | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01538472 |
| Melphalan | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01538472 |
| Ara-C | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01538472 |
| VP -16 | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01538472 |
| BCNU | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01538472 |
| Rituxan | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01538472 |
| In Zevalin | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01538472 |
| Y Zevalin | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT01538472 |
| BIIB017 | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | WITHDRAWN | NCT01337427 |
| BIIB017 | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | WITHDRAWN | NCT01337427 |
| Placebo | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT01440101 |
| Natalizumab (BG00002) | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT01440101 |
| Placebo | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT01440101 |
| Natalizumab (BG00002) | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT01440101 |
| Placebo | Other | Phase PHASE1 | Sciatica | COMPLETED | NCT00961766 |
| BG00010 (Neublastin) | Other | Phase PHASE1 | Sciatica | COMPLETED | NCT00961766 |
| Placebo | Other | Phase PHASE1 | Sciatica | COMPLETED | NCT00961766 |
| BG00010 (Neublastin) | Other | Phase PHASE1 | Sciatica | COMPLETED | NCT00961766 |
| Placebo | Other | Phase PHASE1 | Sciatica | COMPLETED | NCT00961766 |
| BG00010 (Neublastin) | Other | Phase PHASE1 | Sciatica | COMPLETED | NCT00961766 |
| Peginterferon Beta-1a | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01978652 |
| Peginterferon Beta-1a | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01978652 |
| Natalizumab | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00744679 |
| Natalizumab | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00744679 |
| dimethyl fumarate | Other | Preclinical | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT01903291 |
| dimethyl fumarate | Other | Preclinical | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT01903291 |
| natalizumab | Other | Preclinical | Relapsing Multiple Sclerosis | COMPLETED | NCT01070836 |
| Placebo | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT01597297 |
| BIIB041 (PR Fampridine) | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT01597297 |
| Placebo | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT01597297 |
| BIIB041 (PR Fampridine) | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT01597297 |
| peginterferon beta-1a | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | COMPLETED | NCT01332019 |
| oral corticosteroids | Other | Phase PHASE2 | Lupus Nephritis | TERMINATED | NCT01930890 |
| mycophenolate mofetil | Other | Phase PHASE2 | Lupus Nephritis | TERMINATED | NCT01930890 |
| BIIB023 | Other | Phase PHASE2 | Lupus Nephritis | TERMINATED | NCT01930890 |
| interferon beta-1a | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02076841 |
| interferon beta-1a | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02076841 |
| interferon beta-1a | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02076841 |
| BIIB041 (fampridine) | Other | Phase PHASE3 | Multiple Sclerosis, Remittent Progressive | COMPLETED | NCT01917019 |
| Placebo | Other | Phase PHASE3 | Multiple Sclerosis, Remittent Progressive | COMPLETED | NCT01917019 |
| BIIB041 (fampridine) | Other | Phase PHASE3 | Multiple Sclerosis, Remittent Progressive | COMPLETED | NCT01917019 |
| Placebo | Other | Phase PHASE3 | Multiple Sclerosis, Remittent Progressive | COMPLETED | NCT01917019 |
| BIIB041 (fampridine) | Other | Phase PHASE3 | Multiple Sclerosis, Remittent Progressive | COMPLETED | NCT01917019 |
| Placebo | Other | Phase PHASE3 | Multiple Sclerosis, Remittent Progressive | COMPLETED | NCT01917019 |
| Adherence counseling | Other | Phase PHASE4 | Multiple Sclerosis | TERMINATED | NCT02343159 |
| Medication Event Monitoring System (MEMS) | Drug | Phase PHASE4 | Multiple Sclerosis | TERMINATED | NCT02343159 |
| dimethyl fumarate | Other | Phase PHASE4 | Multiple Sclerosis | TERMINATED | NCT02343159 |
| Adherence counseling | Other | Phase PHASE4 | Multiple Sclerosis | TERMINATED | NCT02343159 |
| Medication Event Monitoring System (MEMS) | Drug | Phase PHASE4 | Multiple Sclerosis | TERMINATED | NCT02343159 |
| dimethyl fumarate | Other | Phase PHASE4 | Multiple Sclerosis | TERMINATED | NCT02343159 |
| Placebo | Other | Phase PHASE2 | Primary Inherited Erythromelalgia | COMPLETED | NCT02917187 |
| BIIB074 | Other | Phase PHASE2 | Primary Inherited Erythromelalgia | COMPLETED | NCT02917187 |
| Placebo | Other | Phase PHASE2 | Primary Inherited Erythromelalgia | COMPLETED | NCT02917187 |
| BIIB074 | Other | Phase PHASE2 | Primary Inherited Erythromelalgia | COMPLETED | NCT02917187 |
| Placebo | Other | Phase PHASE1 | Progressive Supranuclear Palsy | COMPLETED | NCT02460094 |
| BIIB092 | Other | Phase PHASE1 | Progressive Supranuclear Palsy | COMPLETED | NCT02460094 |
| Placebo | Other | Phase PHASE1 | Progressive Supranuclear Palsy | COMPLETED | NCT02460094 |
| BIIB092 | Other | Phase PHASE1 | Progressive Supranuclear Palsy | COMPLETED | NCT02460094 |
| Placebo | Other | Phase PHASE2 | Acute Ischemic Stroke | COMPLETED | NCT02730455 |
| natalizumab | Other | Phase PHASE2 | Acute Ischemic Stroke | COMPLETED | NCT02730455 |
| Placebo | Other | Phase PHASE2 | Acute Ischemic Stroke | COMPLETED | NCT02730455 |
| natalizumab | Other | Phase PHASE2 | Acute Ischemic Stroke | COMPLETED | NCT02730455 |
| Fampridine | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT01480063 |
| Placebo | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01749098 |
| Ketamine | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01749098 |
| PF-04958242 | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01749098 |
| Placebo | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01749098 |
| Ketamine | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01749098 |
| PF-04958242 | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01749098 |
| PF-04958242 oral solution | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01646840 |
| PF-04958242 capsule | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01646840 |
| Placebo | Other | Phase PHASE1 | Hearing Loss, Sensorineural | COMPLETED | NCT01518920 |
| PF-04958242 | Other | Phase PHASE1 | Hearing Loss, Sensorineural | COMPLETED | NCT01518920 |
| placebo | Other | Phase PHASE2 | Cognitive Impairment Associated With Schizophrenia (CIAS) | TERMINATED | NCT02855411 |
| PF-04958242 | Other | Phase PHASE2 | Cognitive Impairment Associated With Schizophrenia (CIAS) | TERMINATED | NCT02855411 |
| placebo | Other | Phase PHASE2 | Cognitive Impairment Associated With Schizophrenia (CIAS) | TERMINATED | NCT02855411 |
| PF-04958242 | Other | Phase PHASE2 | Cognitive Impairment Associated With Schizophrenia (CIAS) | TERMINATED | NCT02855411 |
| Placebo | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT02410278 |
| montelukast | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT02410278 |
| dimethyl fumarate | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT02410278 |
| Placebo | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT02410278 |
| montelukast | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT02410278 |
| dimethyl fumarate | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT02410278 |
| Natalizumab | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05925049 |
| BIIB017 (Peginterferon beta-1a) | Other | Phase PHASE4 | Relapsing Multiple Sclerosis | WITHDRAWN | NCT02234869 |
| Interferon Beta | Other | Phase PHASE4 | Relapsing Multiple Sclerosis | WITHDRAWN | NCT02234869 |
| BIIB017 (Peginterferon beta-1a) | Other | Phase PHASE4 | Relapsing Multiple Sclerosis | WITHDRAWN | NCT02234869 |
| Interferon Beta | Other | Phase PHASE4 | Relapsing Multiple Sclerosis | WITHDRAWN | NCT02234869 |
| BIIB017 (Peginterferon beta-1a) | Other | Phase PHASE4 | Relapsing Multiple Sclerosis | WITHDRAWN | NCT02234869 |
| Interferon Beta | Other | Phase PHASE4 | Relapsing Multiple Sclerosis | WITHDRAWN | NCT02234869 |
| Training | Other | Approved | Multiple Sclerosis (Relapsing Remitting) | COMPLETED | NCT01518660 |
| Training | Other | Approved | Multiple Sclerosis (Relapsing Remitting) | COMPLETED | NCT01518660 |
| dimethyl fumarate - Test form | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02171208 |
| dimethyl fumarate - Reference form | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02171208 |
| dimethyl fumarate - Test form | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02171208 |
| dimethyl fumarate - Reference form | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02171208 |
| dimethyl fumarate - Test form | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02171208 |
| dimethyl fumarate - Reference form | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02171208 |
| Glatiramer Acetate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00451451 |
| Placebo | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00451451 |
| BG00012 | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00451451 |
| Glatiramer Acetate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00451451 |
| Placebo | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00451451 |
| BG00012 | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00451451 |
| Placebo | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00420212 |
| BG00012 | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00420212 |
| Placebo | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00420212 |
| BG00012 | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00420212 |
| Rebif | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT02269930 |
| peginterferon beta-1a | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT02269930 |
| Rebif | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT02269930 |
| peginterferon beta-1a | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT02269930 |
| Rebif | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT02269930 |
| peginterferon beta-1a | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT02269930 |
| 14C-BIIB061 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02071121 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02071121 |
| BIIB061 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02071121 |
| 14C-BIIB061 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02071121 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02071121 |
| BIIB061 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02071121 |
| Placebo SC | Other | Phase PHASE1 | Painful Lumbar Radiculopathy | COMPLETED | NCT01842126 |
| Placebo IV | Other | Phase PHASE1 | Painful Lumbar Radiculopathy | COMPLETED | NCT01842126 |
| BG00010 SC | Other | Phase PHASE1 | Painful Lumbar Radiculopathy | COMPLETED | NCT01842126 |
| BG00010 IV | Other | Phase PHASE1 | Painful Lumbar Radiculopathy | COMPLETED | NCT01842126 |
| Placebo SC | Other | Phase PHASE1 | Painful Lumbar Radiculopathy | COMPLETED | NCT01842126 |
| Placebo IV | Other | Phase PHASE1 | Painful Lumbar Radiculopathy | COMPLETED | NCT01842126 |
| BG00010 SC | Other | Phase PHASE1 | Painful Lumbar Radiculopathy | COMPLETED | NCT01842126 |
| BG00010 IV | Other | Phase PHASE1 | Painful Lumbar Radiculopathy | COMPLETED | NCT01842126 |
| dimethyl fumarate | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01924832 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT01397539 |
| BIIB037 | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT01397539 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT01397539 |
| BIIB037 | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT01397539 |
| SC Placebo | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01405820 |
| IV Placebo | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01405820 |
| natalizumab SC | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01405820 |
| natalizumab IV | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01405820 |
| SC Placebo | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01405820 |
| IV Placebo | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01405820 |
| natalizumab SC | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01405820 |
| natalizumab IV | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01405820 |
| BIIB061 | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT02521545 |
| BIIB061 | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT02521545 |
| dimethyl fumarate | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | WITHDRAWN | NCT02090348 |
| dimethyl fumarate | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | WITHDRAWN | NCT02090348 |
| Placebo | Other | Phase PHASE2 | Painful Lumbar Radiculopathy | COMPLETED | NCT01873404 |
| BG00010 | Other | Phase PHASE2 | Painful Lumbar Radiculopathy | COMPLETED | NCT01873404 |
| Placebo | Other | Phase PHASE2 | Painful Lumbar Radiculopathy | COMPLETED | NCT01873404 |
| BG00010 | Other | Phase PHASE2 | Painful Lumbar Radiculopathy | COMPLETED | NCT01873404 |
| Placebo | Other | Phase PHASE2 | Painful Lumbar Radiculopathy | COMPLETED | NCT01873404 |
| BG00010 | Other | Phase PHASE2 | Painful Lumbar Radiculopathy | COMPLETED | NCT01873404 |
| Folate | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00298272 |
| Methylprednisolone | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00298272 |
| Adalimumab | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00298272 |
| Etanercept | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00298272 |
| Methotrexate | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00298272 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00298272 |
| IDEC-C2B8 (rituximab) | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00298272 |
| Folate | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00298272 |
| Methylprednisolone | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00298272 |
| Adalimumab | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00298272 |
| Etanercept | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00298272 |
| Methotrexate | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00298272 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00298272 |
| IDEC-C2B8 (rituximab) | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00298272 |
| exemestane (Aromasin) | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT01004081 |
| BIIB021 | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT01004081 |
| exemestane (Aromasin) | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT01004081 |
| BIIB021 | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT01004081 |
| FCR | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT00801060 |
| Lumiliximab + FCR | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT00801060 |
| BIIB021 | Other | Phase PHASE2 | GIST | COMPLETED | NCT00618319 |
| BIIB021 | Other | Phase PHASE2 | GIST | COMPLETED | NCT00618319 |
| FCR | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT00391066 |
| FCR + Lumiliximab | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT00391066 |
| FCR | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT00391066 |
| FCR + Lumiliximab | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT00391066 |
| Rituximab in combination with placebo | Other | Phase PHASE3 | Lymphoma, Non-Hodgkin's | TERMINATED | NCT00363636 |
| Galiximab in combination with rituximab | Other | Phase PHASE3 | Lymphoma, Non-Hodgkin's | TERMINATED | NCT00363636 |
| Rituximab in combination with placebo | Other | Phase PHASE3 | Lymphoma, Non-Hodgkin's | TERMINATED | NCT00363636 |
| Galiximab in combination with rituximab | Other | Phase PHASE3 | Lymphoma, Non-Hodgkin's | TERMINATED | NCT00363636 |
| Rituximab in combination with placebo | Other | Phase PHASE3 | Lymphoma, Non-Hodgkin's | TERMINATED | NCT00363636 |
| Galiximab in combination with rituximab | Other | Phase PHASE3 | Lymphoma, Non-Hodgkin's | TERMINATED | NCT00363636 |
| Lumiliximab with FCR | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT00103558 |
| Lumiliximab with FCR | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT00103558 |
| Lumiliximab with FCR | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT00103558 |
| natalizumab | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT02137109 |
| natalizumab | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT02137109 |
| Interferon beta-1a | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT01272128 |
| indium In 111 ibritumomab tiuxetan | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00005592 |
| rituximab | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00005592 |
| 90-Y-ibritumomab tiuxetan | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00005592 |
| indium In 111 ibritumomab tiuxetan | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00005592 |
| rituximab | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00005592 |
| 90-Y-ibritumomab tiuxetan | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00005592 |
| indium In 111 ibritumomab tiuxetan | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00005592 |
| rituximab | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00005592 |
| 90-Y-ibritumomab tiuxetan | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00005592 |
| galiximab in combination with rituximab | Other | Phase PHASE3 | Lymphoma, Non-Hodgkin's | TERMINATED | NCT00384150 |
| Placebo | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | WITHDRAWN | NCT02472938 |
| dimethyl fumarate | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | WITHDRAWN | NCT02472938 |
| Placebo | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | WITHDRAWN | NCT02472938 |
| dimethyl fumarate | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | WITHDRAWN | NCT02472938 |
| Placebo | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | WITHDRAWN | NCT02472938 |
| dimethyl fumarate | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | WITHDRAWN | NCT02472938 |
| natalizumab | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01416155 |
| natalizumab | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01416155 |
| Baminercept alfa 5 | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00664716 |
| Baminercept alfa 4 | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00664716 |
| Baminercept alfa 3 | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00664716 |
| Baminercept alfa 2 | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00664716 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00664716 |
| Baminercept alfa 1 | Other | Phase PHASE2 | Rheumatoid Arthritis | COMPLETED | NCT00664716 |
| Baminercept alfa (BG9924) | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00664573 |
| BG9924 | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00523328 |
| BG9924 | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00523328 |
| Placebo Comparator | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00458861 |
| BG9924 | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00458861 |
| Placebo Comparator | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00458861 |
| BG9924 | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00458861 |
| Avonex | Other | Approved | Multiple Sclerosis | COMPLETED | NCT01641120 |
| dimethyl fumarate | Other | Preclinical | Multiple Sclerosis, Relapsing-Remitting | TERMINATED | NCT02323269 |
| dimethyl fumarate | Other | Preclinical | Multiple Sclerosis, Relapsing-Remitting | TERMINATED | NCT02323269 |
| dimethyl fumarate | Other | Preclinical | Multiple Sclerosis, Relapsing-Remitting | TERMINATED | NCT02323269 |
| dimethyl fumarate | Other | Preclinical | Multiple Sclerosis, Relapsing-Remitting | TERMINATED | NCT02323269 |
| Vitamin E δ-Tocotrienol | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT01446952 |
| Vitamin E δ-Tocotrienol | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT01446952 |
| Placebo | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | WITHDRAWN | NCT02428218 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | WITHDRAWN | NCT02428218 |
| Placebo | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | WITHDRAWN | NCT02428218 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | WITHDRAWN | NCT02428218 |
| Aerobic exercise | Other | Approved | Multiple Sclerosis | COMPLETED | NCT02236624 |
| Aerobic exercise | Other | Approved | Multiple Sclerosis | COMPLETED | NCT02236624 |
| Aerobic exercise | Other | Approved | Multiple Sclerosis | COMPLETED | NCT02236624 |
| Vehicle Gel | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis (RRMS) | WITHDRAWN | NCT02568111 |
| brimonidine tartrate | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis (RRMS) | WITHDRAWN | NCT02568111 |
| peginterferon beta-1a | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis (RRMS) | WITHDRAWN | NCT02568111 |
| Vehicle Gel | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis (RRMS) | WITHDRAWN | NCT02568111 |
| brimonidine tartrate | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis (RRMS) | WITHDRAWN | NCT02568111 |
| peginterferon beta-1a | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis (RRMS) | WITHDRAWN | NCT02568111 |
| dimethyl fumarate | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02159573 |
| natalizumab | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02159573 |
| dimethyl fumarate | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02159573 |
| natalizumab | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02159573 |
| dimethyl fumarate | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02159573 |
| natalizumab | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02159573 |
| Itraconazole | Other | Phase PHASE1 | Neuropathic Pain | COMPLETED | NCT02698267 |
| BIIB074 | Other | Phase PHASE1 | Neuropathic Pain | COMPLETED | NCT02698267 |
| Itraconazole | Other | Phase PHASE1 | Neuropathic Pain | COMPLETED | NCT02698267 |
| BIIB074 | Other | Phase PHASE1 | Neuropathic Pain | COMPLETED | NCT02698267 |
| ASA placebo | Other | Phase PHASE3 | Healthy | COMPLETED | NCT01568112 |
| ASA | Other | Phase PHASE3 | Healthy | COMPLETED | NCT01568112 |
| BG00012 placebo | Other | Phase PHASE3 | Healthy | COMPLETED | NCT01568112 |
| BG00012 (dimethyl fumarate) | Other | Phase PHASE3 | Healthy | COMPLETED | NCT01568112 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02228707 |
| BIIB061 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02228707 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02228707 |
| BIIB061 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02228707 |
| BIIB074 | Other | Phase PHASE1 | Neuropathic Pain | COMPLETED | NCT02751905 |
| BIIB074 | Other | Phase PHASE1 | Neuropathic Pain | COMPLETED | NCT02751905 |
| natalizumab | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00831649 |
| natalizumab | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00831649 |
| natalizumab | Other | Phase PHASE4 | Crohn's Disease | WITHDRAWN | NCT00801125 |
| natalizumab | Other | Phase PHASE4 | Crohn's Disease | WITHDRAWN | NCT00801125 |
| natalizumab | Other | Phase PHASE4 | Crohn's Disease | COMPLETED | NCT00280956 |
| natalizumab | Other | Phase PHASE4 | Crohn's Disease | COMPLETED | NCT00280956 |
| natalizumab | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT00078611 |
| natalizumab | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT00078611 |
| natalizumab | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT00078611 |
| natalizumab | Other | Phase PHASE2 | Crohn's Disease | COMPLETED | NCT00055536 |
| natalizumab | Other | Phase PHASE2 | Crohn's Disease | COMPLETED | NCT00055536 |
| natalizumab | Other | Phase PHASE2 | Crohn's Disease | COMPLETED | NCT00055367 |
| natalizumab | Other | Phase PHASE2 | Crohn's Disease | COMPLETED | NCT00055367 |
| natalizumab | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT00032799 |
| natalizumab | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT00032786 |
| natalizumab | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT00032786 |
| natalizumab | Other | Phase PHASE3 | Crohn's Disease | COMPLETED | NCT00032786 |
| Natalizumab | Other | Phase PHASE1 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01884935 |
| Natalizumab | Other | Phase PHASE1 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01884935 |
| Placebo | Other | Phase PHASE2 | Acute Optic Neuritis | COMPLETED | NCT01721161 |
| BIIB033 (anti-LINGO-1 mAb) | Other | Phase PHASE2 | Acute Optic Neuritis | COMPLETED | NCT01721161 |
| Placebo | Other | Phase PHASE2 | Acute Optic Neuritis | COMPLETED | NCT01721161 |
| BIIB033 (anti-LINGO-1 mAb) | Other | Phase PHASE2 | Acute Optic Neuritis | COMPLETED | NCT01721161 |
| Placebo | Other | Phase PHASE2 | Acute Optic Neuritis | COMPLETED | NCT01721161 |
| BIIB033 (anti-LINGO-1 mAb) | Other | Phase PHASE2 | Acute Optic Neuritis | COMPLETED | NCT01721161 |
| Placebo | Other | Phase PHASE2 | Acute Ischemic Stroke | COMPLETED | NCT01955707 |
| natalizumab | Other | Phase PHASE2 | Acute Ischemic Stroke | COMPLETED | NCT01955707 |
| Placebo | Other | Phase PHASE2 | Acute Ischemic Stroke | COMPLETED | NCT01955707 |
| natalizumab | Other | Phase PHASE2 | Acute Ischemic Stroke | COMPLETED | NCT01955707 |
| Placebo | Other | Phase PHASE2 | Acute Ischemic Stroke | COMPLETED | NCT01955707 |
| natalizumab | Other | Phase PHASE2 | Acute Ischemic Stroke | COMPLETED | NCT01955707 |
| Vitamin E δ-Tocotrienol | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT01450046 |
| Vitamin E δ-Tocotrienol | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT01450046 |
| Daclizumab High Yield Process Placebo | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01064401 |
| Interferon beta-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01064401 |
| Interferon beta-1a Placebo | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01064401 |
| BIIB019 (Daclizumab High Yield Process) | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01064401 |
| Daclizumab High Yield Process Placebo | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01064401 |
| Interferon beta-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01064401 |
| Interferon beta-1a Placebo | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01064401 |
| BIIB019 (Daclizumab High Yield Process) | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01064401 |
| Placebo | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00390221 |
| BIIB019 (Daclizumab High Yield Process) | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00390221 |
| Placebo | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00390221 |
| BIIB019 (Daclizumab High Yield Process) | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00390221 |
| Natalizumab | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | TERMINATED | NCT00297232 |
| Natalizumab | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | TERMINATED | NCT00297232 |
| placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00083759 |
| natalizumab | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00083759 |
| placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00083759 |
| natalizumab | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00083759 |
| Dimethyl Fumarate | Other | Phase PHASE4 | Multiple Sclerosis | WITHDRAWN | NCT02675413 |
| Dimethyl Fumarate | Other | Phase PHASE4 | Multiple Sclerosis | WITHDRAWN | NCT02675413 |
| dimethyl fumarate | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT02519413 |
| dimethyl fumarate | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT02519413 |
| Placebo | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00870740 |
| BIIB019 (Daclizumab High Yield Process) | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00870740 |
| Placebo | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00870740 |
| BIIB019 (Daclizumab High Yield Process) | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00870740 |
| Skin Biopsy | Other | Preclinical | Atopic Dermatitis | COMPLETED | NCT02125695 |
| Blood Sampling | Other | Preclinical | Atopic Dermatitis | COMPLETED | NCT02125695 |
| Skin Taping | Other | Preclinical | Atopic Dermatitis | COMPLETED | NCT02125695 |
| Skin Biopsy | Other | Preclinical | Atopic Dermatitis | COMPLETED | NCT02125695 |
| Blood Sampling | Other | Preclinical | Atopic Dermatitis | COMPLETED | NCT02125695 |
| Skin Taping | Other | Preclinical | Atopic Dermatitis | COMPLETED | NCT02125695 |
| natalizumab | Other | Preclinical | Relapsing Multiple Sclerosis | COMPLETED | NCT01070836 |
| Placebo | Other | Phase PHASE1 | Central Nervous System (CNS) Demyelinating Disease | COMPLETED | NCT02641041 |
| BIIB033 | Other | Phase PHASE1 | Central Nervous System (CNS) Demyelinating Disease | COMPLETED | NCT02641041 |
| Placebo | Other | Phase PHASE1 | Central Nervous System (CNS) Demyelinating Disease | COMPLETED | NCT02641041 |
| BIIB033 | Other | Phase PHASE1 | Central Nervous System (CNS) Demyelinating Disease | COMPLETED | NCT02641041 |
| Fampridine | Other | Preclinical | Multiple Sclerosis | TERMINATED | NCT01532154 |
| Placebo | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00468546 |
| Methotrexate | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00468546 |
| MabThera/Rituxan | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00468546 |
| Placebo | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00468546 |
| Methotrexate | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00468546 |
| MabThera/Rituxan | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00468546 |
| Placebo | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00468546 |
| Methotrexate | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00468546 |
| MabThera/Rituxan | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT00468546 |
| rituximab [MabThera/Rituxan] | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT02097745 |
| methotrexate | Other | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT02097745 |
| Dimethyl fumarate | Other | Preclinical | Multiple Sclerosis | UNKNOWN | NCT02736279 |
| BIIB033 (opicinumab) | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT02833142 |
| BIIB033 (opicinumab) | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT02833142 |
| ASA-Placebo | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02090413 |
| acetylsalicylic acid | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02090413 |
| dimethyl fumarate | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02090413 |
| ASA-Placebo | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02090413 |
| acetylsalicylic acid | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02090413 |
| dimethyl fumarate | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02090413 |
| BIIB021 | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT00618735 |
| BIIB021 | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT00618735 |
| BIIB021 | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT00618735 |
| Placebo | Other | Phase PHASE1 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01244139 |
| BIIB033 | Other | Phase PHASE1 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01244139 |
| Placebo | Other | Phase PHASE1 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01244139 |
| BIIB033 | Other | Phase PHASE1 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01244139 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01052506 |
| BIIB033 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01052506 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01052506 |
| BIIB033 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01052506 |
| BIIB028 | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT00725933 |
| BIIB028 | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT00725933 |
| BIIB022 | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT00555724 |
| BIIB022 | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT00555724 |
| BIIB022 | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT00555724 |
| Placebo | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00027300 |
| Natalizumab | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00027300 |
| Placebo | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00027300 |
| Natalizumab | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00027300 |
| Placebo | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00027300 |
| Natalizumab | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00027300 |
| aducanumab | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT02782975 |
| oral corticosteroids | Other | Phase PHASE2 | Lupus Nephritis | TERMINATED | NCT01499355 |
| mycophenolate mofetil | Other | Phase PHASE2 | Lupus Nephritis | TERMINATED | NCT01499355 |
| Placebo | Other | Phase PHASE2 | Lupus Nephritis | TERMINATED | NCT01499355 |
| BIIB023 | Other | Phase PHASE2 | Lupus Nephritis | TERMINATED | NCT01499355 |
| oral corticosteroids | Other | Phase PHASE2 | Lupus Nephritis | TERMINATED | NCT01499355 |
| mycophenolate mofetil | Other | Phase PHASE2 | Lupus Nephritis | TERMINATED | NCT01499355 |
| Placebo | Other | Phase PHASE2 | Lupus Nephritis | TERMINATED | NCT01499355 |
| BIIB023 | Other | Phase PHASE2 | Lupus Nephritis | TERMINATED | NCT01499355 |
| naproxen | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | COMPLETED | NCT01939002 |
| BIIB017 | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | COMPLETED | NCT01939002 |
| naproxen | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | COMPLETED | NCT01939002 |
| BIIB017 | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | COMPLETED | NCT01939002 |
| tetanus diphtheria toxoid vaccine (Td) | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00536120 |
| keyhole limpet hemocyanin (KLH) | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00536120 |
| BG00002 (natalizumab) | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00536120 |
| tetanus diphtheria toxoid vaccine (Td) | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00536120 |
| keyhole limpet hemocyanin (KLH) | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00536120 |
| BG00002 (natalizumab) | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00536120 |
| tetanus diphtheria toxoid vaccine (Td) | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00536120 |
| keyhole limpet hemocyanin (KLH) | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00536120 |
| BG00002 (natalizumab) | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00536120 |
| BIIB074 Treatment D | Drug | Phase PHASE1 | Trigeminal Neuralgia (TN) | COMPLETED | NCT02951221 |
| BIIB074 Treatment C | Drug | Phase PHASE1 | Trigeminal Neuralgia (TN) | COMPLETED | NCT02951221 |
| BIIB074 Treatment B | Drug | Phase PHASE1 | Trigeminal Neuralgia (TN) | COMPLETED | NCT02951221 |
| BIIB074 Treatment A | Drug | Phase PHASE1 | Trigeminal Neuralgia (TN) | COMPLETED | NCT02951221 |
| BIIB074 Treatment D | Drug | Phase PHASE1 | Trigeminal Neuralgia (TN) | COMPLETED | NCT02951221 |
| BIIB074 Treatment C | Drug | Phase PHASE1 | Trigeminal Neuralgia (TN) | COMPLETED | NCT02951221 |
| BIIB074 Treatment B | Drug | Phase PHASE1 | Trigeminal Neuralgia (TN) | COMPLETED | NCT02951221 |
| BIIB074 Treatment A | Drug | Phase PHASE1 | Trigeminal Neuralgia (TN) | COMPLETED | NCT02951221 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02831517 |
| BIIB074 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02831517 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02831517 |
| BIIB074 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02831517 |
| BIIB019 (Daclizumab) | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01462318 |
| Dextromethorphan | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01462318 |
| Omeprazole | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01462318 |
| Vitamin K | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01462318 |
| S-warfarin | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01462318 |
| Caffeine | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01462318 |
| Midazolam | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01462318 |
| BIIB019 (Daclizumab) | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01462318 |
| Dextromethorphan | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01462318 |
| Omeprazole | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01462318 |
| Vitamin K | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01462318 |
| S-warfarin | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01462318 |
| Caffeine | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01462318 |
| Midazolam | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01462318 |
| Placebo | Other | Phase PHASE1 | Systemic Lupos Erythematosus, SLE | COMPLETED | NCT02829541 |
| BIIB068 | Other | Phase PHASE1 | Systemic Lupos Erythematosus, SLE | COMPLETED | NCT02829541 |
| Placebo | Other | Phase PHASE1 | Systemic Lupos Erythematosus, SLE | COMPLETED | NCT02829541 |
| BIIB068 | Other | Phase PHASE1 | Systemic Lupos Erythematosus, SLE | COMPLETED | NCT02829541 |
| Placebo | Other | Phase PHASE1 | Systemic Lupos Erythematosus, SLE | COMPLETED | NCT02829541 |
| BIIB068 | Other | Phase PHASE1 | Systemic Lupos Erythematosus, SLE | COMPLETED | NCT02829541 |
| BG00012 (DMF) | Other | Phase PHASE4 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT01873417 |
| BG00012 (DMF) | Other | Phase PHASE4 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT01873417 |
| Fampridine | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT01480076 |
| Fampridine | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT01480076 |
| dimethyl fumarate | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01156311 |
| dimethyl fumarate | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01156311 |
| BG00002 (natalizumab) | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis (RRMS) | COMPLETED | NCT00871780 |
| BG00002 (natalizumab) | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis (RRMS) | COMPLETED | NCT00871780 |
| BG00002 (natalizumab) | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00306592 |
| BG00002 (natalizumab) | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT00306592 |
| BG00012 (DMF) (Tecfidera®.) | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT02683863 |
| BG00012 (DMF) (Tecfidera®.) | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT02683863 |
| Peanut Butter | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT02217982 |
| Loperamide | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT02217982 |
| Simethicone | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | TERMINATED | NCT02217982 |
| Placebo | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT02219932 |
| fampridine | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT02219932 |
| Placebo | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT02219932 |
| fampridine | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT02219932 |
| Purified chick-embryo cell rabies vaccine | Other | Approved | Rabies | COMPLETED | NCT03093545 |
| Equine Rabies Immunoglobulin | Other | Approved | Rabies | COMPLETED | NCT03093545 |
| Purified chick-embryo cell rabies vaccine | Other | Approved | Rabies | COMPLETED | NCT03093545 |
| Equine Rabies Immunoglobulin | Other | Approved | Rabies | COMPLETED | NCT03093545 |
| Placebo | Other | Phase PHASE1 | Healthy | TERMINATED | NCT02555085 |
| BIIB063 | Other | Phase PHASE1 | Healthy | TERMINATED | NCT02555085 |
| Placebo | Other | Phase PHASE1 | Healthy | TERMINATED | NCT02555085 |
| BIIB063 | Other | Phase PHASE1 | Healthy | TERMINATED | NCT02555085 |
| dimethyl fumarate | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02125604 |
| Placebo | Other | Phase PHASE3 | Multiple Sclerosis, Secondary Progressive | TERMINATED | NCT02430532 |
| dimethyl fumarate | Other | Phase PHASE3 | Multiple Sclerosis, Secondary Progressive | TERMINATED | NCT02430532 |
| Placebo | Other | Phase PHASE3 | Multiple Sclerosis, Secondary Progressive | TERMINATED | NCT02430532 |
| dimethyl fumarate | Other | Phase PHASE3 | Multiple Sclerosis, Secondary Progressive | TERMINATED | NCT02430532 |
| dimethyl fumarate | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT02579681 |
| dimethyl fumarate | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT02579681 |
| Avonex | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT01864148 |
| Placebo | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT01864148 |
| BIIB033 | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT01864148 |
| Avonex | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT01864148 |
| Placebo | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT01864148 |
| BIIB033 | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT01864148 |
| dimethyl fumarate | Other | Phase PHASE3 | Multiple Sclerosis | TERMINATED | NCT02428231 |
| dimethyl fumarate | Other | Phase PHASE3 | Multiple Sclerosis | TERMINATED | NCT02428231 |
| dimethyl fumarate | Other | Phase PHASE3 | Multiple Sclerosis | TERMINATED | NCT02428231 |
| non-pegylated interferon | Other | Phase PHASE2 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT02097849 |
| meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent) | Other | Phase PHASE2 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT02097849 |
| 23-valent pneumococcal polysaccharide vaccine | Other | Phase PHASE2 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT02097849 |
| tetanus diphtheria toxoids vaccine | Other | Phase PHASE2 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT02097849 |
| dimethyl fumarate | Other | Phase PHASE2 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT02097849 |
| non-pegylated interferon | Other | Phase PHASE2 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT02097849 |
| meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent) | Other | Phase PHASE2 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT02097849 |
| 23-valent pneumococcal polysaccharide vaccine | Other | Phase PHASE2 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT02097849 |
| tetanus diphtheria toxoids vaccine | Other | Phase PHASE2 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT02097849 |
| dimethyl fumarate | Other | Phase PHASE2 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT02097849 |
| natalizumab | Other | Phase PHASE4 | Relapsing Multiple Sclerosis | TERMINATED | NCT02241785 |
| natalizumab | Other | Phase PHASE4 | Relapsing Multiple Sclerosis | TERMINATED | NCT02241785 |
| fingolimod | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | TERMINATED | NCT02342704 |
| natalizumab | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | TERMINATED | NCT02342704 |
| fingolimod | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | TERMINATED | NCT02342704 |
| natalizumab | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | TERMINATED | NCT02342704 |
| dimethyl fumarate | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT02969304 |
| Cyclophosphamide | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | COMPLETED | NCT00090051 |
| Fludarabine Phosphate | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | COMPLETED | NCT00090051 |
| Rituximab | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | COMPLETED | NCT00090051 |
| Cyclophosphamide | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | COMPLETED | NCT00090051 |
| Fludarabine Phosphate | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | COMPLETED | NCT00090051 |
| Rituximab | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | COMPLETED | NCT00090051 |
| interferon beta 1a 30 ug IM once weekly | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00179478 |
| interferon beta 1a 30 ug IM once weekly | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00179478 |
| Placebo | Other | Phase PHASE3 | Secondary Progressive Multiple Sclerosis | TERMINATED | NCT01416181 |
| natalizumab | Other | Phase PHASE3 | Secondary Progressive Multiple Sclerosis | TERMINATED | NCT01416181 |
| Placebo | Other | Phase PHASE3 | Secondary Progressive Multiple Sclerosis | TERMINATED | NCT01416181 |
| natalizumab | Other | Phase PHASE3 | Secondary Progressive Multiple Sclerosis | TERMINATED | NCT01416181 |
| Placebo | Other | Phase PHASE3 | Secondary Progressive Multiple Sclerosis | TERMINATED | NCT01416181 |
| natalizumab | Other | Phase PHASE3 | Secondary Progressive Multiple Sclerosis | TERMINATED | NCT01416181 |
| Placebo | Other | Phase PHASE1 | Trigeminal Neuralgia | COMPLETED | NCT02359344 |
| CNV1014802 | Other | Phase PHASE1 | Trigeminal Neuralgia | COMPLETED | NCT02359344 |
| Placebo | Other | Phase PHASE1 | Trigeminal Neuralgia | COMPLETED | NCT02359344 |
| CNV1014802 | Other | Phase PHASE1 | Trigeminal Neuralgia | COMPLETED | NCT02359344 |
| Placebo | Other | Phase PHASE2 | Lumbosacral Radiculopathy | COMPLETED | NCT01561027 |
| CNV1014802 | Other | Phase PHASE2 | Lumbosacral Radiculopathy | COMPLETED | NCT01561027 |
| Placebo | Other | Phase PHASE2 | Lumbosacral Radiculopathy | COMPLETED | NCT01561027 |
| CNV1014802 | Other | Phase PHASE2 | Lumbosacral Radiculopathy | COMPLETED | NCT01561027 |
| CNV1014802 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02551497 |
| CNV1014802 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02551497 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT00955396 |
| GSK1014802 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT00955396 |
| dimethyl fumarate | Other | Phase PHASE2 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT02410200 |
| dimethyl fumarate | Other | Phase PHASE2 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT02410200 |
| Tysabri | Other | Approved | Multiple Sclerosis | COMPLETED | NCT01071512 |
| Placebo | Other | Phase PHASE1 | Pain, Neuropathic | TERMINATED | NCT00964288 |
| GSK1014802 high dose | Other | Phase PHASE1 | Pain, Neuropathic | TERMINATED | NCT00964288 |
| Lidocaine | Other | Phase PHASE1 | Pain, Neuropathic | TERMINATED | NCT00964288 |
| GSK1014802 low dose | Other | Phase PHASE1 | Pain, Neuropathic | TERMINATED | NCT00964288 |
| Placebo | Other | Phase PHASE1 | Pain, Neuropathic | TERMINATED | NCT00964288 |
| GSK1014802 high dose | Other | Phase PHASE1 | Pain, Neuropathic | TERMINATED | NCT00964288 |
| Lidocaine | Other | Phase PHASE1 | Pain, Neuropathic | TERMINATED | NCT00964288 |
| GSK1014802 low dose | Other | Phase PHASE1 | Pain, Neuropathic | TERMINATED | NCT00964288 |
| Lamictal | Other | Phase PHASE1 | Bipolar Disorder | COMPLETED | NCT00488566 |
| Placebo | Other | Phase PHASE1 | Bipolar Disorder | COMPLETED | NCT00488566 |
| GSK drug | Drug | Phase PHASE1 | Bipolar Disorder | COMPLETED | NCT00488566 |
| GSK1014802 | Other | Phase PHASE1 | Bipolar Depression | COMPLETED | NCT00908154 |
| Placebo | Other | Phase PHASE1 | Bipolar Depression | COMPLETED | NCT00908154 |
| BMS-986168 Placebo | Other | Phase PHASE1 | Tauopathies | COMPLETED | NCT02294851 |
| BMS-986168 | Other | Phase PHASE1 | Tauopathies | COMPLETED | NCT02294851 |
| Avonex | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01119677 |
| Avonex | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01119677 |
| Avonex | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01119677 |
| Biopsy | Other | Preclinical | Healthy | COMPLETED | NCT02422407 |
| Biopsy | Other | Preclinical | Healthy | COMPLETED | NCT02422407 |
| CT-guidance | Other | Approved | Healthy | COMPLETED | NCT03218111 |
| MR Imaging | Other | Approved | Healthy | COMPLETED | NCT03218111 |
| CT-guidance | Other | Approved | Healthy | COMPLETED | NCT03218111 |
| MR Imaging | Other | Approved | Healthy | COMPLETED | NCT03218111 |
| BG00012 | Other | Phase PHASE1 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT00837785 |
| BG00012 | Other | Phase PHASE1 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT00837785 |
| BG00012 | Other | Phase PHASE1 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT00837785 |
| dimethyl fumarate | Other | Phase PHASE4 | Multiple Sclerosis | UNKNOWN | NCT03092544 |
| dimethyl fumarate | Other | Phase PHASE4 | Multiple Sclerosis | UNKNOWN | NCT03092544 |
| Placebo Cream | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT03091569 |
| Vitamin K Cream | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT03091569 |
| Placebo Cream | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT03091569 |
| Vitamin K Cream | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT03091569 |
| methotrexate | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00037102 |
| interferon beta 1a | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00037102 |
| Valproic Acid | Other | Phase PHASE1 | Drug Interaction | COMPLETED | NCT03385525 |
| BIIB074 | Other | Phase PHASE1 | Drug Interaction | COMPLETED | NCT03385525 |
| Valproic Acid | Other | Phase PHASE1 | Drug Interaction | COMPLETED | NCT03385525 |
| BIIB074 | Other | Phase PHASE1 | Drug Interaction | COMPLETED | NCT03385525 |
| natalizumab | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01943526 |
| natalizumab | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01943526 |
| Placebo | Other | Phase PHASE2 | Lumbosacral Radiculopathy | COMPLETED | NCT02935608 |
| BIIB074 | Other | Phase PHASE2 | Lumbosacral Radiculopathy | COMPLETED | NCT02935608 |
| Placebo | Other | Phase PHASE2 | Lumbosacral Radiculopathy | COMPLETED | NCT02935608 |
| BIIB074 | Other | Phase PHASE2 | Lumbosacral Radiculopathy | COMPLETED | NCT02935608 |
| Placebo | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT02143167 |
| SR-fampridine | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT02143167 |
| Placebo | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT02143167 |
| SR-fampridine | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT02143167 |
| Fampridine-SR | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT01656148 |
| Fampridine-SR | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT01656148 |
| Dimethyl fumarate | Other | Preclinical | Multiple Sclerosis | TERMINATED | NCT02644083 |
| Placebo | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT03224793 |
| BIIB059 | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT03224793 |
| natalizumab | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT02386566 |
| natalizumab | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT02386566 |
| natalizumab | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT02386566 |
| OC (ethinyl estradiol and levonorgestrel) | Other | Phase PHASE1 | Drug Interactions | COMPLETED | NCT03324685 |
| BIIB074 | Other | Phase PHASE1 | Drug Interactions | COMPLETED | NCT03324685 |
| OC (ethinyl estradiol and levonorgestrel) | Other | Phase PHASE1 | Drug Interactions | COMPLETED | NCT03324685 |
| BIIB074 | Other | Phase PHASE1 | Drug Interactions | COMPLETED | NCT03324685 |
| Dimethyl fumarate | Other | Phase PHASE4 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT02461069 |
| Benepali | Other | Preclinical | Rheumatoid Arthritis | COMPLETED | NCT03327454 |
| Benepali | Other | Preclinical | Rheumatoid Arthritis | COMPLETED | NCT03327454 |
| Benepali | Other | Preclinical | Rheumatoid Arthritis | COMPLETED | NCT03327454 |
| Natalizumab | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00884481 |
| Natalizumab | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00884481 |
| trivalent seasonal influenza vaccine | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01051349 |
| BIIB019 (Daclizumab) | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01051349 |
| trivalent seasonal influenza vaccine | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01051349 |
| BIIB019 (Daclizumab) | Other | Phase PHASE2 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01051349 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01838668 |
| Placebo | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01838668 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01838668 |
| Placebo | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01838668 |
| natalizumab | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02677077 |
| natalizumab | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02677077 |
| Higher Dose of Rituximab | Other | Phase PHASE2 | Immune Thrombocytopenic Purpura | COMPLETED | NCT00774202 |
| Rituxan, Cyclophosphamide, Vincristine, Prednisone | Other | Phase PHASE2 | Immune Thrombocytopenic Purpura | COMPLETED | NCT00774202 |
| Higher Dose of Rituximab | Other | Phase PHASE2 | Immune Thrombocytopenic Purpura | COMPLETED | NCT00774202 |
| Rituxan, Cyclophosphamide, Vincristine, Prednisone | Other | Phase PHASE2 | Immune Thrombocytopenic Purpura | COMPLETED | NCT00774202 |
| Placebo | Other | Phase PHASE2 | Trigeminal Neuralgia | COMPLETED | NCT01540630 |
| CNV1014802 | Other | Phase PHASE2 | Trigeminal Neuralgia | COMPLETED | NCT01540630 |
| Placebo | Other | Phase PHASE2 | Trigeminal Neuralgia | COMPLETED | NCT01540630 |
| CNV1014802 | Other | Phase PHASE2 | Trigeminal Neuralgia | COMPLETED | NCT01540630 |
| Placebo | Other | Phase PHASE2 | Primary Sjögren's Syndrome | TERMINATED | NCT01552681 |
| Baminercept | Other | Phase PHASE2 | Primary Sjögren's Syndrome | TERMINATED | NCT01552681 |
| Placebo | Other | Phase PHASE2 | Primary Sjögren's Syndrome | TERMINATED | NCT01552681 |
| Baminercept | Other | Phase PHASE2 | Primary Sjögren's Syndrome | TERMINATED | NCT01552681 |
| natalizumab | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01485003 |
| BIIB074 | Other | Phase PHASE2 | Neuropathic Pain From Lumbosacral Radiculopathy | TERMINATED | NCT02957617 |
| BIIB074 | Other | Phase PHASE2 | Neuropathic Pain From Lumbosacral Radiculopathy | TERMINATED | NCT02957617 |
| Placebo | Other | Phase PHASE4 | Allergic Rhinitis | COMPLETED | NCT02543346 |
| Cetirizine | Other | Phase PHASE4 | Allergic Rhinitis | COMPLETED | NCT02543346 |
| Placebo | Other | Phase PHASE4 | Allergic Rhinitis | COMPLETED | NCT02543346 |
| Cetirizine | Other | Phase PHASE4 | Allergic Rhinitis | COMPLETED | NCT02543346 |
| Outpatient Muscle Biopsy | Other | Preclinical | Sarcopenia | COMPLETED | NCT02839460 |
| Outpatient Muscle Biopsy | Other | Preclinical | Sarcopenia | COMPLETED | NCT02839460 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT03454126 |
| BIIB095 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT03454126 |
| dimethyl fumarate | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT02525874 |
| dimethyl fumarate | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT02525874 |
| Placebo | Other | Phase PHASE1 | Parkinson's Disease | COMPLETED | NCT02459886 |
| BIIB054 | Other | Phase PHASE1 | Parkinson's Disease | COMPLETED | NCT02459886 |
| Bodyweight training | Other | Approved | Multiple Sclerosis | UNKNOWN | NCT04002492 |
| Bodyweight training | Other | Approved | Multiple Sclerosis | UNKNOWN | NCT04002492 |
| Tylenol Pill | Other | Phase PHASE4 | Multiple Sclerosis | UNKNOWN | NCT03424733 |
| Prednisone | Other | Phase PHASE4 | Multiple Sclerosis | UNKNOWN | NCT03424733 |
| Plegridy | Other | Phase PHASE4 | Multiple Sclerosis | UNKNOWN | NCT03424733 |
| Tylenol Pill | Other | Phase PHASE4 | Multiple Sclerosis | UNKNOWN | NCT03424733 |
| Prednisone | Other | Phase PHASE4 | Multiple Sclerosis | UNKNOWN | NCT03424733 |
| Plegridy | Other | Phase PHASE4 | Multiple Sclerosis | UNKNOWN | NCT03424733 |
| BIIB033 100mg/Kg | Other | Phase PHASE2 | Acute Optic Neuritis | COMPLETED | NCT02657915 |
| Placebo | Other | Phase PHASE2 | Acute Optic Neuritis | COMPLETED | NCT02657915 |
| SC interferon beta-1b | Other | Preclinical | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT03347370 |
| SC interferon beta-1a | Other | Preclinical | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT03347370 |
| SC Peginterferon beta-1a | Other | Preclinical | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT03347370 |
| SC interferon beta-1b | Other | Preclinical | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT03347370 |
| SC interferon beta-1a | Other | Preclinical | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT03347370 |
| SC Peginterferon beta-1a | Other | Preclinical | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT03347370 |
| Daclizumab | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis (RRMS) | TERMINATED | NCT02881567 |
| Daclizumab | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis (RRMS) | TERMINATED | NCT02881567 |
| Daclizumab | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis (RRMS) | TERMINATED | NCT02881567 |
| Ipilimumab | Other | Preclinical | Glioblastoma | NO_LONGER_AVAILABLE | NCT03460782 |
| Ipilimumab | Other | Preclinical | Glioblastoma | NO_LONGER_AVAILABLE | NCT03460782 |
| Ipilimumab | Other | Preclinical | Glioblastoma | NO_LONGER_AVAILABLE | NCT03460782 |
| Ipilimumab | Other | Preclinical | Glioblastoma | NO_LONGER_AVAILABLE | NCT03460782 |
| Placebo | Other | Phase PHASE1 | Hearing Loss, Sensorineural | COMPLETED | NCT01518920 |
| PF-04958242 | Other | Phase PHASE1 | Hearing Loss, Sensorineural | COMPLETED | NCT01518920 |
| Placebo | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01518894 |
| PF-04958242 | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01518894 |
| Placebo | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01518894 |
| PF-04958242 | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01518894 |
| Placebo | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01511510 |
| PF-04958242 | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01511510 |
| Placebo | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01511510 |
| PF-04958242 | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT01511510 |
| dimethyl fumarate | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT02555215 |
| Placebo | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT02201849 |
| Active Control | Other | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT02201849 |
| Study Drug | Drug | Phase PHASE1 | Multiple Sclerosis | COMPLETED | NCT02201849 |
| BIIB019 (Daclizumab) | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | TERMINATED | NCT01797965 |
| BIIB019 (Daclizumab) | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | TERMINATED | NCT01797965 |
| BIIB019 (Daclizumab) | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | TERMINATED | NCT01797965 |
| PF-04958242 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT01365338 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT01365338 |
| PF-04958242 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT01365338 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT01365338 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT01238679 |
| PF-04958242 | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT01238679 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT01238679 |
| PF-04958242 | Other | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT01238679 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT01159483 |
| PF-04958242 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT01159483 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT01159483 |
| PF-04958242 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT01159483 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02228395 |
| PF-04958242 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02228395 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02228395 |
| PF-04958242 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02228395 |
| Itraconazole | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02341482 |
| PF-04958242 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02341482 |
| Itraconazole | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02341482 |
| PF-04958242 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02341482 |
| Placebo | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis (IPF) | COMPLETED | NCT01371305 |
| BG00011 | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis (IPF) | COMPLETED | NCT01371305 |
| Placebo | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis (IPF) | COMPLETED | NCT01371305 |
| BG00011 | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis (IPF) | COMPLETED | NCT01371305 |
| SCH 721015 | Other | Phase PHASE1 | Pleural Mesothelioma | COMPLETED | NCT00299962 |
| Adenoviral-mediated Interferon-beta | Other | Phase PHASE1 | Pleural Mesothelioma | COMPLETED | NCT00299962 |
| dimethyl fumarate | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01930708 |
| dimethyl fumarate | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT01930708 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT03056729 |
| BIIB076 | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT03056729 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT03056729 |
| BIIB076 | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT03056729 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT03056729 |
| BIIB076 | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT03056729 |
| Methylprednisolone | Other | Phase PHASE2 | Graft Versus Host Disease | COMPLETED | NCT02176031 |
| Natalizumab | Other | Phase PHASE2 | Graft Versus Host Disease | COMPLETED | NCT02176031 |
| Methylprednisolone | Other | Phase PHASE2 | Graft Versus Host Disease | COMPLETED | NCT02176031 |
| Natalizumab | Other | Phase PHASE2 | Graft Versus Host Disease | COMPLETED | NCT02176031 |
| BIIB092 | Other | Phase PHASE1 | Supranuclear Palsy, Progressive | TERMINATED | NCT02658916 |
| BIIB092 | Other | Phase PHASE1 | Supranuclear Palsy, Progressive | TERMINATED | NCT02658916 |
| Assessments | Other | Preclinical | Frontotemporal Dementia | COMPLETED | NCT03088956 |
| Assessments | Other | Preclinical | Frontotemporal Dementia | COMPLETED | NCT03088956 |
| Assessments | Other | Preclinical | Frontotemporal Dementia | COMPLETED | NCT03088956 |
| Dimethyl Fumarate | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT03093324 |
| ALKS 8700 | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT03093324 |
| Dimethyl Fumarate | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT03093324 |
| ALKS 8700 | Other | Phase PHASE3 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT03093324 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | TERMINATED | NCT01677572 |
| Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb) | Other | Phase PHASE1 | Alzheimer's Disease | TERMINATED | NCT01677572 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | TERMINATED | NCT01677572 |
| Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb) | Other | Phase PHASE1 | Alzheimer's Disease | TERMINATED | NCT01677572 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT02434718 |
| Aducanumab | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT02434718 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT02434718 |
| Aducanumab | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT02434718 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT02434718 |
| Aducanumab | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT02434718 |
| Interferon-beta | Other | Phase PHASE1 | Glioblastoma Multiforme | COMPLETED | NCT00031083 |
| Interferon-beta | Other | Phase PHASE1 | Glioblastoma Multiforme | COMPLETED | NCT00031083 |
| interferon beta-1b | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT03177083 |
| interferon beta-1a | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT03177083 |
| peginterferon beta-1a | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT03177083 |
| interferon beta-1b | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT03177083 |
| interferon beta-1a | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT03177083 |
| peginterferon beta-1a | Other | Phase PHASE4 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT03177083 |
| Placebo | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | TERMINATED | NCT03573505 |
| BG00011 | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | TERMINATED | NCT03573505 |
| Placebo | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | TERMINATED | NCT03573505 |
| BG00011 | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | TERMINATED | NCT03573505 |
| Placebo | Other | Phase PHASE2 | Supranuclear Palsy, Progressive | TERMINATED | NCT03068468 |
| BIIB092 | Other | Phase PHASE2 | Supranuclear Palsy, Progressive | TERMINATED | NCT03068468 |
| Placebo | Other | Phase PHASE2 | Supranuclear Palsy, Progressive | TERMINATED | NCT03068468 |
| BIIB092 | Other | Phase PHASE2 | Supranuclear Palsy, Progressive | TERMINATED | NCT03068468 |
| Placebo | Other | Phase PHASE2 | Primary Progressive Multiple Sclerosis | COMPLETED | NCT02959658 |
| Dimethyl fumarate | Other | Phase PHASE2 | Primary Progressive Multiple Sclerosis | COMPLETED | NCT02959658 |
| Placebo | Other | Phase PHASE2 | Primary Progressive Multiple Sclerosis | COMPLETED | NCT02959658 |
| Dimethyl fumarate | Other | Phase PHASE2 | Primary Progressive Multiple Sclerosis | COMPLETED | NCT02959658 |
| Avonex® monotherapy (6.0 MIU administered i.m. each week) | Drug | Preclinical | Multiple Sclerosis | COMPLETED | NCT00463710 |
| Placebo | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00835770 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00835770 |
| Placebo | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00835770 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00835770 |
| Enbrel | Other | Preclinical | Rheumatoid Arthritis | COMPLETED | NCT03100734 |
| Benepali | Other | Preclinical | Rheumatoid Arthritis | COMPLETED | NCT03100734 |
| Enbrel | Other | Preclinical | Rheumatoid Arthritis | COMPLETED | NCT03100734 |
| Benepali | Other | Preclinical | Rheumatoid Arthritis | COMPLETED | NCT03100734 |
| nusinersen | Other | Phase PHASE1 | Spinal Muscular Atrophy | COMPLETED | NCT02052791 |
| nusinersen | Other | Phase PHASE1 | Spinal Muscular Atrophy | COMPLETED | NCT02052791 |
| nusinersen | Other | Phase PHASE1 | Spinal Muscular Atrophy | COMPLETED | NCT02052791 |
| nusinersen | Other | Phase PHASE1 | Spinal Muscular Atrophy | COMPLETED | NCT01780246 |
| nusinersen | Other | Phase PHASE1 | Spinal Muscular Atrophy | COMPLETED | NCT01780246 |
| Melatonin | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT02691702 |
| BIIB118 | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT02691702 |
| Melatonin | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT02691702 |
| BIIB118 | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT02691702 |
| Sham Procedure | Procedure | Phase PHASE2 | Spinal Muscular Atrophy | TERMINATED | NCT02462759 |
| Nusinersen | Other | Phase PHASE2 | Spinal Muscular Atrophy | TERMINATED | NCT02462759 |
| Sham Procedure | Procedure | Phase PHASE2 | Spinal Muscular Atrophy | TERMINATED | NCT02462759 |
| Nusinersen | Other | Phase PHASE2 | Spinal Muscular Atrophy | TERMINATED | NCT02462759 |
| BIIB118 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02443740 |
| BIIB118 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02443740 |
| Sham procedure | Procedure | Phase PHASE3 | Spinal Muscular Atrophy | COMPLETED | NCT02292537 |
| Nusinersen | Other | Phase PHASE3 | Spinal Muscular Atrophy | COMPLETED | NCT02292537 |
| Sham procedure | Procedure | Phase PHASE3 | Spinal Muscular Atrophy | COMPLETED | NCT02292537 |
| Nusinersen | Other | Phase PHASE3 | Spinal Muscular Atrophy | COMPLETED | NCT02292537 |
| Sham procedure | Procedure | Phase PHASE3 | Spinal Muscular Atrophy | TERMINATED | NCT02193074 |
| nusinersen | Other | Phase PHASE3 | Spinal Muscular Atrophy | TERMINATED | NCT02193074 |
| Sham procedure | Procedure | Phase PHASE3 | Spinal Muscular Atrophy | TERMINATED | NCT02193074 |
| nusinersen | Other | Phase PHASE3 | Spinal Muscular Atrophy | TERMINATED | NCT02193074 |
| nusinersen | Other | Phase PHASE2 | Spinal Muscular Atrophy | COMPLETED | NCT01839656 |
| nusinersen | Other | Phase PHASE2 | Spinal Muscular Atrophy | COMPLETED | NCT01839656 |
| nusinersen | Other | Phase PHASE1 | Spinal Muscular Atrophy | COMPLETED | NCT01494701 |
| nusinersen | Other | Phase PHASE1 | Spinal Muscular Atrophy | COMPLETED | NCT01494701 |
| test for SMN1 exon 7 deletion | Other | Preclinical | Spinal Muscular Atrophy | COMPLETED | NCT03554343 |
| test for SMN1 exon 7 deletion | Other | Preclinical | Spinal Muscular Atrophy | COMPLETED | NCT03554343 |
| test for SMN1 exon 7 deletion | Other | Preclinical | Spinal Muscular Atrophy | COMPLETED | NCT03554343 |
| Lidocaine | Other | Phase PHASE1 | Healthy Volunteers | WITHDRAWN | NCT04106050 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | WITHDRAWN | NCT04106050 |
| BIIB074 | Other | Phase PHASE1 | Healthy Volunteers | WITHDRAWN | NCT04106050 |
| BIIB095 | Other | Phase PHASE1 | Healthy Volunteers | WITHDRAWN | NCT04106050 |
| Lidocaine | Other | Phase PHASE1 | Healthy Volunteers | WITHDRAWN | NCT04106050 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | WITHDRAWN | NCT04106050 |
| BIIB074 | Other | Phase PHASE1 | Healthy Volunteers | WITHDRAWN | NCT04106050 |
| BIIB095 | Other | Phase PHASE1 | Healthy Volunteers | WITHDRAWN | NCT04106050 |
| BIIB104 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04068532 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04068532 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT03943056 |
| BIIB091 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT03943056 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT03943056 |
| BIIB091 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT03943056 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04079101 |
| BIIB104 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04079101 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04079101 |
| BIIB104 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04079101 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04079101 |
| BIIB104 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04079101 |
| Natalizumab | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05925049 |
| SAGE-217 low dose | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03284931 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03284931 |
| SAGE-217 high dose | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03284931 |
| SAGE-217 low dose | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03284931 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03284931 |
| SAGE-217 high dose | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03284931 |
| Nusinersen Sodium Injection | Other | Preclinical | Muscular Atrophy, Spinal | COMPLETED | NCT04419233 |
| Nusinersen Sodium Injection | Other | Preclinical | Muscular Atrophy, Spinal | COMPLETED | NCT04419233 |
| Placebo | Other | Phase PHASE2 | Ischemic Stroke | WITHDRAWN | NCT05764122 |
| BIIB131 | Other | Phase PHASE2 | Ischemic Stroke | WITHDRAWN | NCT05764122 |
| Nusinersen | Other | Preclinical | Infantile-onset Spinal Muscular Atrophy | NO_LONGER_AVAILABLE | NCT02865109 |
| Nusinersen | Other | Preclinical | Infantile-onset Spinal Muscular Atrophy | NO_LONGER_AVAILABLE | NCT02865109 |
| Nusinersen | Other | Phase PHASE1 | Spinal Muscular Atrophy | COMPLETED | NCT01703988 |
| Nusinersen | Other | Phase PHASE1 | Spinal Muscular Atrophy | COMPLETED | NCT01703988 |
| Placebo | Other | Phase PHASE2 | Small Fiber Neuropathy | TERMINATED | NCT03339336 |
| BIIB074 | Other | Phase PHASE2 | Small Fiber Neuropathy | TERMINATED | NCT03339336 |
| Placebo | Other | Phase PHASE1 | Parkinson's Disease | TERMINATED | NCT03716570 |
| BIIB054 | Other | Phase PHASE1 | Parkinson's Disease | TERMINATED | NCT03716570 |
| Placebo | Other | Phase PHASE1 | Traumatic Brain Injury | COMPLETED | NCT01132703 |
| Glyburide for Injection | Other | Phase PHASE1 | Traumatic Brain Injury | COMPLETED | NCT01132703 |
| Placebo | Other | Phase PHASE1 | Traumatic Brain Injury | COMPLETED | NCT01132703 |
| Glyburide for Injection | Other | Phase PHASE1 | Traumatic Brain Injury | COMPLETED | NCT01132703 |
| Multiple Dose | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01424163 |
| Single dose standard | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01424163 |
| Single dose reduced | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01424163 |
| Multiple Dose | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01424163 |
| Single dose standard | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01424163 |
| Single dose reduced | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT01424163 |
| Brain Imaging | Other | Approved | Stroke, Ischemic | COMPLETED | NCT03662750 |
| Brain Imaging | Other | Approved | Stroke, Ischemic | COMPLETED | NCT03662750 |
| Dosing Interruption of Natalizumab | Other | Phase PHASE4 | Multiple Sclerosis | UNKNOWN | NCT04048577 |
| Dosing Interruption of Natalizumab | Other | Phase PHASE4 | Multiple Sclerosis | UNKNOWN | NCT04048577 |
| [18F]Florbetapir PET imaging | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT01767493 |
| [18F]Florbetapir PET imaging | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT01767493 |
| Placebo | Other | Phase PHASE3 | Alzheimer's Disease | TERMINATED | NCT02484547 |
| Aducanumab (BIIB037) | Other | Phase PHASE3 | Alzheimer's Disease | TERMINATED | NCT02484547 |
| Placebo | Other | Phase PHASE3 | Alzheimer's Disease | TERMINATED | NCT02484547 |
| Aducanumab (BIIB037) | Other | Phase PHASE3 | Alzheimer's Disease | TERMINATED | NCT02484547 |
| Placebo | Other | Phase PHASE3 | Alzheimer's Disease | TERMINATED | NCT02477800 |
| Aducanumab (BIIB037) | Other | Phase PHASE3 | Alzheimer's Disease | TERMINATED | NCT02477800 |
| Placebo | Other | Phase PHASE3 | Alzheimer's Disease | TERMINATED | NCT02477800 |
| Aducanumab (BIIB037) | Other | Phase PHASE3 | Alzheimer's Disease | TERMINATED | NCT02477800 |
| injectable MS DMT | Other | Phase PHASE4 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT02471560 |
| dimethyl fumarate | Other | Phase PHASE4 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT02471560 |
| injectable MS DMT | Other | Phase PHASE4 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT02471560 |
| dimethyl fumarate | Other | Phase PHASE4 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT02471560 |
| No Intervention | Other | Preclinical | Choroideremia | COMPLETED | NCT04795206 |
| No Intervention | Other | Preclinical | Choroideremia | COMPLETED | NCT04795206 |
| No Intervention | Other | Preclinical | Choroideremia | COMPLETED | NCT04795206 |
| Placebo | Other | Phase PHASE2 | Cognitive Dysfunction | TERMINATED | NCT03639987 |
| Aducanumab | Other | Phase PHASE2 | Cognitive Dysfunction | TERMINATED | NCT03639987 |
| Placebo | Other | Phase PHASE2 | Cognitive Dysfunction | TERMINATED | NCT03639987 |
| Aducanumab | Other | Phase PHASE2 | Cognitive Dysfunction | TERMINATED | NCT03639987 |
| nusinersen | Other | Preclinical | Spinal Muscular Atrophy | COMPLETED | NCT04591678 |
| Placebo | Other | Approved | Sarcopenia | UNKNOWN | NCT04702087 |
| OLEP | Other | Approved | Sarcopenia | UNKNOWN | NCT04702087 |
| Placebo | Other | Approved | Sarcopenia | UNKNOWN | NCT04702087 |
| OLEP | Other | Approved | Sarcopenia | UNKNOWN | NCT04702087 |
| No Intervention | Other | Preclinical | Choroideremia | COMPLETED | NCT04750785 |
| No Intervention | Other | Preclinical | Choroideremia | COMPLETED | NCT04750785 |
| Placebo | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT02332798 |
| PF-04958242 | Other | Phase PHASE1 | Schizophrenia | COMPLETED | NCT02332798 |
| CD4 Antigens | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00000721 |
| CD4 Antigens | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00000721 |
| CD4 Antigens | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT00000721 |
| Axitinib | Other | Phase PHASE1 | Endometriosis | WITHDRAWN | NCT03481842 |
| BIBW2992 | Other | Phase PHASE1 | Endometriosis | WITHDRAWN | NCT03481842 |
| Linifanib | Other | Phase PHASE1 | Endometriosis | WITHDRAWN | NCT03481842 |
| Axitinib | Other | Phase PHASE1 | Endometriosis | WITHDRAWN | NCT03481842 |
| BIBW2992 | Other | Phase PHASE1 | Endometriosis | WITHDRAWN | NCT03481842 |
| Linifanib | Other | Phase PHASE1 | Endometriosis | WITHDRAWN | NCT03481842 |
| Placebo | Other | Phase PHASE2 | Epilepsy, Focal Seizures, Partial Seizures | COMPLETED | NCT03283371 |
| Natalizumab | Other | Phase PHASE2 | Epilepsy, Focal Seizures, Partial Seizures | COMPLETED | NCT03283371 |
| Placebo | Other | Phase PHASE2 | Epilepsy, Focal Seizures, Partial Seizures | COMPLETED | NCT03283371 |
| Natalizumab | Other | Phase PHASE2 | Epilepsy, Focal Seizures, Partial Seizures | COMPLETED | NCT03283371 |
| Placebo | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT03626012 |
| BIIB078 | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT03626012 |
| Placebo | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT03626012 |
| BIIB078 | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT03626012 |
| Blood Collection | Other | Phase EARLY_PHASE1 | Angelman Syndrome | COMPLETED | NCT04103333 |
| Lumbar Puncture | Other | Phase EARLY_PHASE1 | Angelman Syndrome | COMPLETED | NCT04103333 |
| Blood Collection | Other | Phase EARLY_PHASE1 | Angelman Syndrome | COMPLETED | NCT04103333 |
| Lumbar Puncture | Other | Phase EARLY_PHASE1 | Angelman Syndrome | COMPLETED | NCT04103333 |
| Blood Collection | Other | Phase EARLY_PHASE1 | Angelman Syndrome | COMPLETED | NCT04103333 |
| Lumbar Puncture | Other | Phase EARLY_PHASE1 | Angelman Syndrome | COMPLETED | NCT04103333 |
| BIIB054 | Other | Phase PHASE2 | Parkinson's Disease | TERMINATED | NCT03318523 |
| Placebo | Other | Phase PHASE2 | Parkinson's Disease | TERMINATED | NCT03318523 |
| BIIB054 | Other | Phase PHASE2 | Parkinson's Disease | TERMINATED | NCT03318523 |
| Placebo | Other | Phase PHASE2 | Parkinson's Disease | TERMINATED | NCT03318523 |
| Natalizumab Injection [Tysabri] | Other | Preclinical | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT04580381 |
| Natalizumab Injection [Tysabri] | Other | Preclinical | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT04580381 |
| Natalizumab Injection [Tysabri] | Other | Preclinical | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT04580381 |
| Placebo Oral Tablet | Other | Phase PHASE1 | Systemic Sclerosis | TERMINATED | NCT02981082 |
| Dimethyl Fumarate (DMF) | Other | Phase PHASE1 | Systemic Sclerosis | TERMINATED | NCT02981082 |
| Placebo Oral Tablet | Other | Phase PHASE1 | Systemic Sclerosis | TERMINATED | NCT02981082 |
| Dimethyl Fumarate (DMF) | Other | Phase PHASE1 | Systemic Sclerosis | TERMINATED | NCT02981082 |
| [11C]-PBR28 | Other | Phase PHASE1 | ALS | TERMINATED | NCT04490096 |
| Placebo | Other | Phase PHASE2 | Multiple Sclerosis | TERMINATED | NCT03222973 |
| BIIB033 (opicinumab) | Other | Phase PHASE2 | Multiple Sclerosis | TERMINATED | NCT03222973 |
| Placebo | Other | Phase PHASE2 | Multiple Sclerosis | TERMINATED | NCT03222973 |
| BIIB033 (opicinumab) | Other | Phase PHASE2 | Multiple Sclerosis | TERMINATED | NCT03222973 |
| Dexpramipexole | Other | Phase PHASE3 | Amyotrophic Lateral Sclerosis | TERMINATED | NCT01622088 |
| Dexpramipexole | Other | Phase PHASE3 | Amyotrophic Lateral Sclerosis | TERMINATED | NCT01622088 |
| Placebo | Other | Phase PHASE4 | Multiple Sclerosis (MS) | COMPLETED | NCT02739542 |
| Tecfidera | Other | Phase PHASE4 | Multiple Sclerosis (MS) | COMPLETED | NCT02739542 |
| Peginterferon beta-1a | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT01911767 |
| Dimethyl fumarate | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT01911767 |
| Diroximel fumarate | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05127564 |
| Diroximel fumarate | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05127564 |
| Diroximel fumarate | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05127564 |
| Clinical assessment | Other | Preclinical | Relapsing Remitting Multiple Sclerosis | UNKNOWN | NCT05446285 |
| ALKS 8700 | Other | Phase PHASE3 | Multiple Sclerosis | COMPLETED | NCT02634307 |
| Rituximab | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00493467 |
| Ibritumomab Tiuxetan (Zevalin) | Other | Phase PHASE2 | Lymphoma | COMPLETED | NCT00493467 |
| peginterferon beta-1a | Other | Preclinical | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT02230969 |
| peginterferon beta-1a | Other | Preclinical | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT02230969 |
| Adalimumab | Other | Preclinical | Arthritis, Rheumatoid | COMPLETED | NCT03662919 |
| Infliximab | Other | Preclinical | Arthritis, Rheumatoid | COMPLETED | NCT03662919 |
| steroids | Other | Phase PHASE2 | Acute Graft Versus Host Disease | COMPLETED | NCT02133924 |
| natalizumab | Other | Phase PHASE2 | Acute Graft Versus Host Disease | COMPLETED | NCT02133924 |
| Placebo | Other | Phase PHASE2 | Alzheimer's Disease | TERMINATED | NCT03352557 |
| BIIB092 | Other | Phase PHASE2 | Alzheimer's Disease | TERMINATED | NCT03352557 |
| Placebo | Other | Phase PHASE2 | Alzheimer's Disease | TERMINATED | NCT03352557 |
| BIIB092 | Other | Phase PHASE2 | Alzheimer's Disease | TERMINATED | NCT03352557 |
| Interferon beta 1a, oral doxycycline | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00246324 |
| Interferon beta 1a, oral doxycycline | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT00246324 |
| Multiple Sclerosis Performance Test (MSPT) | Other | Preclinical | Multiple Sclerosis | TERMINATED | NCT03926637 |
| Multiple Sclerosis Performance Test (MSPT) | Other | Preclinical | Multiple Sclerosis | TERMINATED | NCT03926637 |
| Multiple Sclerosis Performance Test (MSPT) | Other | Preclinical | Multiple Sclerosis | TERMINATED | NCT03926637 |
| Placebo | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT02106897 |
| BIIB059 (litifilimab) | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT02106897 |
| Placebo | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT02106897 |
| BIIB059 (litifilimab) | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT02106897 |
| Other: Assessments | Other | Preclinical | X-Linked Retinitis Pigmentosa | COMPLETED | NCT04926129 |
| Other: Assessments | Other | Preclinical | X-Linked Retinitis Pigmentosa | COMPLETED | NCT04926129 |
| MSPT | Other | Preclinical | Multiple Sclerosis | TERMINATED | NCT04599023 |
| MSPT | Other | Preclinical | Multiple Sclerosis | TERMINATED | NCT04599023 |
| Oral capsules Talazoparib | Other | Phase PHASE1 | Advanced or Recurrent Solid Tumors | WITHDRAWN | NCT03426254 |
| Injections Subcutaneously Talazoparib | Other | Phase PHASE1 | Advanced or Recurrent Solid Tumors | WITHDRAWN | NCT03426254 |
| Oral capsules Talazoparib | Other | Phase PHASE1 | Advanced or Recurrent Solid Tumors | WITHDRAWN | NCT03426254 |
| Injections Subcutaneously Talazoparib | Other | Phase PHASE1 | Advanced or Recurrent Solid Tumors | WITHDRAWN | NCT03426254 |
| BIIB122 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05229562 |
| Aducanumab | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05216887 |
| Aducanumab | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05216887 |
| BIIB104 Test Formulation | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05152485 |
| BIIB104 Reference Formulation | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05152485 |
| BIIB104 Test Formulation | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05152485 |
| BIIB104 Reference Formulation | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05152485 |
| BIIB104 Test Formulation | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05152485 |
| BIIB104 Reference Formulation | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05152485 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05148481 |
| BIIB104 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05148481 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05148481 |
| BIIB104 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05148481 |
| Konectom Application | Other | Approved | Multiple Sclerosis | COMPLETED | NCT04756700 |
| DigiCog (BCCAMS app) | Other | Approved | Multiple Sclerosis | COMPLETED | NCT04756700 |
| Interferon Beta Therapy | Drug | Preclinical | Multiple Sclerosis | COMPLETED | NCT04655222 |
| Interferon Beta Therapy | Drug | Preclinical | Multiple Sclerosis | COMPLETED | NCT04655222 |
| Interferon Beta Therapy | Drug | Preclinical | Multiple Sclerosis | COMPLETED | NCT04655222 |
| Interferon Beta Therapy | Drug | Preclinical | Multiple Sclerosis | COMPLETED | NCT04655222 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04571424 |
| BIIB133 (Dapirolizumab pegol) | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04571424 |
| Itraconazole | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04564612 |
| Rabeprazole | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04564612 |
| BIIB091 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04564612 |
| Itraconazole | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04564612 |
| Rabeprazole | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04564612 |
| BIIB091 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04564612 |
| BIIB078 | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | TERMINATED | NCT04288856 |
| BIIB078 | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | TERMINATED | NCT04288856 |
| Adalimumab | Other | Preclinical | Arthritis, Rheumatoid (RA) | COMPLETED | NCT04089514 |
| Adalimumab | Other | Preclinical | Arthritis, Rheumatoid (RA) | COMPLETED | NCT04089514 |
| Placebo | Other | Phase PHASE1 | Parkinson's Disease | COMPLETED | NCT04056689 |
| DNL151 | Other | Phase PHASE1 | Parkinson's Disease | COMPLETED | NCT04056689 |
| Placebo | Other | Phase PHASE1 | Parkinson's Disease | COMPLETED | NCT04056689 |
| DNL151 | Other | Phase PHASE1 | Parkinson's Disease | COMPLETED | NCT04056689 |
| Placebo | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT03945279 |
| BIIB100 | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT03945279 |
| Placebo | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT03945279 |
| BIIB100 | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT03945279 |
| Placebo | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT03945279 |
| BIIB100 | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | COMPLETED | NCT03945279 |
| Placebo | Other | Phase PHASE2 | Cognitive Impairment Associated With Schizophrenia | COMPLETED | NCT03745820 |
| BIIB104 | Other | Phase PHASE2 | Cognitive Impairment Associated With Schizophrenia | COMPLETED | NCT03745820 |
| Placebo | Other | Phase PHASE2 | Cognitive Impairment Associated With Schizophrenia | COMPLETED | NCT03745820 |
| BIIB104 | Other | Phase PHASE2 | Cognitive Impairment Associated With Schizophrenia | COMPLETED | NCT03745820 |
| Placebo | Other | Phase PHASE3 | Trigeminal Neuralgia | WITHDRAWN | NCT03637387 |
| BIIB074 | Other | Phase PHASE3 | Trigeminal Neuralgia | WITHDRAWN | NCT03637387 |
| Placebo | Other | Phase PHASE3 | Trigeminal Neuralgia | WITHDRAWN | NCT03637387 |
| BIIB074 | Other | Phase PHASE3 | Trigeminal Neuralgia | WITHDRAWN | NCT03637387 |
| Placebo | Other | Phase PHASE3 | Trigeminal Neuralgia | WITHDRAWN | NCT03070132 |
| BIIB074 | Other | Phase PHASE3 | Trigeminal Neuralgia | WITHDRAWN | NCT03070132 |
| Placebo | Other | Phase PHASE3 | Trigeminal Neuralgia | WITHDRAWN | NCT03070132 |
| BIIB074 | Other | Phase PHASE3 | Trigeminal Neuralgia | WITHDRAWN | NCT03070132 |
| Diroximel Fumarate | Other | Preclinical | Relapsing Forms of MS | TERMINATED | NCT04948606 |
| Diroximel Fumarate | Other | Preclinical | Relapsing Forms of MS | TERMINATED | NCT04948606 |
| dimethyl fumarate | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT02047097 |
| dimethyl fumarate | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT02047097 |
| dimethyl fumarate | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT02047097 |
| Diroximel Fumarate | Other | Preclinical | Relapsing Forms of MS | TERMINATED | NCT04746976 |
| Diroximel Fumarate | Other | Preclinical | Relapsing Forms of MS | TERMINATED | NCT04746976 |
| Glatiramer acetate | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | WITHDRAWN | NCT04079088 |
| Interferon-beta1 | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | WITHDRAWN | NCT04079088 |
| BIIB061 | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | WITHDRAWN | NCT04079088 |
| Placebo | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | WITHDRAWN | NCT04079088 |
| Glatiramer acetate | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | WITHDRAWN | NCT04079088 |
| Interferon-beta1 | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | WITHDRAWN | NCT04079088 |
| BIIB061 | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | WITHDRAWN | NCT04079088 |
| Placebo | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | WITHDRAWN | NCT04079088 |
| Voice analysis | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT05561621 |
| Voice analysis | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT05561621 |
| Placebo | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | TERMINATED | NCT03870763 |
| Peginterferon Beta-1a | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | TERMINATED | NCT03870763 |
| Dimethyl Fumarate | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | TERMINATED | NCT03870763 |
| Placebo | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | TERMINATED | NCT03870763 |
| Peginterferon Beta-1a | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | TERMINATED | NCT03870763 |
| Dimethyl Fumarate | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | TERMINATED | NCT03870763 |
| 99mTc-MAG3-BIIB067 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03764488 |
| Tofersen | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03764488 |
| PSP | Other | Preclinical | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT04221191 |
| Dimethyl Fumarate | Other | Preclinical | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT04221191 |
| BIIB132-Matching Placebo | Other | Phase PHASE1 | Spinocerebellar Ataxia Type 3 | TERMINATED | NCT05160558 |
| BIIB132 | Other | Phase PHASE1 | Spinocerebellar Ataxia Type 3 | TERMINATED | NCT05160558 |
| ASA matching placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01281111 |
| BG00012 matching placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01281111 |
| Aspirin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01281111 |
| Dimethyl Fumarate (BG00012) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01281111 |
| ASA matching placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01281111 |
| BG00012 matching placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01281111 |
| Aspirin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01281111 |
| Dimethyl Fumarate (BG00012) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01281111 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01017666 |
| BIIB014 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01017666 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01017666 |
| BIIB014 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01017666 |
| placebo | Other | Phase PHASE2 | Parkinson's Disease | WITHDRAWN | NCT00451815 |
| active drug (BIIB014) at 10, 30, 100, or 300 mg once daily. | Drug | Phase PHASE2 | Parkinson's Disease | WITHDRAWN | NCT00451815 |
| placebo | Other | Phase PHASE2 | Parkinson's Disease | WITHDRAWN | NCT00451815 |
| active drug (BIIB014) at 10, 30, 100, or 300 mg once daily. | Drug | Phase PHASE2 | Parkinson's Disease | WITHDRAWN | NCT00451815 |
| Alefacept | Other | Phase PHASE3 | Chronic Plaque Psoriasis | COMPLETED | NCT00233662 |
| Alefacept | Other | Phase PHASE3 | Chronic Plaque Psoriasis | COMPLETED | NCT00233662 |
| Alefacept | Other | Phase PHASE3 | Chronic Plaque Psoriasis | COMPLETED | NCT00233662 |
| ibritumomab tiuxetan (Zevalin®) | Other | Phase PHASE4 | Lymphoma, Non-Hodgkin | COMPLETED | NCT00168727 |
| BG00012 | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT00168701 |
| BG00012 | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT00168701 |
| peginterferon beta-1a | Other | Phase PHASE4 | Relapsing-Remitting Multiple Sclerosis (RRMS) | COMPLETED | NCT02587065 |
| 6 months weight resistance and balance program | Other | Approved | Multiple Sclerosis | COMPLETED | NCT01816100 |
| specifically design 6 month resistance training program | Other | Approved | Multiple Sclerosis | COMPLETED | NCT01816100 |
| 6 months weight resistance and balance program | Other | Approved | Multiple Sclerosis | COMPLETED | NCT01816100 |
| specifically design 6 month resistance training program | Other | Approved | Multiple Sclerosis | COMPLETED | NCT01816100 |
| Placebo | Other | Phase PHASE2 | Renal Insufficiency | TERMINATED | NCT00745316 |
| Tonapofylline | Other | Phase PHASE2 | Renal Insufficiency | TERMINATED | NCT00745316 |
| Placebo | Other | Phase PHASE2 | Renal Insufficiency | TERMINATED | NCT00745316 |
| Tonapofylline | Other | Phase PHASE2 | Renal Insufficiency | TERMINATED | NCT00745316 |
| Placebo | Other | Phase PHASE3 | Renal Insufficiency | COMPLETED | NCT00709865 |
| tonapofylline | Other | Phase PHASE3 | Renal Insufficiency | COMPLETED | NCT00709865 |
| Placebo | Other | Phase PHASE3 | Renal Insufficiency | COMPLETED | NCT00709865 |
| tonapofylline | Other | Phase PHASE3 | Renal Insufficiency | COMPLETED | NCT00709865 |
| Dimethyl fumarate | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT04756687 |
| Rituximab | Other | Phase PHASE1 | Kidney Insufficiency | WITHDRAWN | NCT00476515 |
| Rituximab | Other | Phase PHASE1 | Kidney Insufficiency | WITHDRAWN | NCT00476515 |
| Rituximab | Other | Phase PHASE1 | Kidney Insufficiency | WITHDRAWN | NCT00476515 |
| Placebo | Other | Phase PHASE1 | Chronic Kidney Disease | TERMINATED | NCT01500798 |
| 20 mg bardoxolone methyl | Other | Phase PHASE1 | Chronic Kidney Disease | TERMINATED | NCT01500798 |
| Placebo | Other | Phase PHASE1 | Chronic Kidney Disease | TERMINATED | NCT01500798 |
| 20 mg bardoxolone methyl | Other | Phase PHASE1 | Chronic Kidney Disease | TERMINATED | NCT01500798 |
| Placebo | Other | Phase PHASE2 | Systemic Lupus Erythematosus | COMPLETED | NCT02847598 |
| BIIB059 (litifilimab) | Other | Phase PHASE2 | Systemic Lupus Erythematosus | COMPLETED | NCT02847598 |
| Placebo | Other | Phase PHASE2 | Systemic Lupus Erythematosus | COMPLETED | NCT02847598 |
| BIIB059 (litifilimab) | Other | Phase PHASE2 | Systemic Lupus Erythematosus | COMPLETED | NCT02847598 |
| Placebo | Other | Phase PHASE2 | Major Depression | COMPLETED | NCT03000530 |
| SAGE-217 | Other | Phase PHASE2 | Major Depression | COMPLETED | NCT03000530 |
| Placebo | Other | Phase PHASE2 | Essential Tremor | COMPLETED | NCT02978781 |
| SAGE-217 | Other | Phase PHASE2 | Essential Tremor | COMPLETED | NCT02978781 |
| Placebo | Other | Phase PHASE2 | Essential Tremor | COMPLETED | NCT02978781 |
| SAGE-217 | Other | Phase PHASE2 | Essential Tremor | COMPLETED | NCT02978781 |
| Placebo | Other | Phase PHASE3 | Major Depressive Disorder | TERMINATED | NCT04007367 |
| SAGE-217 | Other | Phase PHASE3 | Major Depressive Disorder | TERMINATED | NCT04007367 |
| Placebo | Other | Phase PHASE3 | Major Depressive Disorder | TERMINATED | NCT04007367 |
| SAGE-217 | Other | Phase PHASE3 | Major Depressive Disorder | TERMINATED | NCT04007367 |
| Placebo | Other | Phase PHASE3 | Major Depressive Disorder | TERMINATED | NCT03771664 |
| SAGE-217 | Other | Phase PHASE3 | Major Depressive Disorder | TERMINATED | NCT03771664 |
| Placebo | Other | Phase PHASE3 | Major Depressive Disorder | TERMINATED | NCT03771664 |
| SAGE-217 | Other | Phase PHASE3 | Major Depressive Disorder | TERMINATED | NCT03771664 |
| Placebo | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT03672175 |
| SAGE-217 | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT03672175 |
| Placebo | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT03672175 |
| SAGE-217 | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT03672175 |
| Antiparkinsonian Agent(s) | Other | Phase PHASE2 | Parkinson Disease | COMPLETED | NCT03000569 |
| Levodopa | Other | Phase PHASE2 | Parkinson Disease | COMPLETED | NCT03000569 |
| SAGE-217 | Other | Phase PHASE2 | Parkinson Disease | COMPLETED | NCT03000569 |
| Blood | Other | Preclinical | Amyotrophic Lateral Sclerosis | COMPLETED | NCT04819555 |
| Placebo | Other | Phase PHASE3 | Depression, Postpartum | COMPLETED | NCT04442503 |
| SAGE-217 | Other | Phase PHASE3 | Depression, Postpartum | COMPLETED | NCT04442503 |
| Placebo | Other | Phase PHASE3 | Depression, Postpartum | COMPLETED | NCT04442503 |
| SAGE-217 | Other | Phase PHASE3 | Depression, Postpartum | COMPLETED | NCT04442503 |
| BIIB111 | Other | Phase PHASE3 | Choroideremia | COMPLETED | NCT03496012 |
| Placebo | Other | Phase PHASE2 | Bipolar Disorder I | COMPLETED | NCT03692910 |
| SAGE-217 | Other | Phase PHASE2 | Bipolar Disorder I | COMPLETED | NCT03692910 |
| Placebo | Other | Phase PHASE2 | Bipolar Disorder I | COMPLETED | NCT03692910 |
| SAGE-217 | Other | Phase PHASE2 | Bipolar Disorder I | COMPLETED | NCT03692910 |
| SAGE 217 30 mg Capsules | Other | Phase PHASE3 | Postpartum Depression | COMPLETED | NCT02978326 |
| Placebo | Other | Phase PHASE3 | Postpartum Depression | COMPLETED | NCT02978326 |
| SAGE-217 15/20 mg Oral Solution | Other | Phase PHASE3 | Postpartum Depression | COMPLETED | NCT02978326 |
| SAGE 217 30 mg Capsules | Other | Phase PHASE3 | Postpartum Depression | COMPLETED | NCT02978326 |
| Placebo | Other | Phase PHASE3 | Postpartum Depression | COMPLETED | NCT02978326 |
| SAGE-217 15/20 mg Oral Solution | Other | Phase PHASE3 | Postpartum Depression | COMPLETED | NCT02978326 |
| Desvenlafaxine | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT04476030 |
| Duloxetine | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT04476030 |
| Citalopram | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT04476030 |
| Escitalopram | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT04476030 |
| Sertraline | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT04476030 |
| Matching Placebo | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT04476030 |
| SAGE-217 | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT04476030 |
| Desvenlafaxine | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT04476030 |
| Duloxetine | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT04476030 |
| Citalopram | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT04476030 |
| Escitalopram | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT04476030 |
| Sertraline | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT04476030 |
| Matching Placebo | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT04476030 |
| SAGE-217 | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT04476030 |
| Placebo | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT04442490 |
| SAGE-217 | Other | Phase PHASE3 | Depressive Disorder, Major | COMPLETED | NCT04442490 |
| yttrium Y 90 ibritumomab tiuxetan | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00031642 |
| rituximab | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00031642 |
| yttrium Y 90 ibritumomab tiuxetan | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00031642 |
| rituximab | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00031642 |
| Questionnaire | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT05209815 |
| Questionnaire | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT05209815 |
| Questionnaire | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT05209815 |
| BIIB112 | Other | Phase PHASE1 | X-Linked Retinitis Pigmentosa | COMPLETED | NCT03116113 |
| 11^C]BIO-1819578 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05195008 |
| BIIB113-Matching Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05195008 |
| BIIB113 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05195008 |
| 11^C]BIO-1819578 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05195008 |
| BIIB113-Matching Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05195008 |
| BIIB113 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05195008 |
| Natalizumab | Other | Preclinical | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT04832399 |
| Konectom NMD Application | Other | Approved | Spinal Muscular Atrophy | COMPLETED | NCT05109637 |
| Placebo | Other | Phase PHASE2 | Ischemic Stroke | WITHDRAWN | NCT05764122 |
| BIIB131 | Other | Phase PHASE2 | Ischemic Stroke | WITHDRAWN | NCT05764122 |
| BIIB111 | Other | Phase PHASE2 | Choroideremia | COMPLETED | NCT03507686 |
| BIIB111 | Other | Phase PHASE2 | Choroideremia | COMPLETED | NCT03507686 |
| No Intervention | Other | Preclinical | KCNT1-Related Epilepsy | COMPLETED | NCT04924153 |
| No Intervention | Other | Preclinical | KCNT1-Related Epilepsy | COMPLETED | NCT04924153 |
| No Intervention | Other | Preclinical | KCNT1-Related Epilepsy | COMPLETED | NCT04924153 |
| Tysabri | Other | Preclinical | Progressive Multifocal Leukoencephalopathy | COMPLETED | NCT03399981 |
| Tysabri | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00493298 |
| Tysabri | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT00493298 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04593121 |
| BIIB107 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04593121 |
| Natalizumab 300 MG in 15 ML Injection | Other | Phase PHASE4 | Multiple Sclerosis | TERMINATED | NCT05177718 |
| Natalizumab 300 MG in 15 ML Injection | Other | Phase PHASE4 | Multiple Sclerosis | TERMINATED | NCT05177718 |
| Placebo | Other | Phase PHASE2 | Antibody-mediated Rejection | COMPLETED | NCT05021484 |
| Felzartamab | Other | Phase PHASE2 | Antibody-mediated Rejection | COMPLETED | NCT05021484 |
| Placebo | Other | Phase PHASE2 | Antibody-mediated Rejection | COMPLETED | NCT05021484 |
| Felzartamab | Other | Phase PHASE2 | Antibody-mediated Rejection | COMPLETED | NCT05021484 |
| Natalizumab | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis (RRMS) | COMPLETED | NCT05304520 |
| Natalizumab | Other | Preclinical | Relapsing-Remitting Multiple Sclerosis (RRMS) | COMPLETED | NCT05304520 |
| Konectom platform | Other | Preclinical | Multiple Sclerosis (MS) | COMPLETED | NCT05106465 |
| Konectom platform | Other | Preclinical | Multiple Sclerosis (MS) | COMPLETED | NCT05106465 |
| [14C]-BIIB091 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06311786 |
| [14C]-BIIB091 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06311786 |
| Placebo group 2: Placebo powder corresponding to Wasabi leaf powder | Other | Approved | PreDiabetes | RECRUITING | NCT06437938 |
| Placebo group 1: Placebo capsules corresponding to DiaPhyt® Formula 3.0/Berberin Phytoactive Gold | Other | Approved | PreDiabetes | RECRUITING | NCT06437938 |
| Dietary supplement C: DiaPhyt® Formula 3.0 (product of BIOGENA GmbH & Co KG) | Other | Approved | PreDiabetes | RECRUITING | NCT06437938 |
| Dietary supplement B: Berberin Phytoactive Gold (product of BIOGENA GmbH & Co KG) | Other | Approved | PreDiabetes | RECRUITING | NCT06437938 |
| Dietary supplement A: Wasabi leaf powder (product of BIOGENA GmbH & Co KG) | Other | Approved | PreDiabetes | RECRUITING | NCT06437938 |
| Placebo group 2: Placebo powder corresponding to Wasabi leaf powder | Other | Approved | PreDiabetes | RECRUITING | NCT06437938 |
| Placebo group 1: Placebo capsules corresponding to DiaPhyt® Formula 3.0/Berberin Phytoactive Gold | Other | Approved | PreDiabetes | RECRUITING | NCT06437938 |
| Dietary supplement C: DiaPhyt® Formula 3.0 (product of BIOGENA GmbH & Co KG) | Other | Approved | PreDiabetes | RECRUITING | NCT06437938 |
| Dietary supplement B: Berberin Phytoactive Gold (product of BIOGENA GmbH & Co KG) | Other | Approved | PreDiabetes | RECRUITING | NCT06437938 |
| Dietary supplement A: Wasabi leaf powder (product of BIOGENA GmbH & Co KG) | Other | Approved | PreDiabetes | RECRUITING | NCT06437938 |
| natalizumab | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | TERMINATED | NCT02142192 |
| TYSABRI and AVONEX | Other | Phase PHASE4 | Relapsing-remitting Multiple Sclerosis | WITHDRAWN | NCT00771043 |
| TYSABRI and AVONEX | Other | Phase PHASE4 | Relapsing-remitting Multiple Sclerosis | WITHDRAWN | NCT00771043 |
| TYSABRI and AVONEX | Other | Phase PHASE4 | Relapsing-remitting Multiple Sclerosis | WITHDRAWN | NCT00771043 |
| natalizumab | Other | Preclinical | Crohn's Disease | TERMINATED | NCT00707512 |
| natalizumab | Other | Preclinical | Crohn's Disease | TERMINATED | NCT00707512 |
| natalizumab | Other | Preclinical | Crohn's Disease | TERMINATED | NCT00707512 |
| Tofersen | Other | Preclinical | Superoxide Dismutase 1-Amyotropic Lateral Sclerosis | APPROVED_FOR_MARKETING | NCT04972487 |
| Tofersen | Other | Preclinical | Superoxide Dismutase 1-Amyotropic Lateral Sclerosis | APPROVED_FOR_MARKETING | NCT04972487 |
| Natalizumab | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT03689972 |
| Natalizumab | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | COMPLETED | NCT03689972 |
| Natalizumab | Other | Phase PHASE4 | Multiple Sclerosis, Relapsing-Remitting | TERMINATED | NCT05532163 |
| Rabeprazole | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06264440 |
| BIIB122 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06264440 |
| Patient Registry | Other | Preclinical | Spinal Muscular Atrophy | RECRUITING | NCT04292574 |
| Patient Registry | Other | Preclinical | Spinal Muscular Atrophy | RECRUITING | NCT04292574 |
| Moxifloxacin Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01689116 |
| Moxifloxacin 400mg | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01689116 |
| Bardoxolone Methyl Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01689116 |
| Bardoxolone Methyl 80mg | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01689116 |
| Bardoxolone Methyl 20mg | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01689116 |
| Moxifloxacin Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01689116 |
| Moxifloxacin 400mg | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01689116 |
| Bardoxolone Methyl Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01689116 |
| Bardoxolone Methyl 80mg | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01689116 |
| Bardoxolone Methyl 20mg | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01689116 |
| Placebo | Other | Phase PHASE2 | Renal Insufficiency, Chronic | WITHDRAWN | NCT01655186 |
| Bardoxolone Methyl | Other | Phase PHASE2 | Renal Insufficiency, Chronic | WITHDRAWN | NCT01655186 |
| Placebo | Other | Phase PHASE2 | Renal Insufficiency, Chronic | WITHDRAWN | NCT01655186 |
| Bardoxolone Methyl | Other | Phase PHASE2 | Renal Insufficiency, Chronic | WITHDRAWN | NCT01655186 |
| Rosuvastatin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01598363 |
| Digoxin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01598363 |
| Rosuvastatin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01598363 |
| Digoxin | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01598363 |
| Placebo | Other | Phase PHASE2 | End-Stage Renal Disease | WITHDRAWN | NCT01576887 |
| Bardoxolone Methyl 20 mg | Other | Phase PHASE2 | End-Stage Renal Disease | WITHDRAWN | NCT01576887 |
| Placebo | Other | Phase PHASE2 | End-Stage Renal Disease | WITHDRAWN | NCT01576887 |
| Bardoxolone Methyl 20 mg | Other | Phase PHASE2 | End-Stage Renal Disease | WITHDRAWN | NCT01576887 |
| Bardoxolone Methyl | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT01563562 |
| Bardoxolone Methyl | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT01563562 |
| Bardoxolone Methyl | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT01563562 |
| Bardoxolone Methyl | Other | Phase PHASE1 | Renal Insufficiency, Chronic | WITHDRAWN | NCT01551446 |
| Bardoxolone Methyl | Other | Phase PHASE1 | Renal Insufficiency, Chronic | TERMINATED | NCT01549769 |
| Bardoxolone Methyl | Other | Phase PHASE1 | Renal Insufficiency, Chronic | TERMINATED | NCT01549769 |
| bardoxolone methyl | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01503866 |
| Placebo | Other | Phase PHASE2 | Mild Cognitive Impairment (MCI) | RECRUITING | NCT07027072 |
| KDS2010 | Other | Phase PHASE2 | Mild Cognitive Impairment (MCI) | RECRUITING | NCT07027072 |
| Placebo | Other | Phase PHASE2 | Mild Cognitive Impairment (MCI) | RECRUITING | NCT07027072 |
| KDS2010 | Other | Phase PHASE2 | Mild Cognitive Impairment (MCI) | RECRUITING | NCT07027072 |
| • Biological: GYNORYLAQ-TM Personalized Neoantigenic Peptide Vaccine | Other | Phase EARLY_PHASE1 | Endometrial Carcinoma | ENROLLING_BY_INVITATION | NCT07316361 |
| • Biological: GYNORYLAQ-TM Personalized Neoantigenic Peptide Vaccine | Other | Phase EARLY_PHASE1 | Endometrial Carcinoma | ENROLLING_BY_INVITATION | NCT07316361 |
| No Intervention | Other | Preclinical | Muscular Atrophy, Spinal | RECRUITING | NCT05789758 |
| Placebo | Other | Phase PHASE3 | Antibody-mediated Rejection | RECRUITING | NCT06685757 |
| Felzartamab | Other | Phase PHASE3 | Antibody-mediated Rejection | RECRUITING | NCT06685757 |
| Placebo | Other | Phase PHASE3 | Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation | ACTIVE_NOT_RECRUITING | NCT04856982 |
| Tofersen | Other | Phase PHASE3 | Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation | ACTIVE_NOT_RECRUITING | NCT04856982 |
| Placebo | Other | Phase PHASE3 | Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation | ACTIVE_NOT_RECRUITING | NCT04856982 |
| Tofersen | Other | Phase PHASE3 | Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation | ACTIVE_NOT_RECRUITING | NCT04856982 |
| SAGE-217 | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT03864614 |
| SAGE-217 | Other | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT03864614 |
| Natalizumab | Other | Preclinical | Multiple Sclerosis | TERMINATED | NCT05701423 |
| nusinersen | Other | Phase PHASE3 | Spinal Muscular Atrophy | COMPLETED | NCT02594124 |
| nusinersen | Other | Phase PHASE3 | Spinal Muscular Atrophy | COMPLETED | NCT02594124 |
| nusinersen | Other | Phase PHASE3 | Spinal Muscular Atrophy | COMPLETED | NCT02594124 |
| Placebo | Other | Phase PHASE1 | Immune System Diseases | COMPLETED | NCT05928585 |
| HIB210 | Other | Phase PHASE1 | Immune System Diseases | COMPLETED | NCT05928585 |
| Placebo | Other | Phase PHASE1 | Immune System Diseases | COMPLETED | NCT05928585 |
| HIB210 | Other | Phase PHASE1 | Immune System Diseases | COMPLETED | NCT05928585 |
| Placebo | Other | Phase PHASE2 | Immunoglobulin A (IgA) Nephropathy | COMPLETED | NCT05065970 |
| Felzartamab | Other | Phase PHASE2 | Immunoglobulin A (IgA) Nephropathy | COMPLETED | NCT05065970 |
| MOR202 | Other | Phase PHASE2 | Glomerulonephritis | COMPLETED | NCT04733040 |
| MOR202 | Other | Phase PHASE2 | Glomerulonephritis | COMPLETED | NCT04733040 |
| BIIB091 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06640933 |
| Aducanumab | Other | Phase PHASE3 | Alzheimer's Disease | TERMINATED | NCT04241068 |
| Aducanumab | Other | Phase PHASE3 | Alzheimer's Disease | TERMINATED | NCT04241068 |
| MOR202 | Other | Phase PHASE1 | Glomerulonephritis, Membranous | COMPLETED | NCT04145440 |
| MOR202 | Other | Phase PHASE1 | Glomerulonephritis, Membranous | COMPLETED | NCT04145440 |
| Zuranolone | Other | Phase PHASE1 | Major Depressive Disorder | COMPLETED | NCT05655507 |
| Zuranolone | Other | Phase PHASE1 | Major Depressive Disorder | COMPLETED | NCT05655507 |
| Moxifloxacin-matched Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06574828 |
| BIIB091-matched Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06574828 |
| Moxifloxacin | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06574828 |
| BIIB091 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06574828 |
| Moxifloxacin-matched Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06574828 |
| BIIB091-matched Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06574828 |
| Moxifloxacin | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06574828 |
| BIIB091 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06574828 |
| Standard of Care | Other | Approved | Spinal Muscular Atrophy (SMA) | COMPLETED | NCT05354414 |
| Virtual reality | Other | Approved | Spinal Muscular Atrophy (SMA) | COMPLETED | NCT05354414 |
| Standard of Care | Other | Approved | Spinal Muscular Atrophy (SMA) | COMPLETED | NCT05354414 |
| Virtual reality | Other | Approved | Spinal Muscular Atrophy (SMA) | COMPLETED | NCT05354414 |
| Adaptive Optics Ophthalmoscopy (AOO) | Other | Approved | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT04289909 |
| Omaveloxolone | Other | Preclinical | Friedreich Ataxia | RECRUITING | NCT06623890 |
| Omaveloxolone | Other | Preclinical | Friedreich Ataxia | RECRUITING | NCT06623890 |
| Omaveloxolone | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06612879 |
| Omaveloxolone | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06612879 |
| Omaveloxolone | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06612879 |
| Placebo | Other | Phase PHASE3 | Alzheimer's Disease | TERMINATED | NCT05310071 |
| Aducanumab | Other | Phase PHASE3 | Alzheimer's Disease | TERMINATED | NCT05310071 |
| Nusinersen | Other | Phase PHASE3 | Spinal Muscular Atrophy | ACTIVE_NOT_RECRUITING | NCT05067790 |
| Nusinersen | Other | Phase PHASE3 | Spinal Muscular Atrophy | ACTIVE_NOT_RECRUITING | NCT05067790 |
| Natalizumab | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT05236777 |
| Natalizumab | Other | Preclinical | Multiple Sclerosis | COMPLETED | NCT05236777 |
| Dimethyl fumarate | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT05658484 |
| Dimethyl fumarate | Other | Phase PHASE4 | Multiple Sclerosis | COMPLETED | NCT05658484 |
| Nusinersen Injectable Product | Other | Preclinical | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT06978985 |
| Risdiplam | Other | Preclinical | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT06978985 |
| Nusinersen Injectable Product | Other | Preclinical | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT06978985 |
| Risdiplam | Other | Preclinical | Spinal Muscular Atrophy (SMA) | RECRUITING | NCT06978985 |
| BIIB080-matching placebo | Other | Phase PHASE2 | Mild Cognitive Impairment Due to Alzheimer's Disease | ACTIVE_NOT_RECRUITING | NCT05399888 |
| BIIB080 | Other | Phase PHASE2 | Mild Cognitive Impairment Due to Alzheimer's Disease | ACTIVE_NOT_RECRUITING | NCT05399888 |
| BIIB080-matching placebo | Other | Phase PHASE2 | Mild Cognitive Impairment Due to Alzheimer's Disease | ACTIVE_NOT_RECRUITING | NCT05399888 |
| BIIB080 | Other | Phase PHASE2 | Mild Cognitive Impairment Due to Alzheimer's Disease | ACTIVE_NOT_RECRUITING | NCT05399888 |
| Lotion vehicle/placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02029716 |
| RTA 408 Lotion 0.5%, 1%, 3% | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02029716 |
| Bardoxolone methyl | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT00529438 |
| Bardoxolone methyl | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT00529438 |
| RTA 744 injection | Other | Phase PHASE1 | Glioma | COMPLETED | NCT00526812 |
| RTA 744 | Other | Phase PHASE1 | Glioma | COMPLETED | NCT00526812 |
| RTA 744 injection | Other | Phase PHASE1 | Glioma | COMPLETED | NCT00526812 |
| RTA 744 | Other | Phase PHASE1 | Glioma | COMPLETED | NCT00526812 |
| RTA 1701 capsules | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03579030 |
| Placebo oral capsule | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03579030 |
| RTA 1701 capsules | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03579030 |
| Placebo oral capsule | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03579030 |
| Itraconazole capsules 100 mg | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03264079 |
| Bardoxolone methyl capsules 10 mg | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03264079 |
| Itraconazole capsules 100 mg | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03264079 |
| Bardoxolone methyl capsules 10 mg | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03264079 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02666963 |
| RTA 901 Capsules, 10 or 40 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02666963 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02666963 |
| RTA 901 Capsules, 10 or 40 mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02666963 |
| omaveloxolone | Other | Phase PHASE1 | Metastatic or Incurable Non-small Cell Lung Cancer | COMPLETED | NCT02029729 |
| omaveloxolone | Other | Phase PHASE1 | Metastatic or Incurable Non-small Cell Lung Cancer | COMPLETED | NCT02029729 |
| bardoxolone methyl | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT01461161 |
| Bardoxolone Methyl: 20 mg | Other | Phase PHASE3 | Renal Insufficiency, Chronic | TERMINATED | NCT01351675 |
| Placebo | Other | Phase PHASE3 | Renal Insufficiency, Chronic | TERMINATED | NCT01351675 |
| Bardoxolone Methyl: 20 mg | Other | Phase PHASE3 | Renal Insufficiency, Chronic | TERMINATED | NCT01351675 |
| Placebo | Other | Phase PHASE3 | Renal Insufficiency, Chronic | TERMINATED | NCT01351675 |
| Bardoxolone methyl (amorphous dispersion) | Other | Phase PHASE2 | Renal Insufficiency, Chronic | COMPLETED | NCT01053936 |
| Bardoxolone methyl (amorphous dispersion) | Other | Phase PHASE2 | Renal Insufficiency, Chronic | COMPLETED | NCT01053936 |
| Bardoxolone methyl (amorphous dispersion) | Other | Phase PHASE2 | Renal Insufficiency, Chronic | COMPLETED | NCT01053936 |
| Bardoxolone Methyl (RTA 402) | Other | Phase PHASE2 | Chronic Kidney Disease | COMPLETED | NCT00811889 |
| Placebo | Other | Phase PHASE2 | Chronic Kidney Disease | COMPLETED | NCT00811889 |
| Bardoxolone Methyl (RTA 402) | Other | Phase PHASE2 | Chronic Kidney Disease | COMPLETED | NCT00811889 |
| Placebo | Other | Phase PHASE2 | Chronic Kidney Disease | COMPLETED | NCT00811889 |
| RTA 402 (Bardoxolone Methyl) | Other | Phase PHASE2 | Diabetic Nephropathy | COMPLETED | NCT00664027 |
| RTA 402 (Bardoxolone Methyl) | Other | Phase PHASE2 | Diabetic Nephropathy | COMPLETED | NCT00664027 |
| berubicin hydrochloride (RTA 744) | Other | Phase PHASE2 | Brain Metastases | TERMINATED | NCT00538343 |
| berubicin hydrochloride (RTA 744) | Other | Phase PHASE2 | Brain Metastases | TERMINATED | NCT00538343 |
| Placebo | Other | Phase PHASE1 | Pancreatic Neoplasms | TERMINATED | NCT00529113 |
| Gemcitabine | Other | Phase PHASE1 | Pancreatic Neoplasms | TERMINATED | NCT00529113 |
| Bardoxolone methyl | Other | Phase PHASE1 | Pancreatic Neoplasms | TERMINATED | NCT00529113 |
| Placebo | Other | Phase PHASE1 | Pancreatic Neoplasms | TERMINATED | NCT00529113 |
| Gemcitabine | Other | Phase PHASE1 | Pancreatic Neoplasms | TERMINATED | NCT00529113 |
| Bardoxolone methyl | Other | Phase PHASE1 | Pancreatic Neoplasms | TERMINATED | NCT00529113 |
| Placebo | Other | Phase PHASE1 | Pancreatic Neoplasms | TERMINATED | NCT00529113 |
| Gemcitabine | Other | Phase PHASE1 | Pancreatic Neoplasms | TERMINATED | NCT00529113 |
| Bardoxolone methyl | Other | Phase PHASE1 | Pancreatic Neoplasms | TERMINATED | NCT00529113 |
| Moxifloxacin | Other | Phase PHASE1 | Health Adult Subjects | COMPLETED | NCT05927649 |
| Omaveloxolone | Other | Phase PHASE1 | Health Adult Subjects | COMPLETED | NCT05927649 |
| Moxifloxacin | Other | Phase PHASE1 | Health Adult Subjects | COMPLETED | NCT05927649 |
| Omaveloxolone | Other | Phase PHASE1 | Health Adult Subjects | COMPLETED | NCT05927649 |
| Moxifloxacin | Other | Phase PHASE1 | Health Adult Subjects | COMPLETED | NCT05927649 |
| Omaveloxolone | Other | Phase PHASE1 | Health Adult Subjects | COMPLETED | NCT05927649 |
| Efavirenz | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT05909644 |
| Omaveloxolone | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT05909644 |
| RTA 901-Matching Placebo | Other | Phase PHASE2 | Diabetic Peripheral Neuropathic Pain | TERMINATED | NCT05895552 |
| RTA 901 | Other | Phase PHASE2 | Diabetic Peripheral Neuropathic Pain | TERMINATED | NCT05895552 |
| Verapamil Pill | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Itraconazole capsule | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Gemfibrozil Tablets | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Digoxin tablet | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Rosuvastatin | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| MetFORMIN 500 Mg Oral Tablet | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Repaglinide 1 MG | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Midazolam oral solution | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Omaveloxolone | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Verapamil Pill | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Itraconazole capsule | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Gemfibrozil Tablets | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Digoxin tablet | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Rosuvastatin | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| MetFORMIN 500 Mg Oral Tablet | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Repaglinide 1 MG | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Midazolam oral solution | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Omaveloxolone | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Verapamil Pill | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Itraconazole capsule | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Gemfibrozil Tablets | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Digoxin tablet | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Rosuvastatin | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| MetFORMIN 500 Mg Oral Tablet | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Repaglinide 1 MG | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Midazolam oral solution | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| Omaveloxolone | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04008186 |
| [14C]-Omaveloxolone | Other | Phase PHASE1 | Healthy Male Subjects | COMPLETED | NCT03931590 |
| [14C]-Omaveloxolone | Other | Phase PHASE1 | Healthy Male Subjects | COMPLETED | NCT03931590 |
| Omaveloxolone 50 mg capsules | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT03902002 |
| Omaveloxolone 50 mg capsules | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT03902002 |
| Omaveloxolone 50 mg capsules | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT03902002 |
| omaveloxolone | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03664453 |
| omaveloxolone | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03664453 |
| omaveloxolone | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03664453 |
| RTA 402 | Other | Phase PHASE1 | Liver Disease | TERMINATED | NCT00550849 |
| RTA 744 | Other | Phase PHASE1 | Leptomeningeal Carcinomatosis | TERMINATED | NCT00527410 |
| RTA 744 | Other | Phase PHASE1 | Leptomeningeal Carcinomatosis | TERMINATED | NCT00527410 |
| RTA 744 | Other | Phase PHASE1 | Leptomeningeal Carcinomatosis | TERMINATED | NCT00527410 |
| omaveloxolone | Other | Preclinical | Melanoma | NO_LONGER_AVAILABLE | NCT03593499 |
| RTA 402 Dose2 | Other | Phase PHASE2 | Malignant Melanoma | WITHDRAWN | NCT00535314 |
| RTA 402 Dose1 | Other | Phase PHASE2 | Malignant Melanoma | WITHDRAWN | NCT00535314 |
| Placebo oral capsule | Other | Phase PHASE2 | Chronic Kidney Diseases | COMPLETED | NCT04702997 |
| Bardoxolone methyl oral capsule | Other | Phase PHASE2 | Chronic Kidney Diseases | COMPLETED | NCT04702997 |
| Placebo oral capsule | Other | Phase PHASE3 | Autosomal Dominant Polycystic Kidney | TERMINATED | NCT03918447 |
| Bardoxolone methyl oral capsule | Other | Phase PHASE3 | Autosomal Dominant Polycystic Kidney | TERMINATED | NCT03918447 |
| Placebo oral capsule | Other | Phase PHASE3 | Autosomal Dominant Polycystic Kidney | TERMINATED | NCT03918447 |
| Bardoxolone methyl oral capsule | Other | Phase PHASE3 | Autosomal Dominant Polycystic Kidney | TERMINATED | NCT03918447 |
| Bardoxolone methyl | Other | Phase PHASE3 | Chronic Kidney Diseases | TERMINATED | NCT03749447 |
| Bardoxolone methyl | Other | Phase PHASE3 | Chronic Kidney Diseases | TERMINATED | NCT03749447 |
| Bardoxolone methyl | Other | Phase PHASE3 | Chronic Kidney Diseases | TERMINATED | NCT03749447 |
| Bardoxolone methyl capsules | Other | Phase PHASE2 | IgA Nephropathy | COMPLETED | NCT03366337 |
| Bardoxolone methyl capsules | Other | Phase PHASE2 | IgA Nephropathy | COMPLETED | NCT03366337 |
| Bardoxolone methyl capsules | Other | Phase PHASE2 | IgA Nephropathy | COMPLETED | NCT03366337 |
| 3D conformal radiation therapy | Drug | Phase PHASE2 | Breast Cancer | COMPLETED | NCT02142959 |
| Vehicle Lotion | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT02142959 |
| Omaveloxolone Lotion 3% | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT02142959 |
| Omaveloxolone Lotion 0.5% | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT02142959 |
| 3D conformal radiation therapy | Drug | Phase PHASE2 | Breast Cancer | COMPLETED | NCT02142959 |
| Vehicle Lotion | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT02142959 |
| Omaveloxolone Lotion 3% | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT02142959 |
| Omaveloxolone Lotion 0.5% | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT02142959 |
| Omaveloxolone Ophthalmic Suspension 1% | Other | Phase PHASE2 | Corneal Endothelial Cell Loss | COMPLETED | NCT02128113 |
| Omaveloxolone Ophthalmic Suspension 0.5% | Other | Phase PHASE2 | Corneal Endothelial Cell Loss | COMPLETED | NCT02128113 |
| Vehicle Ophthalmic Solution | Other | Phase PHASE2 | Corneal Endothelial Cell Loss | COMPLETED | NCT02128113 |
| Omaveloxolone Ophthalmic Suspension 1% | Other | Phase PHASE2 | Corneal Endothelial Cell Loss | COMPLETED | NCT02128113 |
| Omaveloxolone Ophthalmic Suspension 0.5% | Other | Phase PHASE2 | Corneal Endothelial Cell Loss | COMPLETED | NCT02128113 |
| Vehicle Ophthalmic Solution | Other | Phase PHASE2 | Corneal Endothelial Cell Loss | COMPLETED | NCT02128113 |
| Placebo | Other | Phase PHASE2 | Inflammation and Pain Following Ocular Surgery | COMPLETED | NCT02065375 |
| Omaveloxolone Opthalmic Suspension 0.5% | Other | Phase PHASE2 | Inflammation and Pain Following Ocular Surgery | COMPLETED | NCT02065375 |
| Omaveloxolone Ophthalmic Suspension 1.0% | Other | Phase PHASE2 | Inflammation and Pain Following Ocular Surgery | COMPLETED | NCT02065375 |
| Placebo | Other | Phase PHASE2 | Inflammation and Pain Following Ocular Surgery | COMPLETED | NCT02065375 |
| Omaveloxolone Opthalmic Suspension 0.5% | Other | Phase PHASE2 | Inflammation and Pain Following Ocular Surgery | COMPLETED | NCT02065375 |
| Omaveloxolone Ophthalmic Suspension 1.0% | Other | Phase PHASE2 | Inflammation and Pain Following Ocular Surgery | COMPLETED | NCT02065375 |
| Bardoxolone methyl capsules | Other | Phase PHASE3 | Connective Tissue Disease-Associated Pulmonary Arterial Hypertension | TERMINATED | NCT02657356 |
| Placebo capsules | Other | Phase PHASE3 | Connective Tissue Disease-Associated Pulmonary Arterial Hypertension | TERMINATED | NCT02657356 |
| Bardoxolone methyl capsules | Other | Phase PHASE3 | Connective Tissue Disease-Associated Pulmonary Arterial Hypertension | TERMINATED | NCT02657356 |
| Placebo capsules | Other | Phase PHASE3 | Connective Tissue Disease-Associated Pulmonary Arterial Hypertension | TERMINATED | NCT02657356 |
| Omaveloxolone Capsules (50 mg/capsule) | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT02259231 |
| Omaveloxolone Capsules (10 mg/capsule) | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT02259231 |
| Nivolumab (240 mg) | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT02259231 |
| Ipilimumab (3 mg/kg) | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT02259231 |
| Omaveloxolone Capsules (2.5 mg/capsule) | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT02259231 |
| Nusinersen | Other | Phase PHASE3 | Muscular Atrophy, Spinal | COMPLETED | NCT04089566 |
| Nusinersen | Other | Phase PHASE3 | Muscular Atrophy, Spinal | COMPLETED | NCT04089566 |
| omaveloxolone capsules, 160 mg | Other | Phase PHASE2 | MItochondrial Myopathies | COMPLETED | NCT02255422 |
| omaveloxolone capsules, 80 mg | Other | Phase PHASE2 | MItochondrial Myopathies | COMPLETED | NCT02255422 |
| omaveloxolone capsules, 40 mg | Other | Phase PHASE2 | MItochondrial Myopathies | COMPLETED | NCT02255422 |
| omaveloxolone capsules, 20 mg | Other | Phase PHASE2 | MItochondrial Myopathies | COMPLETED | NCT02255422 |
| Placebo capsules | Other | Phase PHASE2 | MItochondrial Myopathies | COMPLETED | NCT02255422 |
| omaveloxolone capsules, 10 mg | Other | Phase PHASE2 | MItochondrial Myopathies | COMPLETED | NCT02255422 |
| omaveloxolone capsules, 5 mg | Other | Phase PHASE2 | MItochondrial Myopathies | COMPLETED | NCT02255422 |
| Omaveloxolone capsules, 2.5 mg | Other | Phase PHASE2 | MItochondrial Myopathies | COMPLETED | NCT02255422 |
| omaveloxolone capsules, 160 mg | Other | Phase PHASE2 | MItochondrial Myopathies | COMPLETED | NCT02255422 |
| omaveloxolone capsules, 80 mg | Other | Phase PHASE2 | MItochondrial Myopathies | COMPLETED | NCT02255422 |
| omaveloxolone capsules, 40 mg | Other | Phase PHASE2 | MItochondrial Myopathies | COMPLETED | NCT02255422 |
| omaveloxolone capsules, 20 mg | Other | Phase PHASE2 | MItochondrial Myopathies | COMPLETED | NCT02255422 |
| Placebo capsules | Other | Phase PHASE2 | MItochondrial Myopathies | COMPLETED | NCT02255422 |
| omaveloxolone capsules, 10 mg | Other | Phase PHASE2 | MItochondrial Myopathies | COMPLETED | NCT02255422 |
| omaveloxolone capsules, 5 mg | Other | Phase PHASE2 | MItochondrial Myopathies | COMPLETED | NCT02255422 |
| Omaveloxolone capsules, 2.5 mg | Other | Phase PHASE2 | MItochondrial Myopathies | COMPLETED | NCT02255422 |
| Placebo | Other | Phase PHASE2 | Pulmonary Arterial Hypertension | COMPLETED | NCT02036970 |
| Bardoxolone methyl | Other | Phase PHASE2 | Pulmonary Arterial Hypertension | COMPLETED | NCT02036970 |
| Bardoxolone methyl | Other | Phase PHASE3 | Pulmonary Hypertension | TERMINATED | NCT03068130 |
| Bardoxolone Methyl | Other | Phase PHASE2 | Alport Syndrome | COMPLETED | NCT03019185 |
| Placebo Oral Capsule | Other | Phase PHASE2 | Alport Syndrome | COMPLETED | NCT03019185 |
| BIIB112 | Other | Phase PHASE3 | Choroideremia | ENROLLING_BY_INVITATION | NCT03584165 |
| BIIB111 | Other | Phase PHASE3 | Choroideremia | ENROLLING_BY_INVITATION | NCT03584165 |
| BIIB112 | Other | Phase PHASE3 | Choroideremia | ENROLLING_BY_INVITATION | NCT03584165 |
| BIIB111 | Other | Phase PHASE3 | Choroideremia | ENROLLING_BY_INVITATION | NCT03584165 |
| Omaveloxolone | Other | Preclinical | Friedreich Ataxia | RECRUITING | NCT06628687 |
| Omaveloxolone | Other | Preclinical | Friedreich Ataxia | RECRUITING | NCT06628687 |
| Omaveloxolone | Other | Preclinical | Friedreich Ataxia | RECRUITING | NCT06628687 |
| BIIB115-Matching Placebo | Other | Phase PHASE1 | Healthy Volunteer | ACTIVE_NOT_RECRUITING | NCT05575011 |
| BIIB115 | Other | Phase PHASE1 | Healthy Volunteer | ACTIVE_NOT_RECRUITING | NCT05575011 |
| BIIB115-Matching Placebo | Other | Phase PHASE1 | Healthy Volunteer | ACTIVE_NOT_RECRUITING | NCT05575011 |
| BIIB115 | Other | Phase PHASE1 | Healthy Volunteer | ACTIVE_NOT_RECRUITING | NCT05575011 |
| Nusinersen Sodium Injection | Other | Preclinical | Muscular Atrophy, Spinal | ACTIVE_NOT_RECRUITING | NCT04317794 |
| Nusinersen Sodium Injection | Other | Preclinical | Muscular Atrophy, Spinal | ACTIVE_NOT_RECRUITING | NCT04317794 |
| Interferon β-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| Interferon β-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| Interferon β-1a | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| dimethyl fumarate | Other | Phase PHASE3 | Relapsing-Remitting Multiple Sclerosis | COMPLETED | NCT02283853 |
| Dimethyl Fumarate | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05658497 |
| Tysabri | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05658497 |
| Avonex | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05658497 |
| Diroximel Fumarate | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05658497 |
| Dimethyl Fumarate | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05658497 |
| Tysabri | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05658497 |
| Avonex | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05658497 |
| Diroximel Fumarate | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05658497 |
| Zuranolone | Other | Preclinical | Depression, Postpartum | RECRUITING | NCT07047820 |
| Zuranolone | Other | Preclinical | Depression, Postpartum | RECRUITING | NCT07047820 |
| Leukapheresis | Other | Phase PHASE1 | Sickle Cell Disease | COMPLETED | NCT05618301 |
| Natalizumab | Other | Phase PHASE1 | Sickle Cell Disease | COMPLETED | NCT05618301 |
| Motixafortide | Other | Phase PHASE1 | Sickle Cell Disease | COMPLETED | NCT05618301 |
| Leukapheresis | Other | Phase PHASE1 | Sickle Cell Disease | COMPLETED | NCT05618301 |
| Natalizumab | Other | Phase PHASE1 | Sickle Cell Disease | COMPLETED | NCT05618301 |
| Motixafortide | Other | Phase PHASE1 | Sickle Cell Disease | COMPLETED | NCT05618301 |
| BIIB142-Matching Placebo | Other | Phase PHASE1 | Healthy Volunteer | RECRUITING | NCT07133828 |
| BIIB142 | Other | Phase PHASE1 | Healthy Volunteer | RECRUITING | NCT07133828 |
| BIIB142-Matching Placebo | Other | Phase PHASE1 | Healthy Volunteer | RECRUITING | NCT07133828 |
| BIIB142 | Other | Phase PHASE1 | Healthy Volunteer | RECRUITING | NCT07133828 |
| Interferon beta type 1a | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | ACTIVE_NOT_RECRUITING | NCT03958877 |
| BIIB017 (peginterferon beta-1a) | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | ACTIVE_NOT_RECRUITING | NCT03958877 |
| Cold pressor test | Other | Approved | Nitrate | COMPLETED | NCT06602921 |
| Caffeine | Other | Approved | Nitrate | COMPLETED | NCT06602921 |
| TruBeet inorganic beetroot juice | Other | Approved | Nitrate | COMPLETED | NCT06602921 |
| Cold pressor test | Other | Approved | Nitrate | COMPLETED | NCT06602921 |
| Caffeine | Other | Approved | Nitrate | COMPLETED | NCT06602921 |
| TruBeet inorganic beetroot juice | Other | Approved | Nitrate | COMPLETED | NCT06602921 |
| Omaveloxolone | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT07019064 |
| Actemra | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06262477 |
| BIIB800 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06262477 |
| Actemra | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06262477 |
| BIIB800 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06262477 |
| Placebo | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | TERMINATED | NCT04494256 |
| BIIB105 | Other | Phase PHASE1 | Amyotrophic Lateral Sclerosis | TERMINATED | NCT04494256 |
| Nusinersen | Other | Phase PHASE4 | Muscular Atrophy, Spinal | COMPLETED | NCT04488133 |
| Nusinersen | Other | Phase PHASE4 | Muscular Atrophy, Spinal | COMPLETED | NCT04488133 |
| Disease-Modifying Therapies (DMTs) | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05767736 |
| Dimethyl Fumarate | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05767736 |
| Diroximel Fumarate | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05767736 |
| Disease-Modifying Therapies (DMTs) | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05767736 |
| Dimethyl Fumarate | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05767736 |
| Diroximel Fumarate | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05767736 |
| Disease-Modifying Therapies (DMTs) | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05767736 |
| Dimethyl Fumarate | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05767736 |
| Diroximel Fumarate | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05767736 |
| Siponimod | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05688436 |
| Ponesimod | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05688436 |
| Peginterferon beta-1a | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05688436 |
| Ozanimod | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05688436 |
| Ofatumumab | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05688436 |
| Ocrelizumab | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05688436 |
| Natalizumab | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05688436 |
| Interferon beta | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05688436 |
| Glatiramer acetate | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05688436 |
| Fingolimod | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05688436 |
| Alemtuzumab | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05688436 |
| Diroximel Fumarate | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT05688436 |
| Nusinersen | Other | Phase PHASE2 | Spinal Muscular Atrophy | COMPLETED | NCT02386553 |
| Nusinersen | Other | Phase PHASE2 | Spinal Muscular Atrophy | COMPLETED | NCT02386553 |
| Omeprazole | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT07149415 |
| Omaveloxolone | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT07149415 |
| Diroximel fumarate | Other | Phase PHASE3 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT05083923 |
| Diroximel fumarate | Other | Phase PHASE3 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT05083923 |
| Diroximel fumarate | Other | Phase PHASE3 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT05083923 |
| Natalizumab | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | TERMINATED | NCT05265728 |
| Natalizumab | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | TERMINATED | NCT05265728 |
| Natalizumab | Other | Phase PHASE3 | Multiple Sclerosis, Relapsing-Remitting | TERMINATED | NCT05265728 |
| Biological: personalized vaccine Based on genetic and transcriptional sequencing information, personalized peptide vaccines would be designed and produced; | Other | Phase EARLY_PHASE1 | Glioma | RECRUITING | NCT07077616 |
| Biological: personalized vaccine Based on genetic and transcriptional sequencing information, personalized peptide vaccines would be designed and produced; | Other | Phase EARLY_PHASE1 | Glioma | RECRUITING | NCT07077616 |
| Biological: personalized vaccine Based on genetic and transcriptional sequencing information, personalized peptide vaccines would be designed and produced; | Other | Phase EARLY_PHASE1 | Glioma | RECRUITING | NCT07077616 |
| RTA 901-Matching Placebo | Other | Phase PHASE2 | Diabetic Peripheral Neuropathic Pain | TERMINATED | NCT05895552 |
| RTA 901 | Other | Phase PHASE2 | Diabetic Peripheral Neuropathic Pain | TERMINATED | NCT05895552 |
| RTA 901-Matching Placebo | Other | Phase PHASE2 | Diabetic Peripheral Neuropathic Pain | TERMINATED | NCT05895552 |
| RTA 901 | Other | Phase PHASE2 | Diabetic Peripheral Neuropathic Pain | TERMINATED | NCT05895552 |
| Microlyvaq™ (Personalized Multi-Epitope Immunotherapeutic) | Other | Phase EARLY_PHASE1 | NSCLC (Non-small Cell Lung Cancer) | ENROLLING_BY_INVITATION | NCT07285434 |
| Microlyvaq™ (Personalized Multi-Epitope Immunotherapeutic) | Other | Phase EARLY_PHASE1 | NSCLC (Non-small Cell Lung Cancer) | ENROLLING_BY_INVITATION | NCT07285434 |
| Microlyvaq™ (Personalized Multi-Epitope Immunotherapeutic) | Other | Phase EARLY_PHASE1 | NSCLC (Non-small Cell Lung Cancer) | ENROLLING_BY_INVITATION | NCT07285434 |
| Felzartamab | Other | Phase PHASE1 | Lupus Nephritis | ACTIVE_NOT_RECRUITING | NCT06064929 |
| Felzartamab | Other | Phase PHASE1 | Lupus Nephritis | ACTIVE_NOT_RECRUITING | NCT06064929 |
| • Biological: GYNORYLAQ-TM Personalized Neoantigenic Peptide Vaccine | Other | Phase EARLY_PHASE1 | Endometrial Carcinoma | ENROLLING_BY_INVITATION | NCT07316361 |
| Omaveloxolone | Other | Phase PHASE1 | Friedreich Ataxia | RECRUITING | NCT06054893 |
| Omaveloxolone | Other | Phase PHASE1 | Friedreich Ataxia | RECRUITING | NCT06054893 |
| Placebo | Other | Phase PHASE2 | Multiple Sclerosis | RECRUITING | NCT05418010 |
| Tyruko Injectable Product | Other | Phase PHASE2 | Multiple Sclerosis | RECRUITING | NCT05418010 |
| Placebo | Other | Phase PHASE2 | Multiple Sclerosis | RECRUITING | NCT05418010 |
| Tyruko Injectable Product | Other | Phase PHASE2 | Multiple Sclerosis | RECRUITING | NCT05418010 |
| Experimental: COLONYVAQ-CRC + mFOLFOX6 or CAPOX + Nivolumab | Other | Phase EARLY_PHASE1 | Colorectal Cancer Metastatic | RECRUITING | NCT07328087 |
| Experimental: COLONYVAQ-CRC + mFOLFOX6 or CAPOX + Nivolumab | Other | Phase EARLY_PHASE1 | Colorectal Cancer Metastatic | RECRUITING | NCT07328087 |
| Experimental: COLONYVAQ-CRC + mFOLFOX6 or CAPOX + Nivolumab | Other | Phase EARLY_PHASE1 | Colorectal Cancer Metastatic | RECRUITING | NCT07328087 |
| Salanersen | Other | Phase PHASE3 | Muscular Atrophy, Spinal | RECRUITING | NCT07221669 |
| Salanersen | Other | Phase PHASE3 | Muscular Atrophy, Spinal | RECRUITING | NCT07221669 |
| Tofersen | Other | Phase PHASE4 | Amyotrophic Lateral Sclerosis | RECRUITING | NCT07223723 |
| Tofersen | Other | Phase PHASE4 | Amyotrophic Lateral Sclerosis | RECRUITING | NCT07223723 |
| Omaveloxolone Capsules, 150 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 300 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 160 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 80 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 40 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 20 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Placebo | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 10 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 5 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 2.5 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 150 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 300 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 160 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 80 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 40 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 20 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Placebo | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 10 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 5 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Omaveloxolone Capsules, 2.5 mg | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT02255435 |
| Placebo | Other | Phase PHASE3 | Lupus Erythematosus, Systemic | ACTIVE_NOT_RECRUITING | NCT04961567 |
| Litifilimab | Other | Phase PHASE3 | Lupus Erythematosus, Systemic | ACTIVE_NOT_RECRUITING | NCT04961567 |
| Placebo | Other | Phase PHASE3 | Lupus Erythematosus, Systemic | ACTIVE_NOT_RECRUITING | NCT04961567 |
| Litifilimab | Other | Phase PHASE3 | Lupus Erythematosus, Systemic | ACTIVE_NOT_RECRUITING | NCT04961567 |
| Communication with the clinic | Other | Approved | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT02454907 |
| Observational | Other | Preclinical | Spinal Muscular Atrophy | RECRUITING | NCT06955897 |
| Observational | Other | Preclinical | Spinal Muscular Atrophy | RECRUITING | NCT06955897 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | RECRUITING | NCT07225517 |
| BIIB145 | Other | Phase PHASE1 | Healthy Volunteer | RECRUITING | NCT07225517 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | RECRUITING | NCT07225517 |
| BIIB145 | Other | Phase PHASE1 | Healthy Volunteer | RECRUITING | NCT07225517 |
| Tofersen | Other | Phase PHASE2 | ALS (Amyotrophic Lateral Sclerosis) | RECRUITING | NCT07294144 |
| Tofersen | Other | Phase PHASE2 | ALS (Amyotrophic Lateral Sclerosis) | RECRUITING | NCT07294144 |
| Tofersen | Other | Phase PHASE2 | ALS (Amyotrophic Lateral Sclerosis) | RECRUITING | NCT07294144 |
| Zuranolone | Other | Preclinical | Postpartum Depression | RECRUITING | NCT07398469 |
| Placebo | Other | Phase PHASE3 | Lupus Erythematosus, Systemic | ACTIVE_NOT_RECRUITING | NCT04895241 |
| Litifilimab | Other | Phase PHASE3 | Lupus Erythematosus, Systemic | ACTIVE_NOT_RECRUITING | NCT04895241 |
| Placebo | Other | Phase PHASE3 | Lupus Erythematosus, Systemic | ACTIVE_NOT_RECRUITING | NCT04895241 |
| Litifilimab | Other | Phase PHASE3 | Lupus Erythematosus, Systemic | ACTIVE_NOT_RECRUITING | NCT04895241 |
| Omaveloxolone | Other | Phase PHASE1 | Healthy Volunteer | RECRUITING | NCT07297199 |
| Omaveloxolone | Other | Phase PHASE1 | Healthy Volunteer | RECRUITING | NCT07297199 |
| Nusinersen | Other | Phase PHASE3 | Muscular Atrophy, Spinal | ACTIVE_NOT_RECRUITING | NCT04729907 |
| Nusinersen | Other | Phase PHASE3 | Muscular Atrophy, Spinal | ACTIVE_NOT_RECRUITING | NCT04729907 |
| Placebo | Other | Phase PHASE2 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT05798520 |
| DRF | Other | Phase PHASE2 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT05798520 |
| BIIB091 | Other | Phase PHASE2 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT05798520 |
| Placebo | Other | Phase PHASE2 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT05798520 |
| DRF | Other | Phase PHASE2 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT05798520 |
| BIIB091 | Other | Phase PHASE2 | Relapsing Forms of Multiple Sclerosis | COMPLETED | NCT05798520 |
| Omeveloxolone | Other | Approved | Friedreich's Ataxia | NOT_YET_RECRUITING | NCT07444333 |
| Aerobic Exercise | Other | Approved | Friedreich's Ataxia | NOT_YET_RECRUITING | NCT07444333 |
| Tofersen | Other | Preclinical | Amyotrophic Lateral Sclerosis | NOT_YET_RECRUITING | NCT07259980 |
| Salanersen | Other | Phase PHASE3 | Spinal Muscular Atrophy | NOT_YET_RECRUITING | NCT07444476 |
| Sham Procedure | Procedure | Phase PHASE3 | Muscular Atrophy, Spinal | NOT_YET_RECRUITING | NCT07444450 |
| Salanersen | Other | Phase PHASE3 | Muscular Atrophy, Spinal | NOT_YET_RECRUITING | NCT07444450 |
| Sham Procedure | Procedure | Phase PHASE3 | Muscular Atrophy, Spinal | NOT_YET_RECRUITING | NCT07444450 |
| Salanersen | Other | Phase PHASE3 | Muscular Atrophy, Spinal | NOT_YET_RECRUITING | NCT07444450 |
| Placebo | Other | Phase PHASE3 | Prediabetes | NOT_YET_RECRUITING | NCT07448974 |
| Vitamin D (Cholecalciferol ) | Other | Phase PHASE3 | Prediabetes | NOT_YET_RECRUITING | NCT07448974 |
| Placebo | Other | Phase PHASE3 | Prediabetes | NOT_YET_RECRUITING | NCT07448974 |
| Vitamin D (Cholecalciferol ) | Other | Phase PHASE3 | Prediabetes | NOT_YET_RECRUITING | NCT07448974 |
| No Intervention | Other | Preclinical | Muscular Atrophy, Spinal | RECRUITING | NCT05789758 |
| No Intervention | Other | Preclinical | Muscular Atrophy, Spinal | RECRUITING | NCT05789758 |
| Placebo | Other | Phase PHASE3 | Friedreich Ataxia | RECRUITING | NCT06953583 |
| Omaveloxolone | Other | Phase PHASE3 | Friedreich Ataxia | RECRUITING | NCT06953583 |
| Placebo matching fingolimod | Other | Phase PHASE3 | Relapsing Forms of Multiple Sclerosis | NOT_YET_RECRUITING | NCT07483632 |
| Placebo matching DMF | Other | Phase PHASE3 | Relapsing Forms of Multiple Sclerosis | NOT_YET_RECRUITING | NCT07483632 |
| Placebo matching DRF | Other | Phase PHASE3 | Relapsing Forms of Multiple Sclerosis | NOT_YET_RECRUITING | NCT07483632 |
| Fingolimod | Other | Phase PHASE3 | Relapsing Forms of Multiple Sclerosis | NOT_YET_RECRUITING | NCT07483632 |
| Dimethyl Fumarate | Other | Phase PHASE3 | Relapsing Forms of Multiple Sclerosis | NOT_YET_RECRUITING | NCT07483632 |
| Diroximel Fumarate | Other | Phase PHASE3 | Relapsing Forms of Multiple Sclerosis | NOT_YET_RECRUITING | NCT07483632 |
| BIIB080 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06454721 |
| [89Zr]Zr-DFO-BIIB080 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06454721 |
| BIIB080 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06454721 |
| [89Zr]Zr-DFO-BIIB080 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06454721 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| PFS | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| OBI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| Litifilimab | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| PFS | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| OBI | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| Litifilimab | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06741657 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | RECRUITING | NCT05531565 |
| Litifilimab | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | RECRUITING | NCT05531565 |
| Felzartamab | Other | Phase PHASE3 | Antibody-mediated Rejection | NOT_YET_RECRUITING | NCT07444489 |
| Felzartamab | Other | Phase PHASE3 | Antibody-mediated Rejection | NOT_YET_RECRUITING | NCT07444489 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| BIIB059 (litifilimab) | Other | Phase PHASE3 | Subacute Cutaneous Lupus Erythematosus | ENROLLING_BY_INVITATION | NCT06044337 |
| Natalizumab | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05925049 |
| Natalizumab | Other | Preclinical | Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT05925049 |
| Tofersen | Other | Preclinical | Amyotrophic Lateral Sclerosis | RECRUITING | NCT07259980 |
| Litifilimab-matching placebo | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| Litifilimab | Other | Phase PHASE3 | Systemic Lupus Erythematosus (SLE) | ENROLLING_BY_INVITATION | NCT05352919 |
| BIIB059 (litifilimab) | Other | Phase PHASE3 | Subacute Cutaneous Lupus Erythematosus | ENROLLING_BY_INVITATION | NCT06044337 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Placebo | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Felzartamab | Other | Phase PHASE3 | Immunoglobulin A Nephropathy (IgAN) | RECRUITING | NCT06935357 |
| Standard of Care IST | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Tacrolimus | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Felzartamab | Other | Phase PHASE3 | Primary Membranous Nephropathy | RECRUITING | NCT06962800 |
| Placebo | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | RECRUITING | NCT05531565 |
| Litifilimab | Other | Phase PHASE2 | Subacute Cutaneous Lupus Erythematosus | RECRUITING | NCT05531565 |
| Placebo | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Felzartamab | Other | Phase PHASE2 | Microvascular Inflammation | RECRUITING | NCT07219043 |
| Placebo | Other | Phase PHASE2 | Immunoglobulin A (IgA) Nephropathy | COMPLETED | NCT05065970 |
| Felzartamab | Other | Phase PHASE2 | Immunoglobulin A (IgA) Nephropathy | COMPLETED | NCT05065970 |
Total products: 2543